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Summary 
Hepatitis C virus (HCV) causes a chronic infection in the majority of infected patients, 
ultimately leading to liver cirrhosis and hepatocellular carcinoma (HCC). Although the roles 
of the HCV proteins in the viral life cycle are increasingly understood, the precise function of 
the HCV NS5A protein has yet to be elucidated. To date, the only putative direct function 
attributed to NS5A is its transcriptional transactivation properties. Our group has previously 
shown that quasispecies variants of NS5A isolated from the serum samples of the same 
patient bear different transactivating properties according to their amino acid sequence. Based 
on these observations, we performed preliminary phylogenetic and functional analysis of 
NS5A variants isolated from liver tissue of individuals infected with HCV of genotype 1b. 
This analysis revealed genetic and functional compartmentation of NS5A variants in tumoral 
and adjacent non-tumoral tissue. We hypothesized that the natural variability of NS5A may 
impact its proposed transactivation properties. We also hypothesized that NS5A’s putative 
transactivation properties could play a role in HCV replication and in liver pathogenesis. The 
aim of the study presented in this thesis was to investigate the role of NS5A transactivation 
properties in the development of HCV-induced liver pathogenesis as well as in viral 
replication.  
To study the role of NS5A transcriptional activation properties in liver pathogenesis, we 
developed lentiviral vectors for the expression of selected NS5A variants bearing different 
transactivation potentials in cultured primary human hepatocytes. We now intend to extend 
these preparations using RNAseq technology to analyse the, transcriptome of primary 
hepatocytes transduced with lentiviral vectors encoding strongly and weakly transactivating 
NS5A variants to identify the cellular pathways targeted by NS5A, allowing us to decipher 
the role of NS5A mediated host gene regulation in development of HCV induced 
pathogenesis. For in vivo studies, we have begun the development of transgenic mice allowing 
liver-specific conditional expression of NS5A variants with high and low transactivation 
potentials. These transgenic mice will be used to study the possible role of NS5A 
transactivation properties in development of HCC. 
 
To study the role of NS5A transcriptional activation properties in HCV RNA replication, we 
used the sub-genomic replicon system expressing previously characterized NS5A sequences.. 
Using this system, we have demonstrated that a subset of NS5A protein can translocate to the 
nucleus and is recruited to cellular promoters of host cell genes known to be required for 
efficient replication of HCV replicon RNA as well as those implicated in pathogenesis. 
Moreover, we have shown that NS5A directly regulate the expression of these genes. 
Consequently, it was observed that replicons encoding NS5A variants with different 
transactivation potentials exhibited different replication capacities, and that this correlated 
with the transactivation potential of the corresponding NS5A variant. In agreement with these 
observations, inhibition of nuclear translocation of NS5A resulted in the inhibition of 
replication of the HCV subgenomic replicon, further confirming the role of NS5A 
transactivation properties in viral RNA replication.  
In conclusion, we have demonstrated that NS5A-mediated transcriptional regulation of 
cellular genes is required for HCV replication. Such NS5A-mediated modulation of cellular 
genes may also constitute one of the mechanisms involved in HCV-related liver pathogenesis 
and development of HCC, an aspect which is currently under investigation using the tools 
developed during this project. This study will contribute towards deciphering the role of 
NS5A in viral replication as well as providing insight into its role in HCV-induced liver 
pathogenesis. Furthermore, these data might open new anti-HCV drug developments based on 
inhibition of NS5A nuclear translocation.   
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Résumé 
Le virus de l’Hépatite C (VHC), de la famille Flaviviridae, est à l’origine d’une pandémie 
mondiale. L’infection par le VHC provoque le dévelopment d’hépatites chroniques, de 
cirrhoses et de carcinomes hépatocellulaires (CHC). Les fonctions de la majorité des protéines 
virales sont connues, mis à part pour NS5A dont la seule fonction directe attribuée à ce jour, 
équivaut à celle d’un facteur d'activation transcriptionnelle. Notre laboratoire a montré 
précédemment que les variants de quasiespèce de NS5A isolés à partir du sérum d’un même 
patient présentaient des différences significatives dans leurs propriétés intrinsèques de 
transactivation. Fort de ces résultats, nous avons analysé des variants de NS5A isolés à partir 
de tissu hépatique d’un patient chroniquement infecté par le VHC de génotype 1b. Ces 
analyses ont révélé une compartimentation génétique et fonctionnelle des variants de NS5A 
entre le tissu tumoral et le tissu non-tumoral adjacent. Nous avons donc émis l’hypothèse que 
les propriétés transactivatrices de NS5A pourraient jouer un rôle dans la pathogenèse ainsi 
que dans la réplication virale, et que la variabilité naturelle de NS5A pourrait influencer ses 
propriétés transactivatrices. L’objectif de ce travail de thèse était d’analyser le rôle des 
propriétés transactivatrices de NS5A dans la pathogenèse hépatique viro-induite ainsi que 
dans la réplication virale. 
Pour étudier le rôle des propriétés de transactivation de NS5A dans la pathogenèse hépatique, 
nous avons développé des vecteurs lentiviraux pour exprimer dans les hépatocytes primaires 
humains les variants choisis de NS5A portants différents potentiels de transactivation. En 
utilisant la technologie RNA-Seq d’Illumina, l’analyse des transcriptomes d’hépatocytes 
transduits exprimant les variants transactivateurs fort et faible de NS5A, sera utiliser pour 
identifier les voies cellulaires ciblées par les propriétés transactivatrices de NS5A. Pour les 
études in vivo, nous avons lancé le développement des souris transgénique permettant 
l’activation conditionnelle de l’expression des variants de NS5A avec fort et faible potentiel 
de transactivation, spécifiquement dans le foie. Ces souris transgéniques seront utilisées pour 
étudier le rôle potentiel des propriétés transactivatrices dans la pathogenèse VHC induite et 
plus particulièrement dans le développement des cancers. 
Pour étudier le rôle des propriétés de transactivation de NS5A dans la réplication virale, nous 
avons utilisé le système de réplicon subgénomique de VHC exprimant les variants de NS5A 
précédemment caractérisés. Pour exercer ses propriétés transactivatrices, NS5A doit être 
localisée au moins partiellement dans le noyau. Nous avons démontré qu’une partie de NS5A 
se retrouve dans noyau et est recruté sur des promoteurs cellulaires, modulant ainsi 
directement l’expression de gènes cellulaires essentiels pour la réplication de l’ARN viral. 
Nous avons observé que les variants de NS5A avec différents potentiels de transactivation, 
confèrent différentes capacités de réplication au réplicon subgénomique, et corrèlent avec le 
potentiel de transactivation de variant correspondant. En accord avec ces observations, 
l’inhibition de translocation nucléaire de NS5A entraine une inhibition de la réplication virale, 
suggerant un rôle potentiel des propriétés transactivatrices de NS5A dans la réplication l’ARN 
virale. 
En conclusion, nous avons démontré que l’activation transcriptionnelle des gènes cellulaires 
par la NS5A est essentielle pour la réplication de l’ARN du VHC. Cette modulation des gènes 
cellulaires pourrait également être impliquée dans les mécanismes de la pathogenèse viro-
induite. Nous confirmerons cette hypothèse grâce aux souris NS5A. Par ailleurs, ces résultats 
pourraient contribuer au développement de nouvelles thérapies anti-VHC, basées sur 
l’inhibition de translocation nucléaire de NS5A. 
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1.1. Hepatitis C  
 
1.1.1. Discovery of the Pathogen 
 
Before the discovery of hepatitis C virus (HCV), two viral pathogens were known to cause 
hepatitis: hepatitis A (HAV) and B (HBV) viruses.  However, many patients with hepatitis did 
not harbor HAV or HBV infection, and their disease was thus referred to as non-A non-B 
hepatitis (NANBH). NANBH was demonstrated to be infectious and could be transmitted by 
blood transfusion, suggesting the involvement of a viral factor (Bradley et al., 1986). 
Research efforts using novel molecular biology techniques resulted in identification of a new 
RNA virus, renamed hepatitis C virus (HCV), in sequence libraries made from the serum of a 
chimpanzee suffering from chronic NANBH (Choo et al., 1989). It is now estimated that 170 
million people worldwide are chronically infected by hepatitis C virus (WHO, 2000). Even 
two decades after the discovery of pathogen, no vaccine is available against HCV and to date; 
all treatments against HCV are only partially efficient. 
 
1.1.2. Epidemiology and Transmission 
 
Hepatitis C virus is a pandemic infection and is a major public health problem. Industrialized 
countries of North America and Western Europe have the lowest prevalence rates (below 2%) 
whereas HCV infects more than 10% of people in Mongolia, Bolivia and Egypt, the latter 
having the highest prevalence rate (22% , Figure 1.1) (Lavanchy 2011). Use of contaminated 
syringes in nationwide schistosomiasis treatments during the 1970s is considered to be the 
cause of such a high seroprevalence of HCV in Egypt (Frank et al., 2000). France has a 0.84% 
seroprevalence, with an estimated 367,055 people having antibodies to HCV (Figure 1.2) 
(INVS, 2005). 
 
HCV is primarily transmitted through exposure to infected blood. Blood from unscreened 
donors was a major factor in its transmission before the development of systematic blood 
screening methods in the early 1990s (Huber et al., 1996). Currently, injecting drug abuse has 
become the predominant mode of transmission of HCV in industrialized countries whereas 
contaminated blood transfusions and therapeutic injections are still the most frequent modes 
of transmission in the developing world (Figure 1.3) (Shepard et al., 2005). In children, 
mother-to-infant vertical transmission is the most frequent mode of transmission of HCV 
(Alter 2007). Although significant, sexual transmission of HCV is far less frequent than other 
sexually transmitted viruses (Alter 2007).  
Introduction 
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Figure 1.1: The estimated global prevalence of HCV infection in 2010 (% population infected) 
(Lavanchy 2011). 
 
 
 
 
 
Figure 1.2: The estimated prevalence of HCV in France (Source: INVS 2005). 
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Figure 1.3: Sources of HCV infection in the USA (Source: CDC 2009) 
 
 
1.1.3. Natural History and Physiopathology of HCV infection 
 
In majority of cases, acute HCV infection is asymptomatic, although approximately 20-30 % 
of acutely infected patients may develop typical hepatitis symptoms such as weakness, 
anorexia and jaundice 3 to 12 weeks after infection (Alter et al., 2000). HCV RNA can be 
detected in patient serum within 1-2 weeks of exposure to the virus (Thimme et al., 2001). In 
some cases, symptoms of acute infection may be severe, and rapid fulminant hepatitis have 
been reported (Farci et al., 1996). 
 
Although acute infection is self-limiting in 15-25 % of patients, in the majority of cases HCV 
escapes the immune response and infection persists over six months, leading to chronic 
hepatitis (Shimotohno 2000). The majority of chronically-infected patients develop chronic 
hepatitis with symptoms such as lobular injury and portal inflammation (Di Bisceglie 1998).  
The transition to chronic HCV infection is influenced by a wide range of factors such as sex, 
age, co-infection with HIV or HBV and some genes of major histocompatibility complex 
(Lavanchy 2009). Approximately 20 % of chronically-infected patients develop liver cirrhosis 
within 15-20 years post-infection (Yano et al., 1996). Males aged over 50 and consumers of 
alcohol are more prone to cirrhosis development (Lavanchy 2009). Recent data have shown 
that HCV-induced liver injury is responsible for 40-50% of orthotopic liver transplantations in 
the USA (Figure 1.4) (Brown 2005).   
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It is estimated that every year 1-4% of HCV infected cirrhotic patients develop primary liver 
cancer or hepatocellular carcinoma (HCC) (Di Bisceglie 1998; Gordon et al., 1998). Chronic 
HCV infection has become the principal cause of primary liver cancer in Japan as 80-90 % of 
HCC patients are carriers of HCV. Moreover, modeling of ongoing epidemics predicts a 
similar trend in Europe (Aizawa et al., 2000; Kiyosawa et al., 2004; El–Serag et al., 2007). In 
Western Europe, HCV infection is prevalent in the majority of HCC patients, ranging from 
44-66 % in Italy, 27-58 % in France and 60-75 % in Spain (El–Serag et al., 2007). It has been 
estimated that HCV infection increases HCC risk by 17 fold as compared to non-infected 
subjects (Donato et al., 2002). The mean time to develop HCC in HCV infected patients has 
been estimated to be 28+/-11 years post infection (Tong et al., 1995). In industrialized 
countries, liver transplantation has become the principal long term treatment for severe HCV-
induced cirrhosis or HCC (Charlton 2001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4: The various outcomes of HCV infection (Adapted from (Patel et al., 2006)) 
 
 
1.2. Therapeutic Treatment of HCV Infection 
 
Interferon-α treatment was noticed to be beneficial to NANBH patients long before the 
discovery of HCV itself (Hoofnagle et al., 1986). It was demonstrated that interferon-α 
induces an anti-viral state by inducing interferon stimulated genes (ISGs) within infected and 
neighboring cells (Sen 2001). This antiviral state leads to a rapid decline in HCV RNA levels 
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in serum (Lau et al., 1998). However, only 16-20 % of HCV-infected patients showed a 
sustained anti-viral response when treated with interferon-α (Di Bisceglie et al., 2002). The 
number of patients eliciting such a response was increased by two fold with the use of the 
broad spectrum anti-viral drug Ribavirin in combination with interferon-α therapy 
(McHutchison et al., 1999). Ribavirin is a guanosine analogue that has been shown to have 
anti-viral activity against several DNA and RNA viruses such respiratory syncytial virus, 
bovine viral diarrhea virus, and GB virus B. (Lau et al., 1999; Lanford et al., 2001). Despite 
detailed studies, the exact mechanism(s) of action of ribavarin still remains elusive. 
Incorporation of ribavirin by the HCV RNA-dependent RNA polymerase results in chain 
termination, leading to inhibition of viral replication (Maag et al., 2001). It has also been 
suggested that ribavirin causes lethal mutagenesis mediated by RNA-dependent-RNA-
polymerase (Cameron et al., 2001). However, the  study of viral kinetics in ribavirin-treated 
patients showed that chain termination events induced by ribavirin is not the only mechanism 
of action of ribavirin in combination therapy (Pawlotsky et al., 2004).  It has also been 
suggested that ribavirin may exert its anti-viral activity by modulating the immune system and 
interferon signaling pathways (Tam et al., 1999; Feld et al., 2005). Today, interferon-α has 
been replaced by Pegylated interferon-α that has a longer half-life and achieves a better 
virological response (Glue et al., 2000; Bailon et al., 2001). 
 
Currently, combination therapy with pegylated interferon-α and Ribavirin has become the 
standard-of-carefor HCV infection. However, only 40-50% patients infected with genotype 1 
and up to 80% patients with genotypes 2 and 3 can achieve a sustained virological response 
with this therapy (reviewed in (Pawlotsky 2011a)). However, the high rate of non-responders, 
especially in genotype 1 infected patients, and the adverse side effects of the standard 
treatment regimen have necessitated the development of new treatments against HCV. 
Recently, research efforts have focused on the development of direct acting antivirals (DAAs) 
such as inhibitors of viral enzymes and nucleic acid based agents to destroy viral RNA such 
as antisense oligonucleotides and siRNAs (reviewed in (De Francesco et al., 2005)). These 
efforts have resulted in the development of many promising DAAs that are in early or late 
stages of clinical trials, or that are now licensed for use in clinical settings such as telaprevir 
(Kwong et al., 2011) and boceprevir (Poordad et al., 2011).  
 
However it has been demonstrated that DAAs may lead to selection of resistant viruses and 
that they must not be used alone (Tarik 2011; Pawlotsky 2011a). Keeping in mind the 
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possible selection of resistant viruses by DAAs, efforts are underway to develop inhibitors of 
host cell proteins important for viral replication, such as inhibitors of cyclophilins (Goto et 
al., 2006; Paeshuyse et al., 2006). Besides DAAs and cyclophilin inhibitors, synthetic 
immunomodulatory agents such as agonists of toll-like receptors (TLRs) 7 and 9 have shown 
promising potential to control HCV infection (De Francesco et al., 2005). 
 
 
1.3. Hepatitis C Virus 
 
1.3.1. Classification and Genomic Variability of HCV 
 
Early analysis of the HCV genome classified it as a member of Flaviviridae family, at that 
time consisting of two genera: the Flaviviruses (Dengue Virus, West Nile Virus, Yellow 
Fever Virus etc.) and the Pestiviruses (such as Bovine Viral Diarrhea Virus). Similar to 
Flaviviruses and Pestiviruses, the HCV genome consists of single strand RNA of positive 
polarity and codes for a single polyprotein. However due to low sequence homology with 
these viruses, HCV was classified as the sole member of a novel genus Hepacivirus (Miller et 
al., 1990; Choo et al., 1991; Houghton et al., 1991).  
 
Analysis of a large number of sequences of HCV from all over the world demonstrated that 
HCV could be divided into six genotypes that differ by 30-35% in nucleotide homology 
(Figure 1.5) (Simmonds 2004). Similarly, each genotype has been subdivided into several 
subtypes; differing by 20-25% nucleotide sequence homology (Simmonds 2004). HCV 
genotypes and subtypes are heterogeneously distributed in the world. Genotypes 1a and 1b are 
more frequent in America and Europe whereas genotype 3 is dominant in South East Asia. 
Genotype 4 is predominant in Egypt whereas genotype 5 is predominant and almost 
completely limited to South Africa. Similarly, genotype 6 is mainly found in East Asia 
(Figure 1.6) (Zein 2000). 
 
The RNA-dependent RNA polymerase of HCV lacks 5’-3’ exonuclease proofreading activity, 
which leads to the introduction of frequent mutations in viral genomic RNA. Since the rate of 
mutation is very high, HCV evolves at an astonishing rate (Okamoto et al., 1992).  This high 
mutation rate leads to significant variability not only between viral populations amongst 
different patients, but also between viruses in a single infected patient, giving rise to 
quasispecies. Viral quasispecies are composed of a dynamic and complex mixture of 
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genetically distinct but closely related variants (Pawlotsky 2006). Quasispecies confer a 
greater adaptability to HCV and may have important implications in viral persistence, 
treatment response and pathogenicity. (Forns et al., 1999; Lyra et al., 2004; Lerat et al., 
2008). 
 
 
 
 
 
 
Figure 1.5: HCV genotype diversity: 
Neighbor-joining tree of the complete 
genome sequences that formed the basis for 
the plot of the complete genome distances 
(Source: HCV Sequence Database) 
 
 
 
 
 
 
 
Figure 1.6: Global distribution of HCV genotypes (Source: WHO 2009) 
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1.3.2. Virion Morphology 
 
Electron microscopy studies have indicated that in vitro-produced HCV virions have a 
diameter of 50-60 nm, consisting of a nucleocapsid of 30-35 nm and an envelope containing 
viral glycoproteins E1 and E2 (Wakita et al., 2005) (Figure 1.7). This is similar to virions 
produced in vivo and secreted into the serum of infected humans or chimpanzees (Kaito et al., 
1994; Shimizu et al., 1996). HCV virions found in patients’ sera are attached to lipoproteins 
of low or very-low density (LDLs or VLDLs) (Andre et al., 2002). It has also been 
demonstrated that buoyant density of secreted virions (1.03-1.16 g/ml) is lower than that of 
intracellular virions (1.15-1.20 g/ml) (Gastaminza et al., 2006). These observations suggested 
that virions acquire these lipoproteins during the secretion process. Recently, it has been 
demonstrated that in vitro secretion of HCV particles by infected hepatocytes is tightly 
dependent on the secretion of VLDLs (Gastaminza et al., 2008). It has been further 
demonstrated that, even in the absence of other viral proteins, secreted E1 and E2 proteins are 
associated with lipoproteins (Icard et al., 2009). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7: HCV Virion Morphology (Image from Louis E. Henderson (Frederick Cancer Research 
Center))  
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1.3.3. Genome Structure 
 
The HCV genome comprises of a positive sense single stranded 9.6 kbp RNA molecule 
containing a single open reading frame (ORF), encoding a polyprotein of about 3000 amino 
acids, depending on the genotype. This ORF is flanked by highly conserved 5’ and 3’ non-
translated regions (NTRs) of 341 and 230 bp respectively (Penin et al., 2004a) (Figure 1.8a).  
 
1.3.3.1. Non-translated Regions 
 
The highly conserved 5’ NTR is essential for genome translation and replication. It is highly 
structured and contains four major secondary structure domains known as domains I, II, III 
and IV. The 5’ NTR contains an internal ribosome entry site (IRES) that is comprised of 
domains II, III and IV along with the first 30 nucleotides of the ORF, which, in the absence of 
a 5’ cap, ensures translation of the HCV genome (reviewed in (Lindenbach et al., 2005). 
Besides its important role in genome translation, many studies have demonstrated that 5’NTR 
is also crucial for efficient replication of viral RNA (Friebe et al., 2001; Kim et al., 2002; 
Appel et al., 2006). It has been demonstrated that binding of the host cell-encoded microRNA 
(miR-122) to the 5’NTR is essential for viral replication (Jopling et al., 2005). However these 
observations are not supported by  in vivo data, as recently it has been demonstrated that mir-
122 levels are reduced in HCV infected patients poorly responding to interferon therapy 
(Sarasin-Filipowicz et al., 2009). 
 
The length of the 3’ NTR varies between different genotypes. It has a tripartite structure 
differentiated into three regions: a highly variable region of 30-40 nucleotides, a poly-
uracil/pyrimidine tract of variable length and a conserved sequence of 98 nucleotides that is 
organized into three stem-loop structures termed SL1, SL2 and SL3 (reviewed in (Chevaliez 
et al., 2006)). The variable region is not essential for HCV RNA replication in cell culture 
models, whereas the  poly-uracil/pyrimidine region contains a segment of uridine and cytidine 
residues that must be longer than 25 nucleotides to allow viral RNA replication (Friebe et al., 
2002). The conserved region containing SL1, SL2 and SL3 has been demonstrated to be 
indispensable for HCV replication and infectivity (Yanagi et al., 1999; Yi et al., 2003). 
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Figure 1.8: HCV 5’ and 3’ NTRs, Genome organization and Polyprotein processing. (adapted 
from (Dustin et al., 2007)) a) RNA secondary structures in 5’ and 3’ UTRs. b) HCV genome 
translation produces polyprotein precursor. ARFP denotes alternative reading frame protein 
also termed “F” protein c) Polyprotein precursor is processed into mature structural and non-
structural proteins. 
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1.3.3.2. HCV Proteins 
 
The translation of the HCV ORF produces a large polyprotein precursor which is processed 
by viral and cellular proteases to produce eleven viral proteins that make up viral particles 
(structural) or viral replication complex (non-structural) (Figure 1.8b). Host cell proteases 
such as endoplasmic reticulum signal peptidase, first cleave the polyprotein to liberate 
structural proteins, followed by further processing of non-structural proteins by viral proteases 
NS2-3 and NS3-4A (Chevaliez et al., 2006). The amino terminal proteins core and 
glycoproteins E1 and E2 are virion structural proteins whereas a small protein p7 has been 
suggested to function as ion channel (Griffin et al., 2003; Pavlović et al., 2003; Griffin et al., 
2004). The non-structural proteins NS2, NS3, NS4A, NS4B, NS5A and NS5B are 
intracellular coordinators of the viral life cycle (Lindenbach et al., 2005). 
 
 
1.3.3.3. Core Protein  
 
The core protein is the first protein encoded by the HCV genome. It is a highly basic, RNA 
binding protein and the putative construction unit of viral nucleocapsid that encapsulates the 
viral genome (Hijikata et al., 1991). After cleavage from the polyprotein, the immature form 
(21-23kDa) of core undergoes another round of cleavage to produce the 19kDa mature form 
of core (Santolini et al., 1994; Hussy et al., 1996). The mature core protein is organized into 
two domains termed domains 1 (D1) and 2 (D2). D1 is rich in acidic amino acids and interacts 
with the 5’ end of the viral genome to initiate its encapsidation (Boulant et al., 2005). The 
hydrophobic domain 2 of the core protein is essential for its localization on the ER membrane 
as well as its trafficking to lipid droplets (Hope et al., 2000; Suzuki et al., 2005). Core protein 
is essential for viral particle assembly and mutations that disrupt its trafficking to LDs result 
in a significant loss of production of infectious viral particles (Boulant et al., 2007; Miyanari 
et al., 2007; Murray et al., 2007). Although not absolutely indispensible for HCV RNA 
replication, it has been suggested that core protein plays an important role in recruiting viral 
replication complexes  to lipid droplet-associated membranes (Miyanari et al., 2007). More 
recently, core has been reported to induce redistribution of lipid droplets in the cell through its 
interaction with microtubules, bringing them in close contact with membranes bearing viral 
replication complexes, possibly to initiate viral assembly in infected cells (Boulant et al., 
2008; Roohvand et al., 2009). These observations clearly suggest that core protein plays an 
essential role in viral particle assembly and is essential for infectious virion production. 
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Besides being a part of viral capsid, core protein has been shown to interact with host cell 
pathways, possibly contributing to HCV-associated pathogenesis. Transgenic mice expressing 
core protein demonstrate reduced activity of microsomal triglyceride transfer protein (MTP) 
resulting in reduced secretion of VLDL (Perlemuter et al., 2002). In addition, some studies 
have suggested that core protein may stimulate lipogenesis and play a role in liver steatosis in 
HCV infected patients (Piodi et al., 2008; Roingeard et al., 2008). It is interesting to notice 
that HCV might perturb the production of lipids and lipid droplets which are essential for 
HCV life cycle, although no clear relation has been shown so far between steatosis and HCV 
replication. 
 
Although still controversial, it has also been reported that core protein transcriptionally 
regulates host cell proto-oncogenes and bear transforming properties resulting in 
transformation of rat primary hepatocytes (Ray et al., 1996a; Ray et al., 1996b). Another 
study has demonstrated that hepatic expression of core protein induces the development of 
hepatocellular carcinoma in core transgenic mice (Moriya et al., 1998). However these 
findings have been negated by other investigators who have reported no transforming or 
cytopathic effects of core protein on livers of transgenic mice expressing core protein 
(Pasquinelli et al., 1997). 
 
Although core protein has been shown to carry a nuclear localization signal and translocate to 
the nucleus, no precise nuclear function has been ascribed (Suzuki et al., 2005). Core has been 
reported to induce cell growth (Fukutomi et al., 2005) and has also been shown to have 
controversial effects on cell apoptosis (Kountouras et al., 2003; Meyer et al., 2005). More 
recently it has been demonstrated that core protein plays an important role in the development 
of liver fibrosis via interaction with TLR2 (Coenen et al., 2011; Feng et al., 2011). 
 
1.3.3.4. Envelope Glycoproteins E1 and E2 
 
Glycoproteins E1 and E2 are components of the viral envelope and are essential for viral entry 
into the host cells (Nielsen et al., 2004). Depending on the genotype, E1 and E2 are 33-35 
kDa and 70-72 kDa respectively (Deleersnyder et al., 1997). E1 and E2 form stable non-
covalent heterodimers anchored into the endoplasmic reticulum membrane (Ralston et al., 
1993; Dubuisson et al., 1994; Deleersnyder et al., 1997; Michalak et al., 1997). Both E1 and 
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E2 contain hyper variable regions (HVR) that are highly immunogenic and thought to be 
responsible for viral escape from host immune system (Weiner et al., 1991). 
 
1.3.3.5. p7 
 
p7 is a small hydrophobic polypeptide of 63 amino acids (Lin et al., 1994) and is an integral 
membrane protein (Carrere-Kremer et al., 2002). Classified as a member of viroporin family 
of proteins, p7 has been shown to function as cation channel (Griffin et al., 2003; Griffin et 
al., 2004; Steinmann et al., 2007). Although not required for viral RNA replication, p7 is 
essential for release of virions and in vivo infectivity in chimpanzee (Sakai et al., 2003) and 
thus represents a promising target for development of antiviral HCV drugs (Griffin 2010). It 
has been demonstrated that it is essential for infectious virus production and adaptive 
mutations enhance virus production in vitro (Steinmann et al., 2007; Russell et al., 2008). 
Very recently it has been demonstrated that p7 plays an essential role in targeting of NS2 to 
viral replication complexes, and in its interaction with NS5A (Tedbury et al., 2011). 
 
1.3.3.6. Non-structural protein 2 (NS2) 
 
NS2 is a 23kDa non-glycosylated trans-membrane protein that localizes to the ER membrane 
(Santolini et al., 1995). Cleavage of NS2 from the polyprotein is achieved by both cellular 
and viral proteases. NS2 is cleaved from the polyprotein by a host signal peptidase at its N-
terminus, whereas its C-terminus is auto-proteolytically cleaved by the NS2-3 metalloprotease 
on (Lin et al., 1994). Once cleaved from polyprotein, it has a very short half-life and is 
degraded by the proteasome (Franck et al., 2005). NS2 is not required for viral RNA 
replication but it is indispensable for infectious virus production. Recently it has been 
demonstrated that NS2 plays a vital role in organization of virion assembly (Jirasko et al., 
2010).  
 
1.3.3.7. Non-structural protein 3 and 4 (NS3/4A) 
 
NS3 is a 70 kDa multifunctional protein that carries a serine protease activity in its N-
terminus and a helicase/NTPase activity in C-terminal region (reviewed in (Chevaliez et al., 
2006)). NS3 interacts with NS4A as its co-factor (Lin et al., 1994; Failla et al., 1995). NS3 
serine protease activity is required for polyprotein cleavage at the junctions of NS2/3, 
NS3/NS4A, NS4A/4B, NS4B/5Aand NS5A/5B (Grakoui et al., 1993; Kolykhalov et al., 
1994). The NTPase domain of NS3 helicase- binds to RNA, hydrolyses NTPs and uses this 
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energy to travel along the nucleic acid polymer, removing both the complementary strand and 
bound proteins. NS3-NS4A has also been shown to prevent dsRNA detection and the 
subsequent interferon response to viral infection by interfering with toll like receptor 3 
(TLR3) and interferon regulatory factor 3 (IRF3) signaling pathways (Foy et al., 2003; Li et 
al., 2005).  
 
Because it plays a pivotal role in viral life cycle, NS3/4A has been identified as an important 
target for anti-HCV therapy. Two potent inhibitors of NS3 protease activity; Telaprevir and 
Boceprevir have recently been licensed for therapy against HCV (Kwong et al., 2011; 
Poordad et al., 2011; Vermehren et al., 2011). 
 
1.3.3.8. Non-structural protein 4B (NS4B) 
 
NS4B is a 261aa, 27 kDa highly hydrophobic protein that localizes to the endoplasmic 
reticulum. It induces the formation of a specific membrane structure designated the 
membranous web, although the exact mechanisms are still unknown,. This membranous web 
has been shown to serve as a scaffold for HCV RNA replication complex formation (Egger et 
al., 2002; Konan et al., 2003). Besides functioning as a membrane anchor for viral replication 
complexes, NS4B also plays an important role in viral assembly (Jones et al., 2009). 
 
NS4B also plays a role in the pathogenesis of hepatitis C by several mechanisms. It has been 
demonstrated that NS4B induces activation of endoplasmic reticulum stress pathways (Tardif 
et al., 2002). Some studies have suggested that NS4B upregulates fatty acid synthesis and 
play a role in steatosis in chronically infected patients (Waris et al., 2007; Park et al., 2009). 
NS4B has also been reported to transform NIH-3T3 cells when co-expressed with Ha-Ras as 
well as being shown to modulate cellular genes involved in tumor suppression, oncogenesis 
and cellular stress, suggesting that NS4B possesses transforming properties and may play a 
role in carcinogenesis (Park et al., 2000; Zheng et al., 2005). Although the mechanisms 
involved in NS4B-mediated cellular transformation are still not clear, it has been 
demonstrated that GTPase activity of NS4B nucleotide binding motif is essential for its 
transformation activity (Einav et al., 2008). 
 
The non-structural 5A (NS5A) protein, subject of the work presented in this thesis, will be 
described in further detail in Section 1.6. 
Introduction 
 
  16 
1.3.3.9. Non-Structural Protein 5B (NS5B) 
 
NS5B is a 68 kDa membrane associated protein that functions as an RNA dependent RNA 
polymerase. It is anchored to the ER  through an α-helical transmembrane domain in its C-
terminal region (Moradpour et al., 2004). It possesses typical features of a polymerase such as 
“fingers, palm and thumb” structure and Gly-Asp-Asp (GDD) motif (Poch et al., 1989; Ago 
et al., 1999; Bressanelli et al., 1999). The ‘finger’ and ‘thumb’ comprise the template RNA 
binding channel, whereas the ‘palm’ carries the catalytically active GDD motif (Penin et al., 
2004a). Since NS5B is catalytic machinery responsible for viral genome synthesis and 
replication, it has become a very important target for antiviral therapy (Pawlotsky 2006a; 
Koch et al., 2007). 
 
Both viral and cellular proteins interact with NS5B and modulate its activity. NS3 and NS5A 
have both been reported to modulate the activity of NS5B (Piccininni et al., 2002; Shirota et 
al., 2002). Similarly, a cellular protein, cyclophilin B (CypB) has been reported to interact 
with NS5B and modulate its RNA binding capacity,  thus modulating viral replication 
(Watashi et al., 2005). 
 
 
1.4. Model Systems to Study HCV Life Cycle and Pathogenesis 
 
The discovery of the causative agent for non-A non-B hepatitis helped to diagnose and 
prevent new infections, especially in blood receivers through detection of HCV specific 
antibodies in the serum of potentially infected blood donors. However, the lack of robust cell 
culture and small animal models initially made it the study of the viral life cycle and host-
pathogen interactions extremely difficult. However, over the last fifteen years several models 
have been developed and successfully used to study different steps of viral life cycle and to 
identify novel drug targets. Some of the most relevant models have been reviewed in the 
following sections. 
 
1.4.1. In vitro infections 
 
Initially all research related to HCV was conducted almost exclusively by epidemiological 
and serological studies. Cultured cell lines were not susceptible to HCV infection, whilst 
cultured primary hepatocytes isolated from chronically infected patients harbored a very low 
level of viral replication. Many efforts were made to infect in vitro cultured primary 
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hepatocytes by using sera from HCV-infected patients; however, these efforts were hampered 
by low level of HCV replication (Ito et al., 1996; Fournier et al., 1998). Despite low level of 
HCV replication, such experiments have allowed the study of several host cell receptors 
required for HCV infection, as well as the analysis of anti-viral therapies (Castet et al., 2002; 
Molina et al., 2007; Molina et al., 2008). Similarly, in vitro cultured primary hepatocytes 
from Tupaia belangeri were also shown to be infectable by sera from HCV-infected 
individuals (Zhao et al., 2002). However such in vitro infection models are hampered by 
problems with low reproducibility. In addition, the infectivity of patients’ sera differs greatly, 
despite having similar HCV RNA titers. Moreover, viral replication must be estimated by 
negative strand-specific methods, which have several problems including the detection of 
very low levels of negative strand RNA, contamination and false positives due to self-priming 
of viral RNA (Gunji et al., 1994; Lanford et al., 1994; Takyar et al., 2000). Alternatively, 
another group demonstrated that hepatocytes cultured in a 3-D radial flow bioreactor could 
produce infectious viral particles after inoculation with HCV-infected sera (Aizaki et al., 
2003). However, the complexity and cost of this system are major obstacles in its widespread 
use. 
 
1.4.2. Pseudo-Particle Model 
 
HCV pseudo-particles (HCVpp) are chimeric virus particles that are produced by 
incorporation of HCV glycoproteins E1 and E2 into murine leukemia virus (MLV) or human 
immune deficiency virus (HIV) viral capsids containing either GFP or Luciferase reporter 
genes (Hsu et al., 2003; Bartosch et al., 2003a) (Figure 1.9). This model has allowed the 
identification of several cellular receptors that are essential for HCV entry into cells, such as 
LDLR, DC-SIGN, L-SIGN, Claudin-1, Claudin-6, Claudin-9 and most recently Occludin 
(von Hahn et al., 2008; Ploss et al., 2009a). This model is limited to the study of HCV entry 
into cells or to the study of antibodies directed against the HCV envelope proteins (Bartosch 
et al., 2005; Lavillette et al., 2005). 
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Figure 1.9: Production of HCV pseudo particles (adapted from (Voisset et al., 2004). Ѱ indicates 
the retroviral packaging signal, LTR indicates Lateral Terminal Repeats. 
 
1.4.3. HCV infectious clones. 
 
 
The genomic amino acid sequence of HCV has been obtained from multiple PCR 
amplifications of HCV infected sera. In the late 1980s, PCR techniques lacked efficient 
proofreading polymerases and amplified HCV fragments contained many mutations, which 
impaired HCV protein functions and lead to non-replicable clones. Based on this assumption, 
different groups tried to repair these mutations to generate a consensus HCV clone which 
would be fully replicative in chimpanzees. Several groups reported the successful infection of 
chimpanzees by intrahepatic inoculation of infectious HCV RNA transcribed from consensus 
cDNAs constructed by comparison with several full-length clones (Kolykhalov et al., 1997; 
Beard et al., 1999; Lanford et al., 2001). Inoculation of these constructs made the animals 
seropositive for HCV, although these transcripts could not replicate in cell culture 
(Kolykhalov et al., 1997). 
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1.4.3.1. JFH-1 Infectious Clone 
 
A serious drawback of replicon system had been the failure to produce viral particles and the 
ability to passage the infection to naïve cells. A major breakthrough came when a full-length 
replicon was constructed using the JFH-1 clone (Figure 1.10), a genotype 2a HCV genome 
isolated from a Japanese patient suffering from fulminant hepatitis. This replicon efficiently 
replicated in cell culture without the need of any adaptive mutations and produced viral 
infectious particles (Lindenbach et al., 2005; Wakita et al., 2005). These viral particles could 
be isolated by sucrose gradient centrifugation and could be visualized by immuno-electron 
microscopy. Such particles could infect naïve Huh7 cells in culture, and were also infectious 
in vivo when injected in chimpanzees (Wakita et al., 2005; Lindenbach et al., 2006). The 
replication and virion production capacities of JFH-1 replicon were improved by constructing 
a chimeric replicon of JFH-1 that contained structural proteins from another 2a isolate termed 
J6 (Pietschmann et al., 2006). The development of JFH-1 has allowed the study of the 
complete viral life cycle in vitro, including steps that were previously inaccessible such as 
viral particle assembly and infectious particle secretion. 
 
 
1.4.4. HCV Replicon Model 
  
In 1999 Lohmann et al., made a major breakthrough in HCV research when they reported the 
development of the HCV replicon system (Lohmann et al., 1999). It was hypothesized that 
the HCV genome should adapt to the particular environment of cancer-derived hepatocytes in 
culture to form infectious clones. In order to achieve stable autonomous replication of 
subgenomic HCV RNA, this new replicon system contained a Neomycin selection marker 
(Lohmann et al., 1999). The coding sequence of the structural proteins and NS2 of the Con1 
consensus sequence was replaced by Neomycin Phosphotransferase (a selectable antibiotic 
resistance marker) together with the EMCV IRES to produce a bicistronic replicon (Figure 
1.10). When this subgenomic replicon was transfected into HuH7 cells, neomycin sulphate-
resistant colonies were obtained that contained autonomously replicating replicon RNAs 
(Lohmann et al., 1999)., Several mutations (now termed as cell culture adaptive mutations) 
were identified in these autonomously replicating RNAs and it was demonstrated that these 
mutations significantly enhanced the replication of the replicon RNAs (Krieger et al., 2001; 
Lohmann et al., 2001). A major cluster of such mutations was found in NS5A, that increased 
the RNA replication by almost 10,000 fold, along with some mutations present in NS3 and 
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NS5B (Blight et al., 2000; Lohmann et al., 2001). Although some of these mutations have 
been shown to alter the phosphorylation status of NS5A, the exact mechanisms are largely 
unknown (Evans et al., 2004). In 2002 Pietschmann et al. modified the subgenomic replicon 
and generated a selectable full-length replicon containing the entire genome of HCV 
(Pietschmann et al., 2002). This replicon clone could autonomously replicate in vitro, 
although it did not produce any viral particles. Pietschmann et al. hypothesized that Huh7 
cells may lack certain factors that are indispensable for virion production; however this theory 
was disproved by production of viral particles in the same cells by infection with the JFH-1 
clone (Wakita et al., 2005). However, due to the expression of functional viral enzymes, the 
HCV replicon system has proved to be the model of choice for study of viral RNA 
replication, host-pathogen protein interactions and antiviral drug design. 
 
 
Figure 1.10: Schematic representation of the HCV Replicon System. A) sub-genomic replicon, B) 
sub-genomic replicon with all non-structural proteins, C) JFH1 full-length replicon, D) JFH1-J6 
hybrid full-length replicon. Neomycin resistance gene (NeoR) can be replaced by a reporter gene such 
as Luciferase or Secreated Alkaline Phosphatase (SEAP) to produce replicon constructs that can be 
used in transient replication assays. 
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1.4.5. Animal Models 
 
A small animal model is very important to understand the mechanisms that underlie viral 
pathogenesis and would expedite the development of new therapies against HCV infection 
(Ploss et al., 2009b). However HCV has a very limited natural species tropism for humans 
and chimpanzees. Even before the discovery of HCV, infectious studies revealed that the 
chimpanzee (Pan troglodytes) was susceptible to infection by the then-unknown causative 
agent of non-A non-B hepatitis (Alter et al., 1978). Many early studies of NANBH used the 
chimpanzee model. Indeed, the first isolation of HCV was performed in NANBH-infected 
chimpanzee (Choo et al., 1989; Bradley et al., 1991). HCV infection in chimpanzees follows 
a similar course to that observed in humans. Viral RNA is detectable in the plasma within a 
few days after infection, followed by acute hepatitis characterized by a rise in serum 
aminotransferase levels within 2-12 weeks of infection and development of HCV-specific 
antibodies. Although the chimpanzee model has proved to be a relevant model for study of 
functional viral genomics, monoclonal infections, host immune responses and liver gene 
expression (reviewed in (Couto et al., 2006)), its use as an experimental model for HCV 
research is limited for several reasons: firstly, there is a low rate of chronic infection; a lack of 
fibrosis;  a limited availability of animals; their protected species status; ethical constraints 
and high cost of experimentation. The Tupaia belangeri is another primate model of HCV 
infection; however, in a manner similar to chimpanzees, acute infection is quickly resolved 
and these animals rarely develop chronic infection (Xie et al., 1998). No other non-human 
primate has been shown to be permissive to HCV infection.  
 
Perhaps the most promising animal models in the study of HCV are murine models. Several 
groups have developed transgenic mice expressing either one or more HCV proteins (Moriya 
et al., 1997; Pasquinelli et al., 1997) or the complete ORF of HCV (Lerat et al., 2002). 
Although transgenic mouse models have been very useful in study of virally-induced 
pathogenesis, a major drawback of such models is the absence of an immune response against 
these viral proteins. To overcome this limitation, conditional transgenic mice have been 
developed by using Cre/loxP system, in which transgene expression is activated only after 
infection with an adenoviral vector that expresses Cre recombinase (Wakita et al., 2000). 
However, a major flaw of this model is the fact that adenovirus alone has been shown to cause 
hepatitis, hence it remains unclear whether the pathogenic effects observed were caused by 
HCV proteins or by adenoviral proteins.  
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Another murine model is that of xenografted chimeric liver mice, in which human 
hepatocytes, which are permissive for HCV infection, are transplanted into mice. In one such 
model, immunodeficient SCID mice are used which contain a lethal transgene encoding 
urokinase type plasminogen activator (uPA) under the control of a liver specific promoter, 
leading to the targeted destruction of hepatocytes (Mercer et al., 2001; Meuleman et al., 
2005). These depleted hepatocytes are then replaced by a graft of human hepatocytes. These 
mice have been shown to develop a prolonged HCV infection and produce infectious virus 
after inoculation with infected patient’s serum (Mercer et al., 2001) Similarly JFH1 infectious 
viral particles have also been shown to be infective in these mice (Lindenbach et al., 2006; 
Kaul et al., 2007). A similar model was developed by re-colonizing murine liver with human 
hepatocytes in normal mice whose hematopoietic system was reconstituted by using the bone 
marrow of SCID mice after full body irradiation (Ilan et al., 2002). Use of uPA lethal 
transgene makes these mice very difficult to handle because of early hepatotoxicity. Recently 
another similar mouse model, termed the FRG model, has been developed, which  unlike 
uPA-SCID mice, the FRG model allows the prevention of very early hepatotoxic effects via 
the use of 2-(2-nitro-4-trifluoromethylbenzyol)-cyclohexane-1,3-dione (NTBC), thus making 
the mice easier to handle (Azuma et al., 2007).  Despite the fact that these models allow 
researchers to bypass the species barrier of HCV infection, these models have a single major 
drawback: the absence of an immune response. To overcome this flaw, several groups have 
developed parallel xenograft mouse models in which the murine immune system is replaced 
by a functional human immune system by injecting human hematopoietic stem cells. In one 
example, after reconstitution of the immune system, the murine liver cells are destroyed by 
the expression of activated caspase 8 under the control of an inducible liver-specific promoter. 
The murine liver is then re-colonized by human hepatocyte progenitor cells (Washburn et al., 
2011).  
 
As well as being susceptible to HCV infection, these chimeric xenograft mouse models have 
been successfully used in several investigations to test antiviral compounds (Kneteman et al., 
2006; Bissig et al., 2010). Although these models exhibit symptoms of acute HCV infection, 
the development of pathologies associated with chronic infection such as cirrhosis and HCC 
have not yet been reported, indicating that these models are of limited interest for the study of 
chronic HCV associated pathologies (Lerat et al., 2011). In addition, these models require 
human hepatocytes as well as specialized surgical skills, making them technically complex 
models that are therefore not widely available.  
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1.4.6. Viral Vectors for HCV protein expression  
 
HCV subgenomic and full-length replicon systems have been extensively used to study viral 
replication, pathogenesis and protein properties. However, to study the functions and 
pathogenic properties of a particular protein, it may be necessary to analyze that protein out of 
context of other viral proteins or in context of only a few selected viral proteins. Often 
transfection of naked plasmid DNA encoding the gene of interest is used to express a 
particular protein in cultured cells. However, this approach has several drawbacks. Certain 
cell types, particularly primary cells, are resistant to transfection (Gardmo et al., 2005). In 
addition, transfections performed by electroporation or by using transfection reagents affect 
the viability of the transfected cells. Moreover, naked DNA transfections cannot be used to 
deliver transgenes in vivo. Therefore, viral vectors have been developed to as an alternative to 
transfections for delivery of expression vectors into cells. Viral vectors have several 
advantages over transfections: a high transduction efficiency can be achieved without causing 
serious harm to cells, and viral vectors can be used to express transgenes in vivo. However, 
the construction of viral vectors is relatively laborious, hence naked DNA transfections are 
still a method of choice for certain applications.  
 
Hepatoma cells, which are required for efficient culture of HCV in vitro, harbor multiple 
genomic mutations and deletions which impact several cell signaling pathways involved in 
carcinogenesis, therefore impairing any related studies. Therfore, primary cultures of human 
or murine hepatocytes are considered to be the most relevant tools for in vitro studies for 
HCV-induced liver pathogenesis. However, such cells are difficult to transfect by traditional 
methods (as mentioned above). Many studies have reported that viral vectors can be used for 
efficient delivery of transgenes into in vitro cultured primary hepatocytes (Ohashi et al., 2002; 
Seppen et al., 2002), including adeno-associated viral vectors (Snyder et al., 1999; Palmer et 
al., 2005) and baculovirus-derived viral vectors (McCormick et al., 2004), although the latter 
have proved to be less efficient than adenoviral and lentiviral vectors. 
 
1.4.6.1. Adenoviral Vectors 
Adenoviruses are dsDNA viruses of 60-90nm diameter. The main targets of adenoviruses are 
epithelial cells and they cause mild infections of the upper respiratory and gastrointestinal 
tracts. Most infections are self-limiting and asymptomatic, and to date no association between 
adenoviral infections and neoplastic disease has been reported. When injected intravenously, 
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adenoviruses show efficient infection of liver endothelial cells and hepatocytes (Chan 1995). 
This has made modified adenoviruses a promising vehicle for transgene delivery (Benihoud et 
al., 1999). The last-generation adenoviral vector, also called ‘Helper dependent Adenoviral 
vector (HdAd)’ or “gutless adenoviral vector”, has become a vector of choice for in vivo 
transgene delivery (Palmer et al., 2003; Jozkowicz et al., 2005). HdAd are developed by 
deleting all coding sequences from the viral genome and leaving only the inverted terminal 
repeats (ITRs) and a packaging signal ψ (Figure 1.17) (Palmer et al., 2003). The deleted viral 
genes are replaced with a transgene expression cassette and “stuffer” sequence (Kochanek et 
al., 1996). Besides making HdAd safer, the removal of coding sequences also allows the use 
of larger transgene cassettes (Segura et al., 2008). The recombinant adenoviral particles are 
then produced by co-transfection of helper adenovirus genomes into producer cells to obtain 
high titer HdAd vector preparations (Palmer et al., 2003; Sakhuja et al., 2003). These vectors 
have demonstrated an enormous potential as hepatic transgene delivery vehicle without 
causing any chronic inflammation (Brunetti-Pierri et al., 2004; Palmer et al., 2005). Besides 
the high efficacy of transduction, these vectors have been also used for long term transgene 
expression with a single injection of recombinant adenovirus particles (Kim et al., 2001). 
Another important advantage of adenoviral vector is that it is not integration competent and 
has not been associated with any malignant transformations following transduction (Palmer et 
al., 2005). 
 
 
 
Figure 1.11: A schematic diagram of the Helper dependent Adenoviral vector (HdAd) genome. 
The transgene cassette and Stuffer DNA is flanked by inverted terminal repeates (ITR) along with a 
packaging signal (Ψ). 
 
 
1.4.6.2. Lentiviral Vectors 
 
Lentiviral vectors (LVs) developed from Moloney Murine Leukemia Virus (MoMLV) or 
Human Immunodeficiency Virus 1 (HIV-1) have a broad tropism and can stably transduce 
hard-to-transfect quiescent cells (such as neurons and cultured primary hepatocytes) (Lewis et 
al., 1994; Zufferey et al., 1998). Upon entry into the host cell, the ssRNA genome of LVs is 
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reverse transcribed into dsDNA that is actively transported to the host cell nucleus without the 
need of cell division as is  required for other retroviruses (Bukrinsky et al., 1993; Naldini 
1998). Once in the nucleus, viral dsDNA genome is integrated into the host cell DNA hence 
stably transducing the target cell. These characteristics have made LVs an attractive vehicle 
for transgene delivery into mammalian cells. The last generation LVs are replication deficient 
and also lack the accessory genes vpr, vif, nef and vpu hence improving vector safety. Despite 
being replication deficient, LVs are integration competent and have a tendency to integrate 
into transcriptionally active regions (Schroder et al., 2002). This leads to insertional 
mutagenesis and has been reported to cause malignant transformations (Hacein-Bey-Abina et 
al., 2008). The carcinogenetic potential of LVs has created complications for their use as gene 
therapy vectors, although they remain very attractive transgene delivery vehicles for in vitro 
cultured cells (Naldini 1998; Williams 2009). 
 
 
1.5. HCV Life Cycle 
 
Although the liver has been identified as the primary site for HCV replication, some studies 
have suggested the existence of extra-hepatic sites of viral replication. Studies using highly 
specific methods for detection of HCV negative strand RNA have demonstrated that 
peripheral blood mononuclear cells (PBMCs) are permissive for very low levels of HCV 
replication (Cribier et al., 1995; Lerat et al., 1996). It has been further reported that the 
presence of HCV RNA negative strand in PBMCs was higher for genotype 1-infected patients 
as compared to other genotypes and that negative strand RNA could be detected in 
polymorphonuclear leukocytes, monocytes and B lymphocytes but not in T lymphocytes 
(Lerat et al., 1998). Another study has reported the detection of negative strand viral RNA in 
brain tissue of patients with recurrent HCV infection after liver transplantation (Vargas et al., 
2002). However, the existence of extra hepatic reservoirs of HCV is still disputed and role of 
such HCV replication in pathogenesis is yet to be studied. The majority of studies on HCV 
have therefore focused on its hepatic life cycle. 
 
The development of in vitro models capable of sustaining HCV replication and producing 
infectious HCV virions (Lohmann et al., 1999; Wakita et al., 2005); described in detail in 
Section 1.4), have allowed an understanding of viral entry and RNA replication, although the 
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relatively recent discovery of the JFH-1 infectious clone of HCV means that HCV assembly 
and release remain poorly understood (Figure 1.12).  
 
 
 
 
 
 
 
 
 
Figure 1.12: The HCV Life Cycle (from (Pereira et al., 2009) 
The viral particles attach to the cell surface by interacting with receptors. Following endocytosis-
mediated internalization (1, 2), capsids are disintegrated leading to release of genomic RNA into the 
cytoplasm (3). Genomic RNA is used as an mRNA to translate viral proteins (4). Translated viral 
proteins use the genomic RNA to produce negative strand RNA which is then used as template to 
synthesize new genomic RNA strands (5). The new virions are assembled from translated proteins (6) 
and newly-synthesised RNA and exported to the cell surface (7).  
 
 
1.5.1. Virion Attachment and Entry 
 
The viral life cycle starts with virion attachment and subsequent entry into the host cell. Initial 
attachment of the virus to a host cell is believed to be random and nonspecific. It is well 
established that viral particles circulating in the blood of an infected patient are associated 
with LDLs or VLDLs (Nielsen et al., 2006). It has been demonstrated that antibodies against 
Introduction 
 
  27 
LDL-R or the apo-E and apo-B lipoproteins can inhibit HCV infection in a dose-dependent 
manner, suggesting that HCV targets host cells via interaction with the LDL receptor LDL-R 
(Bartosch et al., 2003b; Chang et al., 2007; Molina et al., 2007). Glycosaminoglycans 
(GAGs) have been shown to play an essential but undefined role in HCV virion attachment 
and thus entry into target cells (Barth et al., 2003; Koutsoudakis et al., 2006). It has also been 
reported that two molecules of the C-Type Lectin family; L-SIGN and DC-SIGN, like LDL-R 
and GAGs, help to capture and concentrate circulating viral particles, although they are not 
involved in viral entry(Lai et al., 2006). 
 
Following nonspecific receptors mediated attachment of viral particles to the cell surface; 
virions interact with specific receptors to promote entry into the host cell (reviewed in 
(Dubuisson et al., 2008)).. Several studies have identified four different specific receptors. 
CD81 was the first molecule to be identified as an HCV-specific receptor (Pileri et al., 1998). 
The viral E2 protein has been shown to interact with large extracellular loop (LEL) of CD81 
via four conserved residues L162, I182, N184 and F186 (Drummer et al., 2002; Owsianka et 
al., 2006; Helle et al., 2008). Several studies have confirmed that CD81 is essential for viral 
entry in target cells both in HCVpp and HCVcc models (Bartosch et al., 2003b; Cormier et 
al., 2004; Kapadia et al., 2007). Recently a study has identified certain mutations in envelope 
glycoproteins E1 and E2 that increase their interaction with murine CD81 and enhance viral 
entry into murine hepatocytes by more than 100 fold in the absence of human entry factors 
(Bitzegeio et al., 2010). Although CD81 binding is essential, it is not sufficient for viral entry 
(Zhang et al., 2004; Owsianka et al., 2006).  
 
Another specific viral receptor; the scavenger receptor class B type 1 (SR-B1) is a cell surface 
glycoprotein comprised of two transmembrane domains, one large extracellular loop and two 
short intracellular domains. Inhibition of SR-B1 expression or anti-SR-B1 antibodies have 
been shown to inhibit HCVpp and HCVcc internalization (Voisset et al., 2005; Catanese et 
al., 2007) whereas its over-expression has been shown to increase viral internalization 
(Schwarz et al., 2009). Recently a study has confirmed that SR-B1 plays a specific and direct 
role in HCV penetration into target cells (Catanese et al., 2010). 
 
CD81 and SR-B1 are required but not sufficient for viral entry into target cells. Attempts 
made to identify cellular genes that can render non-permissive cells susceptible to HCV 
infection resulted in identification of Claudin-1 (CLDN1) as an essential viral entry receptor 
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(Evans et al., 2007). CLDN1 is a member of tetraspanin tight junction protein superfamily 
which have play an important role in maintenance of cell permeability and polarity in 
epithelial and endothelial tissues (Lal-Nag et al., 2009). It has been proposed that CLDN1 is 
involved in later stages of viral penetration into target cells, after HCV interaction with CD81 
(Evans et al., 2007). Very recently it has been demonstrated that monoclonal anti-claudin1 
antibodies inhibit HCV infection in cultured primary human hepatocytes (Fofana et al., 2010). 
Although knock-down of CLDN1 expression in cultured hepatocytes makes them less 
permissive, overexpression of CLDN1 does not increase permissiveness to viral entry (Evans 
et al., 2007; Schwarz et al., 2009). 
 
Recently another study has identified another tight junction protein, Occludin (OCLN); as a 
cofactor required for HCV entry (Liu et al., 2009; Ploss et al., 2009a). As for CD81 and SR-
B1, OCLN directly interacts with glycoprotein E2 and functions at late stages of viral entry in 
a similar fashion to CLDN1 (Benedicto et al., 2009; Liu et al., 2009).  
 
When the above described four receptors of human origin (CD81, SR-B1, CLDN1 and 
OCLN) are overexpressed in non-permissive murine or hamster cells (CHO and NIH3T3) 
these cells become infectable by HCVpp suggesting that these four receptors are sufficient for 
viral entry into target cells (Ploss et al., 2009a). These observations gave rise to hopes that a 
murine model permissive to HCV infection was feasible. However  it has been reported that 
transgenic mice expressing all four receptors of human origin were not permissive to infection 
by HCV from patients’ sera nor to entry of HCVpp into hepatocytes (Hikosaka et al., 2011). 
Interestingly, it has been reported very recently that expression of the minimal human factors 
CD81 and occludin is sufficient to allow HCV infection of fully immunocompetent mice 
(Dorner et al., 2011). 
 
It has been suggested that after receptor binding, HCV virions internalized by clathrin-
mediated endocytosis (Hsu et al., 2003; Blanchard et al., 2006; Meertens et al., 2006). After 
endocytosis, viral glycoproteins fuse with the endosomal membrane and release the viral 
genome into cytoplasm (Hsu et al., 2003; Koutsoudakis et al., 2006; Meertens et al., 2006). 
However the detailed mechanisms involved in the fusion and release of viral genetic material 
are still elusive, and require further study. 
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1.5.2. RNA Translation and Polyprotein Processing 
 
Like other single-stranded positive sense RNA viruses, genomic HCV RNA is directly 
translated upon release of the viral genome into the cytoplasm. Host cell ribosomal machinery 
is used to translate the viral genome into the viral polyprotein precursor. Contrary to cellular 
mRNAs, genomic HCV RNA translation is not cap-dependent. Instead, translation occurs 
after binding of the ribosomal 40S subunit to domain II of the IRES, allowing the recruitment 
of eukaryotic initiation factor eIF3 and the subsequent assembly of a complete ribosomal 
complex that translates the viral genome into a polyprotein precursor (Figure 1.13) (Fraser et 
al., 2007) (Tsukiyama-Kohara et al., 1992). This polyprotein precursor is then cleaved by 
viral and cellular proteases to produce ten viral proteins (Grakoui et al., 1993) (for details 
please refer to section 1.3.3.2). 
 
 
 
 
 
Figure 1.13: Schematic diagram of the role of 
the HCV IRES in the assembly of ribosomal 
complexes and translation initiation (adapted 
from (Fraser et al., 2007). 
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1.5.3. RNA Replication, Virion Assembly and Release 
 
HCV genome translation and polyprotein processing leads the release of the HCV proteins, 
and the initiation of viral replication complex formation. The viral replication complex (RC) 
is thought to be formed in modified endoplasmic membrane structures called membranous 
webs (Gosert et al., 2003; Shi et al., 2003). The formation of membranous webs is thought to 
be mediated by NS4B, and it has been demonstrated that NS4B alone can induce such 
structures (Egger et al., 2002). RCs formed inside the membranous web contain the complete 
cellular machinery needed for viral RNA replication (Egger et al., 2002; Waris et al., 2004). 
In a manner similar to other positive strand RNA viruses, the viral genome is transcribed into 
an intermediate RNA of negative polarity which serves as template for the synthesis of 
multiple viral genomic RNAs of positive polarity (Fong et al., 1991; Lohmann et al., 1999). 
Recently it has been demonstrated that negative and positive strand RNAs form a double-
stranded RNA intermediate which undergoes strand displacement to produce nascent strands 
(Targett-Adams et al., 2008). Synthesis of negative polarity RNA as well as positive polarity 
RNA is catalyzed by the viral RNA dependent RNA polymerase (RdRp) NS5B (for detailed 
description of NS5B, please refer to section 1.3.3.9). NS5B has the potential to synthesize 
long RNA molecules without any need of other viral or host cell factors; however, it lacks 
template specificity (Lohmann et al., 1997). It has been propose that other factors (viral and 
cellular) present in the replication complex may play a role to ensure the template specificity 
of the viral RdRp. 
 
The mechanisms surrounding the later steps in viral production are still unclear. It has been 
demonstrated that core protein is found on lipid droplets (LDs) that colocalize with replication 
complexes (Miyanari et al., 2007) and that disruption of interaction between lipid droplets 
and core protein, reduces the production of infective viral progeny (Boulant et al., 2007). 
Newly synthesized viral RNAs destined to serve as genomes for new virions interact with 
LD-associated core protein, inducing its oligomerization and leading to the formation of 
nucleocapsids, which then acquire an envelope derived from host cell membranes carrying 
viral glycoproteins (Figure 1.14) (Tanaka et al., 2000; Nakai et al., 2006; Suzuki 2011). 
Besides the structural proteins, non-structural proteins also play an important role in viral 
assembly. Certain mutations in NS5A that abolish the interaction between NS5A and LDs 
have been shown to reduce the production of infectious particles (Miyanari et al., 2007). 
Other studies have demonstrated important interactions between NS5A and core protein that 
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are essential for viral assembly (Appel et al., 2008; Masaki et al., 2008; Tellinghuisen et al., 
2008). Similarly, several publications have reported the implication of NS2 and NS3 in viral 
assembly (Ma et al., 2008; Dentzer et al., 2009).  
 
 
 
 
Figure 1.14: Assembly of HCV particles. Newly synthesized genomic RNAs (left) come into contact 
with LD–associated Core protein, possibly via an interaction between NS5A and Core. This 
interaction of genomic RNA with Core protein ultimately leads to its encapsidation and nucleocapsid 
formation (right). Then, through still unknown mechanisms, E1 and E2 are added to the nucleocapsid 
and virions are then exported to the cell surface.  
 
 
Newly synthesized virions are then exported to the cell surface via an as-yet-unknown 
mechanism and released into extracellular medium. Not much is known about the further 
maturation and export of virions after nucleocapsid assembly and acquiring of their envelope. 
Some studies have suggested that HCV may exploit LDL/VLDL synthesis and secretion 
pathways to transport progeny virions into the extracellular medium. Another study has 
suggested that, besides secretion, the VLDL secretion pathway may well be important during 
virion assembly (Chang et al., 2007). It has been observed that inhibition of VLDL synthesis 
by inhibitor molecules or by siRNAs targeting apoB reduces the production of infectious 
virions (Huang et al., 2007b; McLauchlan 2009b).   
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1.5.4. Regulation of HCV replication by host factors. 
 
Besides the viral proteins, many host proteins have also been reported to directly or indirectly 
participate in viral replication. HCV RCs appear to be transported to lipid rafts, where HCV 
RNA replication may take place, and it has been demonstrated that HCV replication is closely 
tied to host lipid metabolism (Aizaki et al., 2004). Accordingly, it has been demonstrated that 
apolipoprotein E (apoE) is indispensible for both production and infectivity of virions (Chang 
et al., 2007). More recent studies have reported that the lipid kinase PI4KIIIα is a key factor 
in HCV RNA replication. It has been demonstrated that NS5A plays a role in the activation of 
PI4KIIIα via a direct interaction, and that this interaction is critical for the stability of the 
membranous compartment surrounding the viral RNA replication complex (Borawski et al., 
2009; Vaillancourt et al., 2009; Reiss et al., 2011).  
 
Several host proteins have been reported to directly or indirectly interact with viral proteins 
involved in replication. Cyclophilin B has been shown to directly interact with NS5B, 
regulating its association with viral RNA, and inhibitors of cyclophilin B have been shown to 
reduce viral replication (Watashi et al., 2005). Similarly, cyclophilin A has been reported to 
be essential for HCV replication and suggested to play a role in polyprotein cleavage (Kaul et 
al., 2009). Furthermore, yet other studies have reported that FKBP9, hsp90 and hVAP-B 
proteins interact with NS5A and this interaction is indispensible for viral replication 
(Hamamoto et al., 2005; Okamoto et al., 2006). 
 
Many efforts are currently being made to identify host proteins involved in viral replication. 
Several studies using high-throughput RNAi based screening methods have reported the 
identification of several cellular proteins that are essential for HCV replication (Ng et al., 
2007; Randall et al., 2007; Supekova et al., 2008; Borawski et al., 2009). Although the exact 
mechanisms are not known, these studies have identified several host factors (for example 
TBXA2R, TRAF2, SNARK and PI4KIIIα) whose expression is necessary for efficient HCV 
replication in vitro (Ng et al., 2007). Another study found several host nuclear proteins that 
are essential for viral replication, suggesting that host proteins may also indirectly regulate 
viral replication, possibly via the activation of host cell pathways which impact on HCV RNA 
replication (Li et al., 2009).  
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The high mutation rate of HCV results in the emergence of viral mutants that are resistant to 
antiviral therapies that target viral proteins. Moreover, current antiviral treatment consisting of 
interferon and ribavirin is not equally efficient across different genotypes. Although our 
knowledge about host proteins involved in HCV replication is still very limited, targeting 
interactions between viral and host proteins has been suggested to be a promising approach 
for future design drugs with a greater barrier of resistance as well complementing currently 
available antiviral therapies (Flisiak et al., 2008; Pawlotsky 2011a). 
 
 
1.6. Non-Structural Protein 5A (NS5A) 
 
NS5A is a 446aa proline rich phosphoprotein of 49kDa calculated mass but exists in two 
phosphorylated isoforms: a basal (56kDa) and a hyperphosphorylated (58kDa) form (Tanji et 
al., 1995; Reed et al., 1997). NS5A is a predominantly hydrophilic protein anchored to the ER 
membrane through an amphipathic α-helix present in its N-terminal (Brass et al., 2002; Penin 
et al., 2004b). Despite being essential to viral replication, no precise enzymatic activity has 
been ascribed to it and it is hypothesized that it plays a role in viral replication through its 
interaction with both viral and cellular proteins. 
 
1.6.1. NS5A Structural Features 
 
NS5A is organized into three domains called Domain I (residues 27-213), Domain II (residues 
250-342) and Domain III (residues 356-447) (Figure 1.15) (Tellinghuisen et al., 2004). These 
domains are separated by two linkers known as Low Complexity Sequences (Tellinghuisen et 
al., 2004). The N-terminal region of NS5A carries a highly conserved hydrophobic 
amphipathic alpha helix (residues 1-26) which serves as an ER membrane anchor for NS5A 
(Brass et al., 2002). It has also been suggested that NS5A is a zinc-metalloprotein and can 
form dimers that contain a potential RNA binding groove (Tellinghuisen et al., 2004), a 
suggestion further confirmed by X-ray crystallography studies of NS5A showing that Domain 
I is a zinc binding domain with potential RNA-binding activity (Huang et al., 2005). Recently 
it has been reported that Domain I can also adopt an alternative structure that may be required 
for RNA replication or viral particle assembly (Love et al., 2009). Although the precise 
enzymatic function of Domain I remains elusive, it has proved to be a promising target for 
anti-HCV drugs (Gao et al., 2010). In contrast, Domains II and III are natively unfolded 
(Tellinghuisen et al., 2004; Liang et al., 2007; Hanoulle et al., 2009a; Hanoulle et al., 2010). 
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Although some parts of Domain II can be deleted without any effects, it is indispensible for 
viral RNA replication (Appel et al., 2008; Tellinghuisen et al., 2008; Yang et al., 2010). A 
recent study has demonstrated that Domain II is a substrate for the Peptidyl-prolyl cis/trans 
Isomerase (PPIase) Activity of Cyclophilins A and B (Hanoulle et al., 2009b). Domain III has 
been shown to be not required for viral RNA replication but is essential for viral particle 
assembly in the JFH1 model (Appel et al., 2008; Tellinghuisen et al., 2008). 
 
 
 
Figure 1.15: Schematic diagram of NS5A representing the major structural and functional features. 
NS5A is divided into three domains; Domain I (aa 1- 213), Domain II (aa 250-342) and Domain III 
(aa 356-447) (adapted from (He et al., 2006). 
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1.6.2. Role of NS5A in the viral life cycle 
 
Although no precise enzymatic function is currently known for NS5A, it is an absolutely 
essential component of the HCV replication complex. As described previously, NS5A is a 
zinc binding metalloprotein that is organized into three distinct structural domains 
(Tellinghuisen et al., 2004). The N-teminal Domain I of NS5A has been shown be involved in 
the homodimerization of NS5A. This dimerization results in the formation of a basic cleft that 
shows a high affinity for pyrimidine rich sequences in the untranslated regions of HCV 
genomic RNA (Huang et al., 2005; Tellinghuisen et al., 2005; Love et al., 2009). Interaction 
of NS5A with viral genomic RNA is thought to be critical for viral replication (Huang et al., 
2005). Recently, it has been suggested that NS5A homodimers may come together in large 
oligomer arrays that may transport viral RNA within the cell (Gao et al., 2010). A drug 
(BMS-790052) that is thought to disrupt such NS5A oligomers has proved to be a potent 
inhibitor of HCV replication and is in early clinical trials for anti-HCV therapy (Gao et al., 
2010). 
 
Domain I of NS5A is essential for its interaction with lipid droplets and hence critical for 
virus production (Miyanari et al., 2007). Similarly, Domain III has been shown to play an 
essential role in viral particle assembly (Appel et al., 2008; Tellinghuisen et al., 2008). 
Current data show that there is an inverse correlation between NS5A adaptive mutations that 
facilitate RNA replication and particle assembly (Appel et al., 2005a; Tellinghuisen et al., 
2008). A recent study has reported that phosphorylation of serine 457 in JFH1 replicon 
system regulates viral particle production (Tellinghuisen et al., 2008).  
 
1.6.2.1. NS5A phosphorylation modulates its functions. 
 
NS5A is phosphorylated by several cellular kinases such as casein kinase I-α (CKI-α), casein 
kinase II (CKII), Mitogen activated protein kinase (MAPK), Protein Kinase B (Akt), 
Mitogen-activated protein kinase kinase 6 (MKK6), Glycogen synthase kinase 3 (GSK3) and 
protein kinase alpha (PKA) (Ide et al., 1997; Reed et al., 1997; Kim et al., 1999; Coito et al., 
2004). However, only CKI-α has been shown to be involved in its hyperphosphorylation 
(Quintavalle et al., 2007). NS5A carries three conserved serine clusters in its central and C-
terminal region. These clusters serve as phosphorylation sites; however, only cluster I is 
thought to be responsible for hyperphosphorylation (Quintavalle et al., 2006). It has been 
reported that NS5A phosphorylation occurs after its cleavage from polyprotein precursor and 
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depends upon proper conformation of the protein. Besides cleavage and conformation, NS5A 
phosphorylation also depends on interactions with other viral proteins, for example, 
hyperphosphorylation of NS5A requires the presence of NS3, NS4A and NS4B (reviewed in 
(Huang et al., 2007a)). Although phosphorylation of NS5A does not affect its subcellular 
localization (Tanji et al., 1995), the half-life of NS5A appears to be inversely correlated to its 
degree of phosphorylation (Pietschmann et al., 2001). Cell culture-adaptive mutations 
observed with the subgenomic replicon system which lead to loss of NS5A 
hyperphosphorylation have been reported to enhance viral RNA replication (Blight et al., 
2000; Appel et al., 2005a). Similarly, inhibition of NS5A hyperphosphorylation by using 
small molecule kinase inhibitors enhanced replicon RNA replication (Neddermann et al., 
2004). Moreover, only basally phosphorylated form of NS5A (p56) is found in the 
membranous web along with other viral proteins that make the replication complex (Waris et 
al., 2004). These observations suggest that only the hypo-phosphorylated p56 isoform of 
NS5A is required for HCV RNA replication. As the phosphorylation state of NS5A does 
affect its binding capacity to NS5B RdRp, it was hypothesized that NS5A phosphorylation 
mediates RNA replication through indirect mechanisms. In agreement, it was reported that 
hyperphosphorylation of NS5A inhibits its interaction with human vesicle-associated 
membrane protein-associated protein (hVAP-33) which is involved in intracellular vesicular 
trafficking. This results in a disruption of replication complex formation and an inhibition of 
viral RNA replication (Evans et al., 2004; Gao et al., 2004). More recently it has been 
demonstrated that NS5A phosphorylation may also play direct role in inhibition of viral RNA 
replication by modulating the binding of NS5B to the RNA template (Ivanov et al., 2009).  
 
Taken together, these observations suggest that NS5A may function as a molecular switch 
between viral RNA replication and particle assembly, depending on its phosphorylation state.  
 
1.6.3. Interactions of NS5A with key actors of host cell pathways 
 
Many of the HCV viral proteins interact with host cell signal pathways to modulate them in a 
targeted manner. HCV NS5A has been reported interact with numerous host cell proteins. It 
can be envisaged that both differences in phosphorylation, and the natively unfolded nature of 
Domains II and III,  gives NS5A the ability to adopt different conformations and thus interact 
with many different host proteins (Hanoulle et al., 2009a; Hanoulle et al., 2010). Numerous 
studies have demonstrated that NS5A is involved in the modulation of host immune responses 
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as well as control of the cell cycle and programmed cell death (Gale et al., 1997; Tan et al., 
2001; Macdonald et al., 2005; Verdegem et al., 2011). 
 
NS5A has been implicated in the modulation of host immune responses, especially in the 
inhibition of interferon induced antiviral response through its interaction with the dsRNA-
activated protein kinase (PKR) through its PKR binding region (residues 237-302) (Gale et 
al., 1997). PKR is well known to be involved in the interferon-mediated cellular response to 
viral infections (Hovanessian 1989). However, different studies have shown conflicting 
results regarding the consequences of the interaction between NS5A and PKR. It has been 
reported that NS5A prevents PKR dimerization and thus inhibits interferon antiviral activity 
(Gale et al., 1997; Gale et al., 1998). On the other hand, some studies have suggested that 
NS5A does not interact with PKR and that NS5A-induced inhibition of interferon signaling is 
independent of PKR (Ezelle et al., 2001; Podevin et al., 2001). It has been suggested that, 
besides direct inhibition of the interferon response through interaction with PKR, NS5A may 
also indirectly disrupt interferon response via its interaction with the MAPK signaling 
pathway (He et al., 2002). Furthermore, NS5A has been shown to up-regulate interleukin8 
(IL8, also termed CXCL8) expression, which is known to reduce the antiviral activity of 
interferon, resulting in a weakening of the host antiviral response (Khabar et al., 1997; Polyak 
et al., 2001b). 
Evasion of apoptosis and maintenance of cell survival are very important strategies adopted 
by viruses to ensure persistence of infection. NS5A is able to modulate apoptosis and cell 
growth by interfering with several cellular pathways. Recently it has been described that 
NS5A interacts with FK506-binding protein 38 (FKBP38) and impairs its interaction with 
mammalian target of rapamycin (mTOR) resulting in activation of the mTOR pathway 
leading to inhibition of apoptosis (Peng et al., 2010). Similarly, interactions between NS5A 
and Growth receptor binding protein 2 (Grb2) results in reduced activity of extracellular 
signal regulated kinase (ERK) and MAPK signal transduction pathways resulting in inhibition 
of apoptosis (Chang et al., 2001; He et al., 2002; Georgopoulou et al., 2003). In addition, it 
has been reported that NS5A can interact with the cellular tumor suppressor p53 to cause its 
retention in cytoplasm and reduction of nuclear p53 leading to inhibition of apoptosis (Lan et 
al., 2002). p53 is a transcription factor that induces the transcription of several pro-apoptotic 
genes while inhibiting the transcription of anti-apoptotic genes. Survivin, an anti-apoptotic 
protein that is highly expressed in tumors and often associated with metastasis, is negatively 
regulated by p53 (Muchmore et al., 2000; Sah et al., 2006). A recent study has reported that 
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NS5A activates survivin via the enhanced degradation and interference of nuclear 
translocation of p53, thus contributing to the inhibition of apoptosis in NS5A-expressing 
hepatocytes (Jiang et al., 2011). NS5A has also been reported to interfere with the PI3K-Akt 
cell survival pathway thus providing protection against apoptosis in NS5A expressing cells or 
replicon transfected cells (Street et al., 2004; Macdonald et al., 2005). These studies have 
demonstrated that NS5A can directly activate PI3K through its interaction with p85 regulatory 
subunit and p110 catalytic subunit of PI3K (He et al., 2002). NS5A has also been shown to 
inhibit TNF-dependent apoptosis. It has been demonstrated that NS5A interacts with TNF-R1 
associated death domain (TRADD) and interrupts the TRADD-FADD signaling pathway 
(Majumder et al., 2002; Park et al., 2002; Miyasaka et al., 2003). In addition, another study 
has suggested that NS5A may interact with Bcl2 family proteins to block apoptosis (Chung et 
al., 2003). However these studies have been conducted using either over-expressed or purified 
NS5A and must be interpreted carefully. 
 
Besides preventing programmed cell death by apoptosis, NS5A also induces cell proliferation 
by interfering with cell cycle regulatory pathways. Some studies have suggested that NS5A 
perturbs cell growth by interacting with Grb2 via its C-terminal proline rich region (Tan et al., 
1999; He et al., 2002). NS5A-mediated repression of the Grb2 pathway results in inhibition of 
downstream ERK and MAPK activation (Georgopoulou et al., 2003). Among many other 
activities, the MAPK signaling pathway is known to regulate cell proliferation, suggesting 
that, by interfering with Grb2 and downstream MAPK pathways, NS5A may influence the 
cell cycle.  Cyclin dependent kinases (Cdks) are cell cycle regulatory proteins that control the 
cell cycle progression. The Cdks are in turn regulated by inhibitory proteins such as p15, 
p19and p21Waf1/cip1. Several studies have demonstrated that p21Waf1/cip1 is down-regulated by 
NS5A, resulting in increased cell proliferation (Majumder et al., 2001; Qadri et al., 2002). It 
has been demonstrated that this down regulation of p21Waf1/cip1 byNS5A is dependent on p53, 
where cytoplasmic sequestration inhibition of transcriptional activity of p53 by NS5A results 
in inhibition of p21Waf1/cip1(Majumder et al., 2001; Gong et al., 2004). However these results 
have never been reproduced in vivo or in replicon models that do not use over-expressed 
NS5A. Another study has demonstrated that NS5A forms a heterotrimeric complex with 
TATA box binding protein (TBP) and p53 thus preventing their function as transcription 
factors (Qadri et al., 2002). Although NS5A interactions with cell cycle regulatory proteins 
have been demonstrated, the precise effects of these interactions still remain elusive and need 
further study. 
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Besides above stated pathways, NS5A has been reported to interact with several other cellular 
proteins such as Src-family kinases (Lyn, Lck, Fyn, Hck) (Macdonald et al., 2004), 
amphiphysin II (Zech et al., 2003), karyopherin β3 (Chung et al., 2000) and many others for 
whom exact physiological role remains to be studied. Indeed, some studies have reported that 
inhibition of interaction between a cellular geranylgeranylated protein FBL2 and NS5A 
significantly reduces HCV RNA replication, although the mechanisms underlying these 
observations remain to be detemined (Ye et al., 2003; Wang et al., 2005). 
 
Taken together, these reports suggest that NS5A perturbs the regulation of both apoptosis and 
cell cycle, and therefore may be involved in the initiating events of liver carcinogenesis. 
 
 
1.6.4. Transcriptional activation of host cell genes by NS5A 
 
The central region of NS5A contains two acidic rich (AR) regions: AR1: residues 2143-2184 
and AR2: residues 2220-2273, and one proline rich region (residues 2282-2328) (Figure 1.16) 
(Tanimoto et al., 1997; Tan et al., 1999). These structural characteristics are a typical feature 
of many viral and eukaryotic transcription factors (Hope et al., 1988; Lillie et al., 1989). It has 
been demonstrated that, for transcriptional activation by the HIV-Tat and c-Jun transcriptional 
activators, both acidic and proline-rich regions are essential (Subramanian et al., 1994). In 
accordance with these observations, the central region (residues 163-359) of NS5A has been 
shown to carry transcriptional activation properties and is termed the ‘transcriptional 
activation region’ (Chung et al., 1997; Kato et al., 1997; Tanimoto et al., 1997; Fukuma et al., 
1998). This region is able to transactivate the transcription of the Gal4-lacZ fusion protein in 
yeast simple hybrid experiments. Moreover, it was demonstrated by our group that NS5A 
quasispecies variants isolated from the serum of the same patient, possess different levels of 
transcriptional activation potential in this yeast simple hybrid system (Pellerin et al., 2004). 
The proline rich region of NS5A may play a role in transcriptional activation by providing a 
potential SH3 binding site (Tan et al., 1999; Macdonald et al., 2004). Moreover NS5A also 
carries a putative functional Nuclear Localization Signal (NLS: PPRKKRTVV, residues 354-
362) immediately downstream of the transcriptional activation region.  Although the precise 
role of this NLS is unknown, its presence suggesting that NS5A could be translocated to the 
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nucleus where it may utilize its transcriptional activation properties (Figure 1.13) (Ide et al., 
1996).  
 
 
 
 
Figure 1.16: Schematic representation of the transcriptional activation domain of NS5A. 
 
 
Although NS5A carries a functional NLS, NS5A is localized predominantly in perinuclear 
region (Ide et al., 1996) as it has been demonstrated that the 27 N-terminal amino acids of 
NS5A constitute a small amphipathic alpha-helix that serves as an ER-membrane retention 
signal (Brass et al., 2002). Accordingly, N-terminal deletion mutants of NS5A almost 
exclusively localize to the nucleus, whereas this 27aa alpha helix is sufficient to retain a 
nuclear protein in the cytoplasm (Satoh et al., 2000; Brass et al., 2002). These findings 
suggest that for the NLS to induce nuclear localization, NS5A must first be liberated from its 
N-terminal region anchored into the ER membrane. Accordingly, several studies have 
reported that NS5A is indeed cleaved by both cellular caspases and calpain-like enzymes to 
produce shorter isoforms of NS5A, and that this proteolytic processing of NS5A could be 
inhibited by universal caspase inhibitor zVAD-fmk (Satoh et al., 2000; Goh et al., 2001; 
Kalamvoki et al., 2004). In addition, a recent study has demonstrated that caspase-cleaved 
isoforms of NS5A can translocate to the nucleus (Sauter et al., 2009). 
 
These observations suggest that N-terminally truncated forms of NS5A can translocate to the 
nucleus, where they may play a role in the transcriptional activation of host cell genes. 
Transcriptional activation of host genes by viral proteins may be one of the mechanisms 
adopted by the viral pathogen to interfere with the host immune response and cell cycle and to 
activate the expression of host factors required for viral replication. Such transactivation by 
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viral proteins may also have important consequences in pathogenesis. For example, chronic 
HCV infection is associated with increased serum IL8 levels that may play an important role 
in interferon resistance (Khabar et al., 1997; Polyak et al., 2001a). IL8 is known to reduce the 
antiviral activity of interferon, thus weakening the host cell response against viral pathogens 
(Khabar et al., 1997). It has been demonstrated that by its transactivation activity, NS5A can 
directly enhance activity of the IL8 promoter in reporter construct assays (Polyak et al., 
2001b; Girard et al., 2002).  
 
As mentioned in section 1.1.3, chronic infection by HCV often leads to the development of 
liver cirrhosis and primary hepatocellular carcinoma (HCC). Although cirrhosis is an 
important factor in development of HCC in HCV infected patients, it is likely that the viral 
proteins also play a direct role in the carcinogenesis, although this role is still unclear. As 
previously mentioned, NS5A has been shown to interact with cellular proteins such as p53 to 
modulate the expression of host genes involved in apoptosis and cell cycle regulation. It is 
also possible that the transcactivational activity of NS5A may also play a direct role in the 
development of these pathologies. As described above, NS5A can transactivate the IL8 
promoter (Polyak et al., 2001b). Besides inhibiting IFN response, aberrant levels of IL8 are 
also known to induce angiogenesis, an important factor in development of tumors (Lin et al., 
2004). Similarly, it has been shown that NS5A can transactivate the NS5ATP9 protein (Shi et 
al., 2008). NS5ATP9, also called p15PAF, has been shown to be over-expressed in many 
tumoral tissues including esophageal tumor tissue (Yu et al., 2001), pancreatic cancer cells 
(Hosokawa et al., 2007) and thyroid carcinoma cells (Mizutani et al., 2005), suggesting that 
NS5A mediated activation of NS5ATP9 may play a role in tumorigenesis.  
 
Taken together, these observations suggest that cleavage and translocation of NS5A to the 
nucleus could result in transcriptional activation or inhibition of certain cellular genes, 
including those linked with oncogenesis. Indeed, many viral oncogenic proteins have 
transcriptional regulation activity and can regulate host cell gene expression (Yoshida 1994; 
Kovelman et al., 1996; Van Tine et al., 2004). This hypothesis is further supported by the fact 
that NS5A is the only nonstructural protein of HCV that can be trans-complemented, 
suggesting that NS5A plays a key role in viral replication independent from its role in 
replication complex (Appel et al., 2005b). However, no experimental proof currently exists 
which demonstrates a direct role of NS5A in transcriptional regulation of cellular genes. One 
of the major focuses of research described in this thesis has been to study the direct role of 
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NS5A in transcriptional regulation of cellular genes. As described in the Results section of 
this thesis, I have successfully demonstrated that NS5A is recruited to host gene promoter 
sequences and can control their transcription to enhance HCV RNA replication.  
 
 
1.7. Aims of the Study 
 
As is evident from the above review regarding the functions of the NS5A protein, we are still 
lacking a comprehensive understanding of the complex mechanisms of HCV replication and 
HCV pathogenesis involving NS5A. Although indispensable for HCV replication, no clear 
direct NS5A function have been described so far. 
 
As stated above, HCV is a highly variable virus: in an infected individual, it exists in the form 
of a quasispecies; a complex, unstable mixture of genetically distinct but closely-related 
variants arising from the same inoculum. We propose that the random introduction of 
mutations in the HCV genome may confer novel or enhanced functions to the various HCV 
proteins. This may happen in any given hepatocyte and as a consequence, may trigger 1) the 
initiation of mechanisms leading to the development of liver pathologies such as 
hepatocellular carcinoma and 2) may confer different replication advantages to the 
corresponding virus. In agreement with this hypothesis,  it has been previously demonstrated 
in our laboratory that the transcriptional activation potential differs significantly between 
different NS5A quasispecies variants isolated from serum of an HCV infected patient 
(Pellerin et al., 2004).  
 
Based on these findings, we hypothesized that: (i) similar differences in terms of 
transcriptional activation potential may exist among naturally occurring NS5A quasispecies 
variants isolated from the liver tissue of an HCV infected patient; (ii) that NS5A variants with 
high transcriptional activation properties might interfere with cellular mechanisms thus 
exerting transforming effects on hepatocytes and may result in development of HCC; (iii) and 
that NS5A variants with high transcriptional activation potentials might give replication 
advantages to the corresponding virus in the tumoral environment. 
 
In this context, the initial aims of this project were to develop a novel murine model in which 
patient-isolated NS5A sequences were to be chronically expressed in a liver specific fashion 
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by using a last generation helper dependent adenoviral vector (HdAd). Such a vector would 
also be used for the transduction of difficult-to-transfect primary cell cultures. Then, this new 
model was to be used to understand the impact of the natural variability of NS5A on both the 
replication of viral RNA and on viral pathogenesis. 
 
 
Experimental design:  
 
NS5A variants were first isolated from a patient chronically infected with genotype 1b HCV. 
For the study of the role of NS5A transactivation properties in the development of liver 
pathology, different NS5A variants were screened according to their transactivation properties 
tested in the yeast one-hybrid model. Selected clones were then cloned into a helper 
dependent adenoviral vector, with a view to inducing a lifelong transgene expression in 
transduced mice to enable the study of HCV-related liver pathologies. However, due to 
insurmountable technical difficulties with this system, alternative viral vectors were 
developed. These permitted the pangenomic analysis of cell transcriptomes from NS5A-
expressing primary hepatocytes to identify host cell pathways targeted by NS5A 
transactivation function. In parallel, a sub-genomic HCV replicon model was used to study 
the role of NS5A transactivation properties in viral RNA replication. 
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2 - MATERIALS AND METHODS 
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2.1. Genetic and phylogenetic analysis of NS5A transcriptional activation domain 
quasispecies compartmentalization 
 
Nucleotide and amino acid sequences were aligned with the Clustal X program, 
version 1.8. Distances between pairs of sequences were calculated using the DNADIST and 
PROTDIST modules of the PHYLIP package, version 3.572. The calculation was based on a 
Kimura two-parameter distance matrix with a transition-to-transversion ratio of 4.0 (Smith et 
al., 1997). The mean±SEM within-sample genetic distances were calculated for each sample, 
as well as the mean±SEM between-sample genetic distances (i.e. the genetic distances 
between different compartments from the same patient). To determine whether or not the viral 
quasispecies isolated from different compartment in the same patient were genetically 
different, the mean within-sample and between-sample genetic distances were compared by 
means of the t test. The average number of synonymous substitutions per synonymous site 
was compared to the average number of nonsynonymous substitutions per nonsynonymous 
site within and between each sample, after calculation by means of the Jukes-Cantor 
correction for multiple substitutions (Nei et al., 1986) with the program MEGA [S. Kumar, K. 
Tamura, M. Nei, Molecular Evolutionary Genetics Analysis (MEGA) version 1.02, Institute 
of Molecular Evolutionary Genetics, Pennsylvania State University].  
For phylogenetic analysis, the median branch lengths were calculated by means of a Kimura 
two-parameter distance matrix to create a neighbor-joining tree using the NEIGHBOR 
program in PHYLIP (Felsenstein, J., Cladistics 1989). Bootstrap support was determined by 
1000 resamplings of the sequences. Phylogenetic trees were constructed with both nucleotide 
and amino acid sequences 
 
2.2. Cell Culture 
 
2.2.1. Human Primary Hepatocyte Culture 
 
Cryopreserved primary human hepatocytes were purchased from ZenBio Inc, NC, USA. 
Hepatocytes were thawed according to supplier’s instructions. After thawing, hepatocytes 
were centrifuged for 10 minutes at 4 °C and 100 g, on a PBS-buffered 25% Percoll (Sigma 
Aldrich, St. Louis, MO, USA) gradient prepared in Hepatocyte Plating Medium (ZenBio 
Inc.). Supernatant was discarded and the hepatocyte pellet was resuspended in cold Plating 
Medium. The number and viability of resuspended hepatocytes was analysed using Trypan 
blue (Sigma Aldrich) and a haemocytometer. After counting, cells were resuspended in warm 
Plating Medium and were plated into six-well Primaria Culture Plates (BD Bioscience, MA, 
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USA) at 7.5 x 105 cells/well. Seeded hepatocytes were maintained at 37 °C with 5% CO2 
throughout the experiment. Eight hours post-plating, Plating Medium was replaced with 2mL 
Hepatocyte Maintenance Medium (ZenBio Inc.). 
 
 
2.2.2. NG and 293FT Cells Culture 
 
Hepatoma (NG; Abbott Laboratories, IL, USA) cells were maintained in Dulbecco’s Modified 
Eagle’s Medium (DMEM) supplemented with 10% Fetal Calf Serum (FCS), 100 units/ml 
Penicillin and 100µg/ml Streptomycin (Invitrogen Life Technologies, CA, USA). Human 
kidney cells (293FT; Invitrogen, CA, USA) cells were cultivated in identical media 
supplemented with 1X Non-Essential Amino Acids (Invitrogen).  
 
 
2.3. RNA Isolation 
 
2.3.1. RNA Isolation from Liver Tissue 
 
Liver tissue samples were obtained from patients infected with HCV of genotype 1b. Total 
RNA was isolated from hepatic tissue using a PARIS kit (Ambion, TX, USA) according to 
the manufacturer’s protocol. The quantity and quality of RNA were determined by NanoDrop 
and Agilent Bioanalyser analyses respectively (Agilent Technologies, CA, USA). Only the 
RNA samples with RNA integrity (RIN) > 8 were retained for downstream experiments. RNA 
was stored at -80°C until use. 
 
2.3.2. RNA Isolation from Cultured Cells 
 
RNA was isolated from cultured cells using a PARIS kit, and the quantity and quality of the 
resulting RNA was analysed as described above (section 2.2.1). 
 
2.4. Complementary DNA (cDNA) Synthesis 
 
Total RNA (2µg) isolated from liver tissues or cultured cells was used as a template to 
synthesize complementary DNA using a High Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems, CA, USA) according to the manufacturer’s protocol and stored at -
20°C.   
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2.5. Molecular Cloning 
 
2.5.1. Restriction Enzymes Digests 
 
Typically, two micrograms of DNA were digested with 10-15 U of the  respective restriction 
enzyme (Promega Corporation, Madison, WI, USA; New England BioLabs, Ipswich, MA, 
USA) in a total volume of 50µl using the manufacturer’s recommended buffer. Digestion 
reactions were incubated at 37 °c for 1 hour. After digestion, DNA was treated with 1µl SAP 
(Promega Corporation) which was then inactivated by incubation at 85 °C for 10 minutes. 
Digested DNA samples were electrophoresed on 1% agarose gels, and bands corresponding to 
the expected size(s) were excised and purified with a QIAQuick Gel Extraction Kit (Qiagen, 
Hilden, Germany) according to the manufacturer’s protocol. Purified DNA was eluted in 20µl 
Elution Buffer and stored at -20 °C. 
 
 
2.5.2. Ligation Reactions 
 
Ligation reactions were performed with the Rapid DNA Ligation Kit (Roche Applied Science, 
Indianapolis, IN, USA) according to the manufacturer’s instructions. Fifty nanograms of 
digested and dephosphorylated vector DNA was used for each ligation reaction, with a 1:3 
molar ratio of vector: insert. Ligation reactions were incubated for 10 minutes at room 
temperature and then kept on ice. 
 
 
2.5.3. TOPO Cloning 
 
For all TOPO cloning reactions, 1 µl of purified PCR product was mixed with 1µl TOPO 
Vector (Invitrogen), 1 µl of Salt Solution (Invitrogen) and 3 µl of DNase-free water. 
Reactions were incubated at room temperature for 5 minutes and then kept on ice. 
 
 
2.5.4. Transformation of competent bacteria 
 
For each transformation reaction, 25 µl Top10 One Shot competent E. coli (Invitrogen) were 
thawed on ice. Two microliters of ligation mixture was mixed with competent cells and 
incubated on ice for 15 minutes, followed by heat shocking at 42 °C for 30 seconds in a water 
bath. Cells were again incubated on ice for 2 minutes followed by the addition of 250 µl pre-
warmed SOC medium without antibiotics (Invitrogen) and incubated at 37 °C for 1 hour in 
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shaker incubator at 200 rpm. Cells were then spread on BHI-agar plates containing the 
appropriate antibiotics and plates were incubated at 37 °C overnight. 
 
 
2.5.5. Colony Screening 
 
Colony screening was performed by PCR analysis. The appropriate PCR primers flanking the 
insertion site in the vector were used to amplify the insert. Selected colonies were picked with 
sterile inoculation loops (Sarstedt, France) and resuspended in 25 µl sterile nuclease free 
water in 96-well plates. Five microliters of this suspension was used as a template for 
screening PCR, and a further 5µl was used to inoculate 4 mL of liquid BHI medium (BD 
Bioscience) containing the appropriate antibiotics to make stock cultures for subsequent 
plasmid DNA isolations. 
 
Amplified PCR products were analyzed on 1 % agarose gels, and colonies that produced 
appropriately sized fragments were considered positive. The amplification products from 
these positive colonies were sequenced to confirm the orientation and integrity of the insert.  
 
 
2.5.6. Nucleotide Sequencing 
 
To identify quasispecies variants, to determine orientation of insert or to confirm the integrity 
of cloned constructs, DNA was sequenced by the dye termination method in an ABI 377 
DNA Sequencer (Applied Biosystems) with the ABI PRISM BigDye Terminator v3.0 Cycle 
Sequencing Kit (Applied Biosystems) according to the manufacturer’s instructions. The 
sequence data obtained were analyzed using BioEdit and Vector NTI (Invitrogen) software. 
 
 
2.5.7. Plasmid DNA Purification 
 
2.5.7.1. Small Scale DNA Purification 
 
Plasmid minipreps were performed by alkaline lysis method using a PureLink HQ Plasmid 
Miniprep Kit (Invitrogen) according to manufacturer’s protocol. Plasmid DNA was eluted 
with 75µl TE buffer and quantified with a spectrophotometer using 260 nm wavelength. DNA 
purity was evaluated by ratio of optical density at 260 nm over 280 nm. Only the samples that 
showed 260/280 ratio greater than 1.6, were used in downstream applications. Purified DNA 
was stored at -20°C.  
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2.5.7.2. Large Scale Isolation 
 
Plasmid maxipreps were performed by alkaline lysis method using PureLink HiPure 
Maxiprep Kit (Invitrogen) according to manufacturer’s protocol. After elution, DNA was 
precipitated with isopropanol after centrifugation at 10000 xg for 45 minutes at 4 °C. After 
centrifugation, supernatant was discarded and DNA pellet was air dried and resuspended in 
300µl nuclease free water. DNA was quantified using a spectrophotometer as described 
previously (section 2.4.7.1). DNA concentration was adjusted to 1 µg/µl and stored at -20 °C. 
 
2.5.8. Yeast One-Hybrid Assays 
 
To create yeast one-hybrid vectors, the transcriptional activation domain of isolated NS5A 
sequences (aa 163-359) were cloned into yeast expression vector pGBT9 (Clontech, Takara 
Bio Inc. Shiga, Japan) (Figure 2.1). The NS5A transcriptional activation domain sequences 
were amplified using NS5A-tr-EcoRI and NS5A-tr-BamHI primers. Amplified PCR products 
were purified by a Microcon PCR Purification Column (Millipore, MA, USA). Two 
micrograms of purified DNA and 2µg pGBT9 vector DNA was digested with EcoRI and 
BamHI and ligated to obtain pGBT9-NS5Atr (Figure 2.1). Ligation products were 
transformed into competent cells and colonies were screened as described in sections 2.4.4 
and 2.4.5 respectively. 
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Figure 2.1: Cloning of NS5A transcriptional activation domain into pGBT9. pGBT9 
plasmid DNA and amplified NS5A transcriptional activation domains were digested with 
EcoRI and BamHI enzymes and ligated to produce pGBT9-NS5Atr. 
 
 
2.5.9. Mammalian Expression Vector 
 
For expression of NS5A in cultured cells, HCV quasispecies variants were cloned into the 
pHM6 vector (Roche Life Science). For this purpose, full-length NS5A sequences were PCR 
amplified with NS5A-HindIII and NS5A-BamHI primers. Amplified DNA and vector DNA 
was digested with the appropriate restriction enzymes and then ligated as described in sections 
2.4.1 and 2.4.2 respectively to give pHM6-NS5A (Figure 2.2). Ligation products were 
transformed into competent cells and colonies were screened for the correct inserts as 
described in sections 2.4.4 and 2.4.5 respectively. 
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Figure 2.2: Vector map of pHM6-NS5A. NS5A was cloned into pHM6 using the HindIII 
and BamHI restriction sites. Expression of NS5A in eukaryotic cells is driven by the CMV 
promoter. 
 
 
2.5.10. Subgenomic Replicon Shuttle Vector 
 
A shuttle Vector (p1071) for the subgenomic HCV replicon (genotype 1b) was obtained from 
the Global Research and Development Center (Abbott Laboratories, IL, USA). This replicon 
shuttle vector carries NotI and PacI restriction sites in the 3' regions of NS4B and NS5A 
respectively (Figure 2.3).. However, as the NotI restriction site is present in NS4B at 97 bases 
upstream of NS5A, this site could not be used to clone already isolated full-length NS5A 
quasispecies variant sequences not containing downstream 97 bases of NS4B. To enable the 
cloning of already isolated NS5A quasispecies variants, a silent mutation encoding a 
restriction site for SacII was introduced in both the shuttle vector and in patient derived NS5A 
inserts by site directed mutagenesis 88 bp into NS5A. Subsequently, the region between the 
NotI and PacI restriction sites encoding NS4B and the N-teminus of NS5A was PCR-
amplified from p1071 and cloned into pCR2.1-TOPO. The SacII-PacI fragment 
(encompassing nucleotides 89-1328 of NS5A) in pCR2.1-TOPO was then replaced with the 
SacII-PacI fragment of patient isolated NS5A sequences. Finally the NotI-PacI fragment from 
intermediate vector containing patient derived NS5A, was cloned into replicon shuttle vector 
(Figure 2.3). In addition, the in vitro fitness mutation S2204I (REF) was introduced by site 
pHM6-NS5A
6773 bp
Neomycin resistance
Ampicillin resistance
NS5A-446T5
HA tag
HIS tag
BGH pA
SV40 pA
CMV pro
T7
SP6
f1 ori
SV40 ori/pro
ColE1 ori
BamHI (2212)
HindIII (934)
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directed mutagenesis into all NS5A sequences before being cloned into replicon shuttle 
vector.  
 
 
 
Figure 2.3: The subgenomic replicon shuttle vector. Patient isolated NS5A sequences were 
cloned using NotI and PacI restriction sites. 
 
 
2.5.11. Lentiviral NS5A Expression Vector 
 
For cloning into a Lentiviral expression vector, full-length NS5A sequences were amplified 
by PCR using NS5A-kozak-S containing a modified kozak sequence followed by a start 
codon and NS5A-stop-AS containing two stop codons. Amplification was performed with 
Advantage 2 Polymerase Mix (Clontech) and following cycle: 
 
95°C  5 min 
95°C  20 sec   
58°C  20 sec        35 cycles 
70°C  90 sec 
4°C  Hold 
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NS3
NS4A
NS4B
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Amplified NS5A fragments were cloned into pLenti6.3/V5-TOPO Vector (Invitrogen) as 
described in section 2.4.3 and ligation products were transformed into Stbl3 competent cells 
(Invitrogen) as described in section 2.4.4. Colonies were screened and the inserts were 
sequenced to verify their integrity, as described in section 2.4.5. The pLenti6.3/V5-TOPO 
vectors containing cloned transgene sequences were used to produce Lentiviral particles 
(described in section 2.7). 
 
 
 
Figure 2.4: Vector map of pLenti6.3/V5-TOPO-NS5A. After amplification with NS5A-
kozak-S and NS5A-stop-AS primers, TOPO-TA cloning (section 2.4.3) was used to clone 
NS5A inserts into this vector. 
 
 
2.5.12. Functional analysis of Acid Rich 2 region of NS5A 
 
To study the role of naturally occurring mutations present in Acid Rich 2 region (AR2) of 
NS5A, AR2 regions from strong and weak transactivating NS5A variants were swapped using 
a PCR based swapping strategy adapted from (Deminie et al., 1993) as illustrated in Figure 
2.5. Briefly, AR2 amplification primers B-NS5A-swap and C-NS5A-swap were designed 
such that their 5’ ends were complementary to the ‘receiving’ NS5A sequence whereas their 
3’ ends were complementary to the ‘donor’ NS5A. Primers A (NS5A-NotI primer) and D 
(NS5A-HindIII primer) were entirely complementary to the receiving NS5A sequence. In the 
first step, NS5A fragments that flank the AR2 sequence were amplified from receiving NS5A 
pLenti6.3-NS5A
9047 bp
NS5A
Pcmv
WPRE
Blasticidin
EM7
Ampicillin
pUC ori
HIV-1 psi packaging signal
RRE
SV40 pA
cPPT
pRSV/5'LTR
SV40 promoter
deltaU3/3'LTR
TOPO Site
TOPO Site
RSV promoter
HIV-1 5' LTR
V5 epitope
delta U3
3' LTR
bla (amp) promoter
3 stops
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by primer sets AB and CD, whereas the AR2 sequence was amplified from donor NS5A using 
primer set BC. In the second step, these three fragments were mixed and PCR was performed 
by primer set AD to amplify full-length chimeric NS5A sequences. 
 
 
 
 
Figure 2.5: Schematic representation of PCR based strategy to produce chimeric NS5A 
by exchanging AR2 sequence from another NS5A variant. The dashed lines represent the 
variant NS5A-a while solid lines represent the NS5A-b variant. Straight arrows (labeled A, B, 
C, D, E and F) represent oligonucleotides while bent arrows indicate that oligonucleotide is 
homologous to NS5A-a in one half and to NS5A-b in other half. AB, CD and EF represent 
three amplification products. Adapted from (Deminie et al., 1993). 
 
 
2.5.13. Site-Directed Mutagenesis 
 
To introduce point mutations in cloned sequences, PCR based site-directed mutagenesis was 
performed using the QuickChange II XL Site-Directed Mutagenesis Kit (Agilent 
Technologies). Primers for mutagenesis were designed with QuickChange Primer Design 
Tool (Agilent Technologies) according to the manufacturer’s guidelines. Mutagenesis PCR 
NS5A‐a
NS5A‐b
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reaction was performed according to the manufacturer’s protocol using 50 ng of template 
DNA.  
 
2.6. Construction of an NS5A Adenoviral Vector 
 
To clone patient-isolated NS5A sequences into the helper dependent adenoviral vector, we 
developed a strategy that uses two intermediate plasmids that can be easily recombined by 
Gateway LR recombination to produce the complete NS5A expression cassette. Gateway LR 
recombination uses the specific recombination sites of bacteriophage  and allows quick and 
efficient insertion of a DNA sequence into a plasmid without any restriction digestion. The 
two intermediate plasmids are termed as the Entry and Destination Vectors. The Entry Vector 
contains patient-isolated NS5A sequence that is transferred to the Destination Vector after 
recombination. The Destination vector contains the rest of the sequences required for liver-
specific expression of NS5A (notable: the PEPCK promoter, human factor IX, huGHpA and 
polyadenylation signal). Construction of these vectors and recombination are described in 
following sections. 
 
 
2.6.1. Construction of the Entry Vector 
 
The construction of the entry vector was carried out in following steps: 
 
1)  The T2A chisel sequence was synthesized by PCR using two complementary primers that 
also introduced SrfI and BglI restriction sites at the 5’ and 3’ ends of the T2A sequence 
respectively. The PCR-generated T2A sequence was cloned into pCR2.1-TOPO vector 
(Invitrogen) to produce pCR2.1-TOPO-T2A-SrfI-BglI. Then the sequence between SrfI and 
XhoI sites (125bp) was PCR amplified from pCR2.1-TOPO-T2A-SrfI-BglI using CACC-SrfI-
T2A-S and TopoT2A-XhoI-AS primers. This fragment was cloned into pENTR/D-TOPO 
(Invitrogen) between the attL1 and attL2 sites. This plasmid, pENTR-T2A-XhoI, contained a 
BglI restriction site immediately downstream of the T2A sequence.  
 
2)  As the AscI restrictions sites of pENTR-T2A-XhoI were to be used to clone the complete 
expression cassette into adenoviral genome, the elimination of an extra AscI restriction site in 
pENTR-T2A-XhoI was necessary. To remove this restriction site, pENTR-T2A-XhoI was 
digested with AscI and then treated with the Klenow fragment of Polymerase I (Invitrogen) to 
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fill-in the sticky ends. The blunt ends obtained were ligated with Rapid DNA Ligation Kit 
(Roche Lifescience) to obtain pENTR-T2A-XhoI-ΔAscI. 
 
3) Patient-isolated NS5A sequences were amplified with Bgl1-NS5Apop28-S and NS5A-
Stop-XhoI-AS primers containing BglI and XhoI restriction sites respectively. NS5A-Stop-
XhoI-AS primer also introduced a stop codon at the 3’ end of NS5A.NS5A sequences were 
cloned into the BglI and XhoI restriction sites of pENTR-T2A-XhoI-ΔAscI, and the resulting 
vector was termed pENTR-T2A-NS5A.  
 
2.6.2. Construction of the Destination Vector 
 
A plasmid (pPEPCK-FIX) containing all the sequences required for liver-specific expression 
of the target gene (NS5A) was kindly provided by Dr. Nicola Brunetti-Pieri at Department of 
Molecular and Human Genetics, Baylor College of Medicine, Houston, USA. Two stop 
codons immediately downstream of human Factor IX (FIX) sequence in pPEPCK-FIX 
plasmid were removed by site-directed mutagenesis using QuickChange Mutageneis Kit 
(Agilent Technologies). After deleting the two stop codons, pPEPCK-FIX was converted into 
a Gateway Destination Vector using the Gateway Vector Conversion System (Invitrogen). 
This kit allows the insertion of an LR recombination cassette into any plasmid to convert it to 
a Destination Vector. This kit also allows the insertion of recombination cassette in any of the 
three reading frames to allow continued translation from upstream sequences. We inserted the 
recombination cassette for Reading Frame A (RFA). For this purpose, pPEPCK-FIX was 
digested with SrfI and RFA cassette was ligated into pPEPCK-FIX vector to produce 
pPEPCK-FIX-Dest (Figure 2.10). The ligation products were transformed into ccdB Survival 
Cells (Invitrogen). The RFA gateway conversion cassette encodes a gene conveying 
Chloremphenicol Resistance (CmR) as transformation selection marker as well as the ccdB 
gene  that functions as negative selection lethal gene after homologous recombination (Figure 
2.10). The insertion sites were sequenced to confirm insertion and integrity of the correct 
reading frame.  
 
 
2.6.3. Generation of an NS5A Expression cassette by LR Recombination 
 
The Entry Vector (pENTR-T2A-NS5A) and Destination Vector were recombined to obtain a 
final expression clone (pPEPCK-FIX-T2A-NS5A (Figure 2.11)) containing patient-isolated 
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NS5A sequences as well as all sequences required for their liver-specific expression. This 
recombination was performed using LR Clonase II Enzyme (Invitrogen) according to 
manufacturer’s instructions. Recombination results in the production of a complete expression 
clone and another byproduct plasmid that contains the ccdB lethal gene. After transformation 
of bacteria, expression of ccdB lethal gene results in elimination of all cells that contain the 
byproduct plasmid thus resulting in the survival of only those colonies that contain pPEPCK-
FIX-T2A-NS5A.  
 
2.6.4. Production of Recombinant Adenoviral Particles 
 
Recombinant helper-dependent adenoviral particles were produced in collaboration with Dr. 
Nicola Brunetti-Pieri as described in (Palmer et al., 2003). Briefly, the complete NS5A 
expression cassette (pPEPCK-FIX-T2A-NS5A) was cloned into the AscI restriction sites of 
the helper-dependent adenoviral genome. Recombinant helper-dependent viral genomes was 
transfected into 293Cre cells along with the helper virus AdNG163 . Recombinant viral 
particles were characterized as previously described (Palmer et al., 2003). 
 
 
Figure 2.6: Schematic representation of helper-dependent adenoviral particle 
production. Ѱ indicates the viral genome packaging signal whereas ΔѰ indicates non-
functional packaging signal. ITR = inverted terminal repeats. Red color indicates the 
adenoviral sequence. Green color indicates stuffer DNA sequence while yellow color 
indicates our transgene expression cassette (Adapted from (Palmer et al., 2003)). 
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2.7. Injection of Recombinant Adenoviruses into Mice 
 
Four month old C57Bl6 male mice were transduced with 5 x 105 vp/Kg recombinant 
adenoviruses encoding NS5A or hFIX. Mice were anaesthetized with intra-peritoneal 
injections of 40 mg/Kg body weight sodium pentobarbital (Sigma Aldrich). A fine catheter 
was surgically inserted into the jugular vein and a 20 µl suspension of viral particles in sterile 
isotonic saline solution was administered into jugular vein through the catheter. After 
administration of the viral particles, the catheter was retrieved, the open area was sutured and 
mice were kept in aseptic cages. Blood samples were collected by tail vein incision. Sacrifice 
took place by CO2 euthanasia to collect blood, liver, spleen and kidney tissue samples. 
 
 
2.8. In vitro Transcription and Purification of Replicon RNA 
 
2.8.1. Plasmid Linearization 
 
Twnety-five micrograms of replicon plasmid DNA was linearized by XhoI digestion in a  
final reaction volume of 200µl. After XhoI digest, plasmid DNA was purified by 
Phenol:Chloroform extraction. For this, 200µl Phenol: Chloroform: Isoamyl alcohol (25:24:1) 
(Invitrogen) was mixed with the digested DNA and the sample was transferred to a microfuge 
tube containing PhaseLock Heavy Gel (5Prime). The sample was centrifuged at 10000 g for 5 
minutes to separate the phases, and the aqueous phase was transferred to a new microfuge 
tube.  Then 1/10 volume of 3M NaOAc and 2.5 volumes of 100% ethanol were added, and the 
mixture incubated at -20 °C for 1 hour. Samples were centrifuged at 14000 g for 20 minutes, 
the supernatant discarded and the DNA pellet was washed with ice cold 70% ethanol. The 
resulting pellet was air dried and resuspended in 30 µl of nuclease free water. Linearized 
replicon plasmid DNA was analyzed on a 0.8% agarose gel along with 0.5µg 1kb DNA 
Ladder Plus (Fermentas). DNA concentration was determined using GeneTools software 
(SynGene). 
 
 
2.8.2. In vitro Transcription 
 
Replicon RNA was transcribed from the linearized replicon plasmid DNA using T7 
MegaScript Kit (Ambion) according to the manufacturer’s instructions. 
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2.8.3. Purification and Quantification of in vitro Transcribed RNA  
 
In vitro transcribed RNA was purified using the RNeasy Mini Kit (Qiagen) according to the 
RNA Cleanup Protocol provided by the manufacturer. Purified RNA was quantified with a 
spectrophotometer and the final RNA concentration was adjusted to 1µg/µl. The RNA sample 
was divided into 2µl single use aliquots and stored at -80°C. 
 
 
2.9. Generation and Titration of Lentiviral Particles 
 
pLenti6.3/V5-TOPO vectors containing cloned NS5A sequences (section 2.4.11) were used to 
produce lentiviral particles using the ViraPower HiPerform Lentiviral Expression System 
(Invitrogen) according to the following protocol: 
 
 
2.9.1. Transfection of 293FT Cells 
 
The day before transfection, 5x10 6 293FT cells (Invitrogen) were plated in 10 cm tissue 
culture plates. The next day, culture medium was replaced with 5 mL of Opti-MEM I Medium 
(Invitrogen) supplemented with 10% fetal calf serum and NEAA. In a sterile 15 mL tube, 9 
µg of ViraPower Packaging Mix and 3 µg of pLenti expression plasmid were mixed with 36 
µl Lipofectamine 2000 in 3 mL Opti-MEM I Medium without serum. The mix was incubated 
at room temperature for 20 minutes to allow the DNA-Lipofectamine 2000 complexes to 
form. After incubation, the complexes were added drop-wise to the monolayer of 293FT cells. 
The plates were then incubated at 37 °C in a humidified incubator with 5% CO2. Six hours 
after transfection, the medium was replaced with 10 mL fresh culture medium without 
antibiotics (DMEM supplemented with 10% serum). Transfected 293FT cells were then left 
for 72 hours before harvesting of the infected media. 
 
 
2.9.2. Harvest and Concentration of Lentiviral Particles 
 
Seventy-two hours after transfection, virus-containing culture medium was transferred to a 15 
mL falcon tube and centrifuged at 2000 x g for 15 minutes at 4°C to pellet cellular debris. 
After centrifugation, virus-containing supernatant from three replicate transfections was 
pooled into a fresh 50 mL tube. The cleared supernatant  was mixed with 10mL of 4X LentiX 
Concentrator (Clontech) and incubated at 4 °C for 2 hours, before being centrifuged at 1500 x 
g for 45 minutes at 4°C. After centrifugation, the supernatant was discarded and the virus-
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containing pellet was re-suspended in 3 mL DMEM. The viral suspension was divided into 
single use aliquots containing 1 x 106 cfu and stored at -80°C. 
 
 
2.9.3. Titration of Lentiviral Stock   
 
For the titration of lentiviral stocks, 1 x 105 Huh7.5 cells/well were plated in 6-well cell 
culture plates (Day 0). The next day, the culture medium was replaced with 1 mL of 10-fold 
serial dilutions (10-1, 10-2, 10-3, 10-4, 10-5 and –ve Control) of lentiviral stocks prepared in 
complete culture medium (DMEM supplemented with 10% fetal calf serum and antibiotics) 
(Day 1). The following day, the culture media was replaced with fresh complete culture media 
(Day 2). On day 3, the selection antibiotic Blasticidin (Invitrogen) was added to the culture 
media to a final concentration of 4µg/mL. The culture media was replaced every three days 
with fresh culture medium containing 4µg/mL Blasticidin. On day ~13, when no living cells 
were evident in non-transduced control wells, the cells were fixed with 1 % paraformaldehyde 
in PBS and stained with 0.1 % Crystal Violet in 10 % ethanol. The number of colonies was 
counted in each well and the viral titer was calculated for each well using the following 
formula. The average viral titer for all wells was considered as the viral titer of the stock. 
 
No. of Colonies     = cfu/mL  D = Dilution Factor 
       D x V    V= Volume of diluted virus added to the well 
 
 
2.9.4. Transduction of Cultured Cells 
 
2.9.4.1. Transduction of Primary Hepatocytes 
 
Primary human hepatocytes (1 x 106 cells/well) were plated in 6-well culture plates as 
described in section 2.1.1. Eight hours after plating, Plating Medium was replaced with 1 mL 
Maintenance Medium. Aliquots of lentiviral stocks were thawed at 37 °C in a water bath, and 
3 x 106 cfu (an MOI of 3) was added to each well of primary hepatocytes. The next day, the 
medium was replaced with 2 mL of fresh Maintenance Medium. 
 
 
2.9.4.2. Transduction of Huh7.5 Cells 
 
Huh7.5 cells (2 x 105 cells/well) were plated in 6-well culture plates as described in section 
2.1.2. Six hours after plating, aliquots of lentiviral stocks were thawed at 37 °C in a water 
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bath and 2 x 105 c.f.u (an MOI of 1) were added to each well. The following day, the culture 
medium containing lentiviral particles was replaced with 2 mL of fresh complete medium. 
 
 
2.10. Cell Transfections 
 
2.10.1. Transient DNA Transfections 
 
Transient DNA transfections were carried out using Lipofectamine LTX (Invitrogen) and Plus 
Reagent (Invitrogen). Briefly, NG cells were seeded at 1.5 x 105 cells/well in 6-well culture 
plates in complete culture medium. The next day, liposome complexes containing 2 µg of 
plasmid DNA were prepared according to the manufacturer’s instructions, and incubated at 
room temperature for 30 minutes to allow the formation of DNA-liposome complexes. During 
incubation, the culture medium of cells was replaced with 1.5 mL DMEM supplemented with 
5 % fetal bovine serum. After incubation, 500 µl of the DNA-liposome mix was added drop 
wise to each monolayer and incubated at 37 °C in a humidified incubator with 5 % CO2. After 
6 hours, the culture media was replaced with 2 mL fresh culture medium.  
 
 
2.10.2. RNA Transfections 
 
Transient RNA transfections were carried out using a TransIT mRNA Kit (Mirus Bio LLC, 
WI, USA). Huh7.5 cells were seeded at 2 x104 cells/well in 48-well culture plates in complete 
culture medium. The next day, 250 ng RNA was diluted in 25 µl Opti-MEM I Medium 
(Invitrogen), and  0.25 µl of RNA Boost Reagent was added. Then, 0.5 µl TransIT mRNA 
Reagent was added, mixed well and RNA-liposome complexes incubated at room temperature 
for 5 minutes. During incubation, the culture medium of cells was replaced with 100 µl Opti-
MEM I supplemented with 5 % fetal bovine serum. After incubation, 25 µl of RNA-liposome 
mix was added drop wise to the monolayers, which were then incubated at 37 °C in a 
humidified incubator with 5 % CO2. After 4 hours, the culture media was replaced with 200 
µl fresh culture medium. 
 
 
2.11. Inhibition of Cellular Caspases 
 
To inhibit the activity of cellular caspases, the pan-caspase inhibitor z-VAD-fmk (R&D 
Systems, MN, USA) was added to the culture medium at a final concentration of 20 µM. If 
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the cultured cells were to be kept more than 24 hours, fresh z-VAD-fmk was added every 24 
hours.  
 
 
2.12. Immunofluorescence Analysis 
 
Monolayers of cells were grown on 4-chamber Labtek Chamber Slides (Thermo Scientific). 
The following day, the media was removed and the monolayers were washed twice with PBS. 
Cells were then fixed with -20 °C 100 % Methanol at room temperature for 10 minutes. After 
three further rinses in PBS, cells were incubated with the appropriate primary antibodies in 
PBS for 90 minutes. Cells were again washed three times with PBS, and incubated for one 
hour at room temperature with the appropriate fluorophore-coupled secondary antibodies. 
Cells were then washed twice with PBS and incubated for five minutes at room temperature 
with 1 nM of To-Pro-3 Stain (Invitrogen). Finally, cells were washed two times with PBS and 
once with distilled water and air dried for two minutes before being mounted mounted with 
VectaShield Mounting Medium (Vector Laboratories Inc., CA, USA). 
 
Cells were observed with confocal laser scanning microscope (Leica DMRE-7/TCSSP2, 
Wetzlar, Germany) in conjunction with 62X and 40X objectives using 488 nm argon and 633 
nm He-Ne lasers. Image acquisition and analysis was performed with Leica TCS SP Software 
(Leica Microsystems), and reconstruction of 3D image projections from confocal z-stacks was 
done using Imaris Software (Bitplane AG, Zurich). 
 
 
2.13. Real Time Quantitative Gene Expression Profiling 
 
The expression of cellular geneswas analyzed using custom designed TaqMan Gene 
Expression Array plates (Applied Biosystems) according to the manufacturer’s guidelines. In 
brief, 20 ng of cDNA was used per well (reverse transcribed from total RNA as described in 
section 2.3) and reactions were performed with an Applied Biosystems 7300 Thermal Cycler.  
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2.14. Chromatin Immunoprecipitation Assay 
 
Chromatin Immunoprecipitation (ChIP) assays were performed as described below: 
 
2.14.1. Antibody coating of Protein A Mag Sepharose Beads 
 
Ten microliters of Protein A Mag Sepharose beads (GE Life Sciences, Chalfont St-Giles, UK) 
were resuspended in 1 mL PBS containing 5% bovine serum albumin (Sigma) and 1X 
Protease Inhibitor Cocktail (Roche Life Science). After incubation at 4°C for 3 hours on a 
rotator, an appropriate amount of beads were isolated for use as a Bead Only Control (BOC), 
and8 µl anti-NS5A sheep serum was added to the remainder. Both tubes were then incubated 
at 4°C overnight on a rotator. The following day, 200 µl aliquots of antibody-coated beads 
were transferred to fresh 1.5 mL microfuge tubes and kept on ice until use. 
 
 
2.14.2. Cross-linking and preparation of Chromatin 
 
Transduced Huh7.5 cells or primary human hepatocytes (described in section 2.7.4)  were 
harvested after 72 hours post-transduction. Briefly, the culture medium from cells was 
removed and 2.7 mL fresh DMEM containing 10% FCS was added. Then cells were 
crosslinked by the addition of 0.3 mL 10% formaldehyde solution for 10 minutes at RT. To 
stop cross-linking, 0.3 mL 1.375M Glycine solution was added. Plates were transferred to ice 
and washed three times with cold PBS containing 0.5 mM PMSF. Monolayers were scraped 
and the cells transferred to a fresh 1.5mL microfuge tube, with cells from duplicate wells 
being pooled into a single tube. After centrifugation at 1500 g to pellet the cells, the 
supernatant was discarded and cell pellets were resuspended in 300 µl ChIP Lysis Buffer (10 
mM HEPES, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT, 0.1% NP-40, 1X Protease Inhibitor 
Cocktail). After incubation on ice for 20 minutes, tubes were centrifuged at 5000 g for 5 
minutes at 4 °C to isolate nuclei. The supernatant was discarded and nuclei were resuspended 
in 400 µl Nuclei Lysis Buffer (50 mM Tris-HCl pH 8, 10 mM EDTA, 1% SDS, 1X Protease 
Inhibitor Cocktail). After 30 minutes incubation on ice, each sample was sonicated with a 
VibraCell 75115 Sonicator (BioBlock) for 7 cycles of 20 seconds each at 25% amplification 
with 60 seconds interval on ice after each cycle. After sonication, lysates were centrifuged at 
10000 g for 10 minutes at 4 °C and the resulting chromatin was transferred to a fresh tube. 
The upper lipid layer was discarded. Chromatin was pre-cleared with 5 µl Protein A Mag 
Sepharose beads, and the pre-cleared chromatin was transferred to fresh microfuge tubes and 
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kept on ice. A 50 µl aliquot of pre-cleared chromatin was transferred to another tube and 
stored at -80°C for preparation of Input DNA. 
 
2.14.3. Immunoprecipitation, Washes and Elution of Immune Complexes 
 
For immunoprecipitation, the supernatant of antibody-coated beads (section 2.12.1) was 
removed and 300 µl of pre-cleared chromatin was added. Tubes were incubated at 4 °C 
overnight on a rotator. The next day, tubes were placed on a magnetic rack and supernatant 
was discarded. Beads were then washed three times with 300 µl ChIP Lysis Buffer and 
transferred to fresh microfuge tubes. Immune complexes were eluted by adding 50µl ChIP 
Elution Buffer (20 mM Tris-HCl pH 8, 5 mM EDTA, 1% SDS, 50 mM NaCl, 50µg/ml 
proteinase K) and incubating at 68 °C for 15 minutes in a water bath. This step was repeated 
twice and the two elutes were pooled together. In parallel, input DNA samples were thawed 
and 100µl Elution buffer was added. 
 
 
2.14.4. Reverse cross-linking and DNA purification 
 
Both Input DNA samples and eluted immune complexes were incubated at 68 °C for 6 hours 
to reverse cross-linking.  The volume of each sample was brought to 300 µl with nuclease free 
water and 300 µl Phenol/Chloroform/Isoamyl alcohol (25:24:1) was added to each sample. 
Tubes were vortexed and samples were centrifuged at 10000 g for 5 minutes at 4 °C. The 
resulting aqueous phases were transferred to fresh tubes and 1.5 µl GenElute-LPA DNA 
carrier (Sigma) was added to each sample. DNA was precipitated by adding 0.1 volumes of 
3M NaOAc and 2.5 volumes of cold 100% ethanol. Following incubation for 30 minutes at -
20 °C, tubes were centrifuged at 15000 g for 15 minutes at 4 °C. The supernatant was 
discarded and DNA pellets were rinsed with 70 % ethanol before air drying. The purified 
DNA pellets were resuspended in 20 µl nuclease free water and stored at -20 °C until 
analysis. 
 
 
2.14.5. PCR Analysis 
 
PCR was used to detect the presence of specific promoter DNA sequences in ChIP samples. 
One microliter of ChIP DNA was used in each PCR reaction using the primers described in 
Table 2.1 (sequences in Appendix: Primers). PCR was performed with Advantage Polymerase 
in a Mastercycler Ep thermocycler (Eppendorf). PCR conditions were as follows: 95°C for 5 
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minutes; then 35 cycles of 95°C for 20 seconds, annealing temperature (Table 2.1) for 30 
seconds, 70°C for 45 seconds; followed by 70°C for 10 minutes. Amplification products were 
analyzed on a 1.5 % agarose gel. 
 
 
Gene Primers Annealing 
temperature 
Expected 
Product Size 
Interleukin 8 (IL8) IL8-prom3-S 
IL8-prom3-AS 60 °C 252 bp 
Lymphotoxin β (LTB) LTB-prom1-S 
LTB-prom1-AS 58 °C 155 bp 
NUAK2 NUAK2-prom1-S 
NUAK2-prom1-AS 58 °C 175 bp 
TRAF2 TRAF2-prom-S 
TRAF2-prom-AS 59 °C 249 bp 
MAP2K7 MAP2K7-prom-S 
MAP2K7-prom-AS 57 °C 231 bp 
FBXL2 FBXL2-prom-S 
FBXL2-prom-AS 57 °C 200 bp 
 
 
Table 2.1: List of primers used for ChIP Assays (sequences detailed in Appendix: Primers).  
 
2.15. Protein Analysis 
 
2.15.1.   Protein Quantification 
 
The protein content of cellular lysates was quantified using the Dc Protein Assay (BioRad) 
according to manufacturer’s instructions. Briefly, 2 µl sample aliquots of samples were 
analyzed by a modified Lowry assay, and the resulting absorbance at 690nm was measured. 
Protein concentrations were calculated with reference to the absorptions of protein standards, 
and were expressed as µg/µl total protein. 
 
 
2.15.2.   Western Blotting 
 
2.15.2.1. Denaturing Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
 
Thirty micrograms of protein were combined with XT Sample Buffer (BioRad) and XT 
Reducing Agent (BioRad) at final concentrations of 1X in a total volume of 30 ul. 
Polypeptides were denatured by incubation for 10 minutes at 95 °C and then kept on ice. 
Twenty micrograms denatured samples were loaded on 4-12% Bis-Tris Criterion XT Precast 
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Gels (BioRad) and electrophoresed in XT-MOPS Buffer (BioRad, CA, USA) using Criterion 
Electrophoresis Cells (BioRad) according to manufacturer’s instructions.  
 
 
 
2.15.2.2. Immunoblotting of Polyacrylamide Gels 
 
After electrophoresis, separated proteins were transferred to a Hybond-ECL Nitrocellulose 
Membrane (GE Lifescience) in Transfer Buffer (25 mM Tris, 192 mM glycine, 20% 
methanol).  for 1 hour at 100 V. After transfer, membranes were stained with Ponceau S 
Solution (BioRad) to confirm protein transfer. After saturation for 1 hour in 5 % milk powder 
in TBS containing 0.1% Tween-20 (Sigma), membranes were incubated overnight with 
primary antibodies diluted in 5% fat-free milk in TBST at 4°C on a tube roller. The following 
day, membranes were washed three times with TBS containing 0.1% Tween-20 (TBST) and 
then incubated for 1 hour with the appropriate HRP conjugated secondary antibody diluted in 
5% fat-free milk in TBST. Membranes were again washed three times with TBST, and bound 
antibody was detected with ECL Advance (GE Lifescience) according to manufacturer’s 
instructions. Bands were visualized using a ImageQuant LAS 4000 Mini System (GE 
Lifescience). 
 
 
2.16. Yeast One-Hybrid Assay 
 
For yeast one hybrid assays, S. cerevisiae reporter strain Y187 (MATa, ura3-52, his3-200, 
ade2-101, trp1-901, leu2-3, 112, met-, gal4D, gal80D, URA3::GAL1UAS-GAL1TATA-lacZ 
; Clontech) was used (Clontech).  Y187 contains a stably integrated LacZ reporter gene 
regulated by a wild-type GAL1 promoter. Yeast were transformed with plasmids encoding the 
transcriptional activation domains of isolated NS5A (section 2.4.8) by the lithium acetate 
method following the manufacturer’s recommended protocol provided with the YeastMaker 
Yeast Transformation System (Clontech). pCL1 plasmid (Clontech), encoding wild-type 
GAL4, was used as a positive control for transformation. Transformants were grown on 
tryptophan-deficient synthetic dropout (SD) (trp-) media plates for 3 days at 30 °C. 
 
Reporter gene β-galactosidase activity was measured by a quantitative luminescent assay 
using the Galacto Star kit (Tropix, Perkin Elmer) according to the manufacturer’s protocol. 
Briefly, well-isolated transformed yeast colonies were grown overnight in trp- SD medium for 
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plasmid maintenance. When the optical density (OD600) reached 1.5, 2 ml of this culture was 
then used to inoculate 8 ml of YPD medium (1% bacto-yeast extract, 2% bacto-peptone, 2% 
dextrose) and grown in a shaking incubator at 30 °C up to mid-log phase (OD600 : 0.4 to 0.6). 
A 1.5 mL aliquot was used to prepare cell extracts. For this, the culture was centrifuged and 
the yeast pellet was resuspended in 300 µl of Z lysis buffer provided in the Galacto Star kit. A 
100 µl aliquot was subjected to 2 freeze-thaw cycles, and 20 µl was mixed with 300 µl of 
reaction buffer containing the Galacto Star substrate. After incubation for 20 min at room 
temperature, light emission was measured using Mithras LB940 Luminometer (Berthold 
Technologies). All assays were repeated in triplicate using three independent transformants 
for each construct. The β-galactosidase activity was calculated as a relative value over that of 
vector pGBT9 alone. 
 
 
2.17. Luciferase Reporter Activity Assay 
 
Cells transfected with subgenomic HCV replicons containing the luciferase reporter gene 
were washed with PBS and lysed with Cell Culture Lysis Buffer (Promega). Fifty microliters 
of the lysate was mixed with 25µl Luciferin solution (Promega) and luciferase activity was 
measured with a Mithras LB940 Luminometer (Berthold Technologies). All luciferase 
activity measurements were performed in triplicate. 
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 Phylogenetic and functional analysis of NS5A quasispecies variants 
 
3.1.1. Genetic Compartmentalization of NS5A Quasispecies Variants 
 
In order to investigate the quasispecies sequence variability in the liver tissues, total RNA was 
isolated from tumoral and adjacent non-tumoral liver tissues from six patients infected with 
genotype 1b HCV, and the NS5A sequences amplified by RT-PCR and cloned into pCR2.1-
TOPO vector. For each sample, 30 randomly generated colonies were selected and the 
corresponding NS5A transcriptional activation domain was sequenced. A total of 358 
sequences were generated. Phylogenetic analysis of these sequences allowed the 
characterization of NS5A quasispecies variants in both tumoral and non-tumoral adjacent 
tissue in terms of both quasispecies complexity (Figure 3.1-A) and genetic distance (Figure 
3.1-B). Such analyses revealed that there was lower quasispecies complexity within tumoral 
tissue (lower Shannon Entropy). Moreover, for 3 out of 6 patients, we observed a higher 
genetic distance between quasispecies variants isolated from tumoral tissue versus those 
isolated from non-tumoral adjacent tissue.  
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[B] 
  Amino acid distances +/‐ SD  t test p value 
Patients  Inter N versus T  Intra N  Intra T  N versus T 
1  0.020  0.018  0.020  NS 
2  0.017  0.017  0.015  0.001 
3  0.010  0.007  0.011  0.001 
4  0.030  0.023  0.022  NS 
5  0.044  0.019  0.032  0.001 
6  0.023  0.018  0.018  NS 
 
 
Figure 3.1: The complexity of NS5A transcriptional activation domain quasispecies 
variants in non-tumoural and tumoural liver. [A] A: Normalized Shannon’s entropy was 
calculated for NS5A transcriptional activation domain quasispecies variants (amino acid 
sequences) isolated from tumoral and non-tumoral adjacent tissues from all 6 patients. 
Shannon’s entropy value is 0 when there is no difference i.e., only one variant whereas it is 1 
when all variants differ from each other and are equally represented. [B] To calculate genetic 
distances, CLUSTAL W program was used to align amino acid sequences Distances between 
pairs of amino acid sequences were calculated by using the PROTDIST module in the 
PHYLIP package version 3.572. Calculation was based on a Kimura two-parameter distance 
matrix with a transition-transversion ratio of 4.0. The mean +/-standard deviation within-
sample genetic distances were calculated for each tissue. 
 
 
3.1.2. Functional Compartmentalization of NS5A Quasispecies Variants 
 
As described above, phylogenetic analyses showed a genetic compartmentalization of NS5A 
quasispecies variants in tumoral and non-tumoral adjacent tissues. I next hypothesized that the 
genetic compartmentalization was linked to a functional compartmentalization of NS5A 
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quasispecies variants. As described in section 3.1, our group has previously demonstrated that 
there is a significant difference of transcriptional activation potential among NS5A 
quasispecies variants isolated from serum of an HCV infected patient (Pellerin et al., 2004). 
Therefore, to investigate this hypothesis, I studied the transcriptional activation potential of 
NS5A quasispecies variants.  
 
For this purpose, I cloned the transcriptional activation domains of the isolated NS5A 
quasispecies variants into the yeast one hybrid vector pGBT9 (Figure 3.2) and performed 
yeast one-hybrid assay to analyse the ability of different variants to transactivate the yeast 
GAL4 promoter.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2: Schematic representation of yeast one-hybrid constructs encoding NS5A 
variants. The NS5A transcriptional activation domains (NS5A TrD) were amplified from 
patient’s cDNA and cloned into pGBT9, giving fusions of the Gal4 DNA binding domain 
(BD) with the respective NS5A transactivation domains for each variant. 
 
 
In agreement with previous results (Pellerin et al., 2004), the results of these analyses 
demonstrated that the isolated quasispecies variants of NS5A possessed significantly different 
transcriptional activities irrespective of the compartment (non-tumoral vs tumoral) studied 
(Figure 3.3).  
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Figure 3.3: Transcriptional activation potential of NS5A variants.  The transcriptional 
activation domains of NS5A quasispecies variants isolated from the patients were cloned into 
yeast one-hybrid vector pGBT9 as described in figure 3.3. Yeast one hybrid vectors 
expressing NS5A TrD – GAL4 DNA BD fusion proteins were transfected into yeast. The 
potential of the hybrid proteins to activate transcription of LacZ gene was analyzed by 
quantification of β-galactosidase activity. Results obtained from the variants isolated from 
two of the six patients are expressed as mean ± SEM transactivation levels obtained from at 
least three independent experiments. Dotted bars represent major variants. AU = arbitrary 
units. 
 
 
Interestingly, statistical analysis of the distribution of variants according to their 
transactivation potential and tissue origin demonstrated a significant functional 
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compartmentalization of variants for 4 out of 6 patients (patients 3, 4, 5, 6; Figure 3.4). 
Among these 4 patients, 3 (patients 3, 4 and 6) exhibited a trend whereby variants with 
highest transactivation properties were in tumoral tissue, while one patient (patient 5) 
displayed the opposite trend. Interestingly, of the six patients, the two which developed 
cirrhosis were the two which displayed no functional compartmentalization of NS5A variants. 
 
 
 
 
 
Figure 3.4: Functional compartmentalization of NS5A variants. To analyze the functional 
compartmentalisationtion of NS5A quasispecies variants, the transactivation potential of 
variants isolated from tumoral and non-tumoral adjacent tissues was statistically analyzed 
using a Mann Whitney Rank Sum test. Results are illustrated as box plots, with the median 
transactivation potential of all NS5A variants isolated from tumoral or non-tumoral adjacent 
tissues of each patient depicted. Empty and shaded boxes represent non-tumoral adjacent 
tissues and tumoral tissues respectively. 
 
 
Two hypotheses could be drawn from these observations: i) That quasispecies variants with 
high transcriptional activation potentials were involved in the onset or development of HCC 
by transactivating genes involved in carcinogenesis, and viruses bearing these variants had 
since replicated in the tumors; ii) that variants with high transcriptional activation potentials 
were better adapted to the selective tumoral environment (e.g. highly replicating hepatocytes) 
and were selected for at the expense of others. We investigated both hypotheses, and the 
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results are dealt with in section 3.2 (the first hypothesis) and section 3.3 (the second 
hypothesis) 
 
 
3.2. Role of NS5A transactivational properties in HCV-induced liver pathogenesis 
 
In order to study the role of NS5A variants in cellular transformation and development of 
HCC, we required an expression vector that could be used for long-term expression of NS5A 
variants in vivo in murine livers, as well as for in vitro transient expression in cultured 
primary hepatocytes. We chose to use an adenoviral vector as, on one hand, it can be used to 
transduce mice for long term in vivo expression of transgene, and on the other hand it can be 
used to transduce in vitro cultured primary human or murine hepatocytes for transient 
transgene expression.  To study the role of naturally occurring NS5A quasispecies variants in 
transformation of hepatocytes in vivo and development of hepatocellular carcinoma, we 
selected two NS5A variants from those isolated from tumoral tissues based on their 
transactivation potential and cloned them into a helper dependent adenoviral transgene 
expression vector. 
 
 
3.2.1. Construction of NS5A Adenoviral Vector 
 
Two NS5A variants isolated from patient 4 bearing high and low transactivation potentials 
were selected for the construction of adenoviral vectors for in vivo and in vitro expression of 
NS5A. These variants, renamed from 4T17 and 4T26 to NS5A-V1 and NS5A-V5 
respectively, were selected because they respectively showed the highest and lowest 
transactivation potentials in yeast one-hybrid assays (Figure 3.3). Construction of 
recombinant adenoviral vectors was performed in two major steps; i) Construction of NS5A 
expression cassettes and ii) cloning of NS5A expression cassettes into helper-dependent 
adenoviral genomes and production of recombinant adenoviral particles. 
 
 
3.2.1.1. Construction of NS5A expression cassette 
 
NS5A expression cassettes were designed as bicistronic constructs for the hepatic expression 
of NS5A concomitantly with the expression of human factor IX as a reporter gene (Figure 
3.5). We used the PEPCK promoter to drive liver-specific transgene expression. Human factor 
IX was chosen as reporter gene due to its easy detection by ELISA in the plasma of 
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transduced animals, to the absence of interference with murine hepatocyte functions and its 
non-immunogenicity in mice.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5: NS5A expression cassette for adenoviral vector development. The bicistronic 
expression cassette for NS5A, containing the PEPCK promoter and human Apo1 intron 
sequences located upstream of an open reading frame (ORF) consisting of human factor IX, 
T2A chisel and NS5A sequences, in turn followed by the polyadenylation signal from human 
growth hormone was cloned into a helper-dependent adenoviral vector using AscI restriction 
sites. The recombinant adenoviral genome was then used to produce adenoviral particles 
carrying NS5A expression cassettes in their genome. 
 
 
The construction of NS5A expression cassette necessitated a strategy to easily clone patient-
isolated NS5A sequences. To achieve this, the NS5A expression cassette was constructed by 
Gateway homologous recombination which consists of a recombination of two plasmids 
termed Entry and Destination vectors. The entry vector (pENTR-T2A-NS5A) contained T2A 
Chisel and NS5A variant sequences flanked by the homologous recombination sites attL1 and 
attL2. The 2A-like peptide from the insect virus Thosea asigna (TaV), abbreviated as T2A 
peptide, is a small polypeptide of 19 residues (Donnelly et al., 2001a). All 2A-like peptides 
have a rare consensus motif associated with a novel cleavage mechanism. This cleavage does 
not occur by classical proteolytic mechanism, but rather by inducing a “ribosomal skip” that 
impairs normal peptide bond formation between two amino acids without affecting the 
continuity of downstream translation (Donnelly et al., 2001b). We used the T2A sequence in 
place of an IRES in our bicistronic transgene expression cassette since the use of 2A peptides 
has been demonstrated to produce equal quantities of all genes in a multicistronic transgene 
cassette. Moreover, the relatively small sequence length of 2A peptides (57 bases compared to 
> 300 bases for IRES) can help reduce expression cassette size. 
Results 
 
  76 
 
The destination vector (pPEPCK-FIX-DEST) contained factors needed for efficient 
expression of NS5A including the PEPCK promoter, the human ApoA intron, human factor 
IX, a polyA signal and a homologous recombination cassette inserted between human factor 
IX and the polyA signal. Phosphoenolpyruvate Carboxykinase (PEPCK) is a key enzyme in 
glucose synthesis pathway and is specifically expressed in liver and to a very small extent in 
kidney cells (Hanson et al., 1997). Thanks to the liver-specific expression of PEPCK, the 
PEPCK promoter sequence has become one of the promoters of choice for use in in vivo long-
term liver specific transgene expression (Perales et al., 1994; Kiang et al., 2006). The PEPCK 
promoter is not as strong a promoter as some other liver specific promoters such as hAAT and 
Albumin; indeed it has been demonstrated that PEPCK promoter is ~20 fold weaker than 
albumin promoter, and is hence better adapted to achieve physiologically relevant levels of 
transgene expression for which strong expression is not desired such as viral pathogen 
proteins (Hafenrichter et al., 1994). Human factor IX (FIX) is a blood coagulation factor of 54 
KDa consisting of 415 residues. It has been observed that human FIX is not immunogenic in 
C57BL/6 mice and can be expressed in immunocompetent mice without provoking an 
immune reaction (Herzog et al., 1997). Human FIX is secreted into blood plasma and can be 
easily quantified by ELISA, and can thus be used as a heterologous reporter gene for in vivo 
transgene expression studies in C57BL/6 mice. 
 
 
3.2.1.1.1. Construction of entry vector 
 
The entry vector was constructed in two steps: i) cloning of T2A sequence into pENTR/D-
TOPO to produce pENTR-T2A-XhoI and ii) cloning of NS5A variants into pENTR-T2A-
XhoI. In the first step, the T2A sequence and downstream BglI and XhoI restriction sites was 
amplified by PCR, and cloned into pENTR/D-TOPO by TOPO-TA cloning. (strategy outlined 
in Figure 3.6).  
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An undesirable AscI restriction site in pENTR/D-TOPO was removed by AscI digestion of 
plasmid DNA followed by filling in sticky ends using Klenow fragment of DNA polymerase 
I. Upon relegation, the plasmid was now termed pENTR-T2A-XhoI-ΔAscI (Figure 3.7). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7: Construction of entry vector: Removal of AscI restriction site. To remove the 
unwanted AscI restriction site present in pENTR-T2A-XhoI, plasmid DNA was digested with 
AscI, then treated with Klenow fragment of Polymerase I to fill-in the sticky ends before 
religation. 
 
 
In the second step, patient-derived NS5A sequences were amplified and cloned into pENTR-
T2A-XhoI-ΔAscI to give pENTR-T2A-NS5A (Figure 3.8A). Successful cloning was 
confirmed by BglI and XhoI digestion of plasmid DNA isolated from several colonies. 
Agarose gel electrophoresis analysis of digested DNA revealed two bands corresponding to 
expected fragments of 1343bp and 2661bp (Figure 3.8B). Integrity of the insert was verified 
by nucleotide sequencing. 
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Figure 3.8: Construction of entry vector: Cloning of NS5A into Entry Vector. [A]. NS5A 
was PCR amplified using primers containing BglI and XhoI restriction sites. The amplified 
NS5A was cloned between these sites in pENTR-T2A-XhoI-ΔAscI to obtain pENTR-T2A-
NS5A. [B] Insertion of NS5A into pENTR-T2A-XhoI-ΔAscI vector was confirmed by 
digestion of plasmid DNA with BglI and XhoI, revealing bands of the expected sizes. 
 
 
 
 
[A]
[B]
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3.2.1.1.2. Construction of destination vector 
 
The plasmid pPEPCK-FIX containing all sequences required for liver-specific expression of 
NS5A was kindly provided by Dr. Nicola Brunetti-Pierri  (Baylor College of Medicine, 
Houston, TX). As decribed in Materials and Methods, two stop codons present immediately 
downstream of human Factor IX (FIX) were first removed by site directed mutagenesis 
(Figure 3.9).  
 
 
 
Figure 3.9: Construction of destination vector: Strategy for the removal of stop codons. 
To allow continued expression of downstream sequences, two stop codons present at the end 
of FIX sequence in pPEPCK-FIX plasmid were removed by site directed mutagenesis. 
 
 
pPEPCK-FIX was next converted into a Gateway Destination Vector (Figure 3.10A). A CmR 
resistance marker in the conversion cassette allowed the selection of colonies that contained 
the gateway conversion cassette insert. Restriction analysis of plasmid DNA isolated from 
several colonies by digestion with AscI enzyme revealing the two fragments of expected sizes 
corresponding to 2872bp and 6339bp, confirming the conversion of the plasmid into a 
Gateway Destination Vector (Figure 3.10B). Finally the plasmid DNA was sequenced to 
confirm the integrity and orientation of the insert.  
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Figure 3.10: Construction of destination vector: Generation of Destination Vector [A] To 
convert the vector pPEPCK-FIX-delStop to a gateway cloning compatible destination vector, 
Reading Frame A (RFA) conversion cassette was ligated into blunt ends of SrfI digested 
plasmid pPEPCK-FIX-delStop. The complete destination vector was termed pPEPCK-FIX-
DEST. [B] AscI restriction analysis of plasmid DNA isolated from several colonies to confirm 
the insertion of RFA conversion cassette. 
 
 
3.2.1.1.3. Generation of complete NS5A expression cassette 
 
The Entry (pENTR-T2A-NS5A) and Destination (pPEPCK-FIX-Dest) vectors were 
recombined to obtain pPEPCK-FIX-T2A-NS5A plasmid that carried a complete NS5A 
expression cassettealong with the PEPCK promoter, human Factor IX, human ApoA1 intron, 
T2A, NS5A and human GH pA term sequences (Figure 3.11A). A byproduct plasmid 
produced during recombination was eliminated by antibiotic resistance selection of bacteria 
transformed with the recombination products. Insertion of the T2A and NS5A sequences was 
confirmed by AscI restriction analysis of plasmid DNA isolated from transformed colonies 
[A]
[B]
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(Figure 3.11B). The integrity of inserted sequence, continuity of the reading frame and correct 
orientation of the insert were analyzed by nucleotide sequencing of the resulting vector. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11: Generation of complete NS5A expression cassette. [A] Entry and destination vectors 
were recombined to generate the plasmid that carried the complete NS5A expression cassette. This 
plasmid was termed pPEPCK-FIX-T2A-NS5A and contained NS5A and T2A sequences fused in 
frame with human factor IX reporter gene sequence. [B] AscI restriction analysis of pPEPCK-FIX-
T2A-NS5A-v1 (Lane 1) and pPEPCK-FIX-T2A-NS5A-v5 (Lane 2) plasmid DNA. 
 
[A]
[B]
Results 
 
  83 
3.2.1.2. Production of recombinant adenoviral particles 
 
Before proceeding to the production of adenoviral vector particle stocks, pPEPCK-FIX-T2A-
NS5A carrying complete expression cassettes for NS5A variants v1 or v2 were transfected 
into Huh7 cells and NS5A expression was analyzed 48 hours after transfection by western 
blot. As demonstrated in figure 3.12, no NS5A could be detected in transfected cells, 
suggesting that the vectors did not express NS5A in vitro.  
 
 
 
 
Figure 3.12: Immunoblotting for NS5A expression in transfected cells. Protein extracts 
from cells transfected with indicated plasmids were analyzed by western blotting to detect 
NS5A. Polyclonal sheep anti-NS5A serum was used at 1/500 dilution to detect NS5A. HRP 
conjugated rabbit anti-sheep antibody at 1/10000 dilution was used as secondary antibody. 
Western blot was revealed with ECL Advance reagent. Cells transfected with plasmids 
pHM6-NS5A-V1 and pHM6-NS5A-V5 were used as positive control for NS5A expression. 
 
 
During the course of these experiments, a literature search revealed that the PEPCK promoter 
is strongly suppressed by glucose and insulin, both of which are present at high 
concentrations in cell culture medium (Quinn et al., 2005). This suggested that, although the 
adenoviral vector construct may be functional, the expression of NS5A in transfected cells 
may have been suppressed in cell culture, although this may not have been the case in vivo. 
Following this, we decided to continue with the production of adenoviral particle stocks. 
Plasmids encoding complete expression cassettes for NS5A variants v1 and v2 were sent to 
Dr. Nicola Brunetti-Pierri’s  laboratory where further cloning of NS5A expression cassettes 
into helper dependent adenoviral vector genome and production of infectious adenoviral 
particles was performed. A plasmid carrying expression cassette encoding human FIX was 
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used to produce adenoviral particles to be used as a negative control for adenoviral vector 
based experiments. These cloning and adenoviral production procedures were performed as 
published previously (Palmer et al., 2003). Adenoviral particle stocks were produced for 
NS5A-v1, NS5A-v2 and human FIX and termed as Ad-NS5A-v1, Ad-NS5A-v5 and Ad-FIX 
respectively.  Viral titers of these stocks were determined to be 1.27 x 1013 vp/mL, 5.15 x 1012 
vp/mL and 9.7 x 1012 vp/mL respectively.  
 
3.2.2. Transduction of Murine Livers with NS5A Adenoviral Vectors 
 
Adenoviral vector particles were used to infect mice to induce hepatic expression of the 
various NS5A variants. To study the contribution of NS5A transactivation properties in 
development of HCC, it was important to express equal quantities of both NS5A variants. 
This necessitated the injection of precisely the same number of infectious adenoviral particles 
for each recombinant virus. The tail vein is often used for intravenous injections in mice: 
however, this vein is very fragile and not suitable for the precise injection of small volumes 
(20-30 µl) since a non-quantifiable loss of viral particles into tail tissues cannot be excluded. 
Therefore we chose to inject the viral particles through the jugular vein, after prior insertion 
of a fine catheter by minor surgery. This technique allows the delivery of precise small 
volume doses (20-30µl) without any loss into surrounding tissues. Three C57Bl6 mice per 
clone were injected with recombinant adenoviruses Ad-NS5A-v1, Ad-NS5A-v5 and Ad-FIX 
as described in section 2.6. Blood samples were collected at day 0 (D0; before injection), D1, 
D3, D5, D7, D14 and D21. . As the PEPCK promoter is involved in gluconeogenesis and its 
maximum activation is achieved during fasting, mice were fasted for 12 hours before being 
sacrificed. Sacrifice took place at D3, D7 and D21 by CO2 euthanasia to collect blood, liver, 
spleen and kidney tissue samples. Hepatic protein extracts of sacrificed mice were separated 
on 12 % SDS-PAGE gels, and western blotting was performed to detect NS5A or human FIX 
proteins. Protein extracts from NG cells transfected with pHM6-NS5A plasmid, and human 
serum, were used as positive controls for NS5A and human FIX respectively. Such analyses 
revealed that only mice infected with Ad-FIX expressed human factor IX in their livers. 
Specific bands for neither FIX reporter protein nor NS5A could be detected in Ad-NS5A-v1- 
and Ad-NS5A-v5-transduced mice (Figure 3.13 A and B). GAPDH was used as loading 
control.  
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Figure 3.13: Immunoblotting for FIX and NS5A proteins in transduced mice. Protein 
extracts from the liver tissues of HdAd-infected mice were analyzed by western blotting to 
detect reporter gene human factor IX [A] and NS5A [B]. Pooled human plasma was used as a 
positive control for human FIX western blotting, whereas proteins from liver tissue of a non-
transduced mouse served as a negative control. Similarly, proteins from NG cells transfected 
with pHM6-NS5A were used as a positive control for NS5A western blotting whereas 
proteins from liver tissue of a non-transduced mouse served as negative control. GAPDH was 
used as endogenous loading control. Bands corresponding to 55kDa human FIX, 56kDa 
NS5A and 36kDa GAPDH are indicated. Data are representative of two independent 
experiments. 
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Serum samples from injected mice were assayed by ELISA to detect the presence of secreted 
human FIX. Pooled human serum was used as a positive control. These experiments 
confirmed the presence of secreted human factor IX in plasma of Ad-FIX transduced mice, 
whereas it was absent from the plasma of Ad-NS5A-v1 and Ad-NS5A-v5 transduced mice 
(Figure 3.14). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.14:  ELISA for FIX protein secretion in the plasma of adenovirus-transduced 
mice. Expression of secreted human factor IX reporter protein was analyzed by ELISA in 
plasma of mice transduced with indicated adenoviruses at the indicated time intervals. Pooled 
plasma from non-transduced mice served as negative control. 
 
Taken together, these results suggested that mice infected with adenoviruses encoding NS5A 
(Ad-NS5A-v1 and Ad-NS5A-v5) failed to express both the reporter gene and NS5A transgene 
in transduced mice. One of the possible reasons for these observations may be the low number 
of adenoviral particles used to transduce the mice. To investigate this hypothesis, we repeated 
the above experiment using three times higher doses of adenoviral particles i.e., 1.5x106 vp / 
Kg. However the use of higher doses of adenoviral vector particles resulted in the death of 
injected mice within 24 hours, suggesting a strong acute immune reaction to the higher dose 
of adenoviral vector particles injected intravenously. For these mice, we were not able to 
harvest any blood or tissue samples. 
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3.2.3.  Alternative Strategy: Development of Lentiviral Vector for NS5A Expression 
and Transgenic Mice Expressing NS5A in Liver Tissue 
 
As described in the previous section, we failed to efficiently express NS5A variants in vivo 
using adenoviral vectors. Besides adenoviral vectors, two other viral vectors are appropriate 
for efficient transgene delivery:  retroviral and lentiviral vectors. Two serious drawbacks of 
retroviral vectors are their inability to transduce non-dividing cells such as cultured primary 
hepatocytes, and the random insertion of the viral genome into the host cell DNA. In contrast, 
lentiviral vectors can efficiently transduce non-dividing cells, and thus were chosen as an 
alternative approach to express NS5A variants in cultured hepatocytes, in order to study the 
role of these variants in transactivating host genes. However, as for retroviral vectors, the 
lentiviral vector genome is integration competent, and its use as an in vivo transgene delivery 
vehicle is often associated with cellular transformations leading to development of carcinoma. 
Because of this oncogenic potential, the lentiviral vector system cannot be used for long-term 
in vivo liver transduction, and therefore not for the study of role of NS5A in liver 
carcinogenesis. As an alternative solution for the long-term in vivo expression of NS5A 
variants, we decided to produce transgenic mice expressing strong and weak transactivating 
NS5A variants (detailed in section 3.1.2). 
 
 
3.2.3.1. Construction of Lentiviral Vector for the in vitro study of NS5A 
transactivation properties and their role in pathogenesis 
 
Lentiviral vectors were constructed in two steps: i) the cloning of NS5A into the lentiviral 
vector genome, and ii) the production and characterization of recombinant lentiviral particles. 
 
 
3.2.3.1.1. Cloning of NS5A into lentiviral vector genome 
 
To clone high- and low-transactivating NS5A variants into the lentiviral vector genome, 
NS5A variants v1 and v5 were amplified by PCR (Figure 3.15A) as described in section 
2.4.11. The amplified NS5A fragments were cloned into pLenti6.3/V5-TOPO by TOPO-TA 
cloning and plamsid DNA from the resulting colonies was restriction digested with BamHI 
and analyzed by agarose gel analysis to confirm the insertion of NS5A into the vector (Figure 
3.15D). pLenti6.3-NS5A-v1 and pLenti6.3-NS5A-v5 (Lanes 1 and 3 of Figure 3.15D) exhibited a 
band corresponding to the expected size of 9047 bp, while empty control vector (Lane 2) did not. 
Moreover the plasmid DNA was sequenced to confirm the integrity and orientation of NS5A 
fragments. The resulting plasmids were termed pLenti6.3-NS5A-v1 and pLenti6.3-NS5A-v5 
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pLenti6.3-NS5A
9047 bp
NS5A
Pcmv
WPRE
Blasticidin
EM7
Ampicillin
pUC ori
HIV-1 psi packaging signal
RRE
SV40 pA
cPPT
pRSV/5'LTR
SV40 promoter
deltaU3/3'LTR
TOPO Site
TOPO Site
RSV promoter
HIV-1 5' LTR
V5 epitope
delta U3
3' LTR
bla (amp) promoter
3 stops
pLenti‐NS5A‐v1 NS5A‐V1cPPT pCMV WPRE pSV40
pLenti‐NS5A‐v5
pLenti‐βGAL
NS5A‐V5cPPT pCMV WPRE pSV40
Β‐GalcPPT pCMV WPRE pSV40
(Figure 3.15 B and C). A similar plasmid expressing β-Galactosidase (pLenti6.3-βGal) instead 
of NS5A was used as a negative control. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.15: Schematic representation of NS5A cloning into lentiviral vector. [A] NS5A 
sequences were amplified using the NS5A-kozak-S and NS5A-stop-AS primers. The amplified NS5A 
sequences were then cloned between TOPO cloning sites in the pLenti6.5/V5-TOPO vector. Dotted 
lines depict continued sequences. A complete plasmid map of pLenti6.3-NS5A vector is presented in 
panel [B]. [C] Schematic representation of lentiviral vectors containing indicated NS5A variants or β-
galactosidase gene. [D] Vector DNA was linearized by digestion with BamHI and electrophoresed on 
0.8% agarose gel.  
 
 
[A] 
[B] 
[C] 
[D] 
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3.2.3.1.2. Production and characterization of recombinant lentiviral particles 
 
To produce recombinant lentiviral particles encoding NS5A variant sequences, pLenti6.3-
NS5A was transfected into 293FT cells along with ViraPower Packaging Mix as described in 
section 2.7. Lentiviral particles were harvested from the culture supernatant and titrated using 
NG cells as described in section 2.7.3. The titrations of Lenti-NS5A-v1 and Lenti-NS5A-v5 
are represented in figures 3.16 A and B respectively. Viral titers were determined to be 1.59 x 
106 cfu/mL and 6 x 106 cfu/mL for NS5A-v1 and NS5A-v5 respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.16: Characterization of lentiviral vector stocks: Titration [A] and [B] NG cells 
monolayers in 6-well culture plates were transduced with indicated 10 fold serial dilutions of lentiviral 
particle stocks Lenti-NS5A-v1 or Lenti-NS5A-v5 respectively. Colonies of transduced cells were 
selected against blasticidin resistance and revealed as Crystal Violet stained colonies.  
 
 
 
[A] 
[B] 
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To characterize the NS5A expression in hepatocytes transduced with these lentiviruses, 
cultured human primary hepatocytes were transduced with Lenti-NS5A-v1, Lenti-NS5A-v5 
and Lenti-βGal stocks at an MOI of 3. Extracts of transduced cells were prepared at 72 hours 
post-transduction and examined by western blot analysis (Figure 3.17). NS5A was expressed 
in both Lenti-NS5A-v1 and Lenti-NS5A-v5 transduced cell extracts, but not in Lenti-βGal 
transduced cell extracts. These results demonstrated that lentiviral vector particles for NS5A 
expression could efficiently transduce primary hepatocytes and express the NS5A variants 
encoded. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.17: Characterization of lentiviral vector stocks: Immunoblotting. NS5A expression in 
lentivirus transduced cells. Protein extracts of primary human hepatocytes transduced with indicated 
lentiviruses was analyzed by immuno-blotting at 72 hours post transduction. Actin was used as 
endogenous loading control. Specific bands for 56kDa NS5A and 42kDa actin are indicated. 
 
 
 
3.2.3.1.3. Effect of NS5A transactivation properties on global host cell gene 
expression 
 
We hypothesized that the transactivation properties of NS5A could interfere with host cell 
mechanisms and have a transforming effect on liver cells. In order to investigate this 
hypothesis, we studied the impact of naturally-occurring NS5A variants with high and low 
transactivation potentials on host cell gene expression. For this, cultured primary human 
hepatocytes (from commercially available batches) were transduced with Lenti-NS5A-v1, 
Lenti-NS5A-v2 or Lenti-βGal stocks at an MOI of 3. At 72 hours post-transduction cells were 
harvested and total RNA was extracted. RNA from two independent experiments was pooled 
and subjected to RNAseq analysis using Illumina deep sequencing in collaboration with 
GenoScreen Laboratories in Lille, France. This collaboration is ongoing, and the results of 
these analyses are not yet available.  
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3.2.3.2. Transgenic mice for in vivo studies 
 
As described above, the in vivo study of the role of NS5A transactivation properties in liver 
pathogenesis requires the stable expression of patient-isolated NS5A variants in the hepatic 
tissues of mice. However our first attempt to achieve this goal by using helper-dependent 
adenoviral vectors was unsuccessful, as mice transduced with these vectors failed to express 
NS5A. As an alternative approach, we chose to develop transgenic mice for conditional 
expression of patient-isolated NS5A variants. Traditional methods of transgenesis are based 
on the injection of foreign DNA into the male pronucleus, leading to the random insertion of 
transgene DNA into the host genome. However, such random insertion presents several 
problems, notably the mutation or inactivation of host genes affected by transgene insertion. 
Another problem associated with random insertion is the high variability of transgene 
expression dependent upon the integration site. Therefore, to develop our transgenic mouse 
models, we chose a recently developed technique termed as “Quick knock-in”. This technique 
allows the targeted insertion of transgene DNA into the Rosa26 locus, a neutral locus situated 
in euchromatin. This targeted transgenesis bypasses the risk of host gene mutations and the 
variable expression levels of transgenes. 
 
Using Quick knock-in, we have started the development of two transgenic mouse lines 
expressing NS5A-v1 and NS5A-v5, the highly and weakly transactivating NS5A variants 
respectively. This targeted transgenesis will be combined with a strategy for the conditional 
activation of transgene expression by inserting a loxP-flanked STOP codon between the 
ubiquitous promoter and NS5A transgene sequences. Thus, the activation of NS5A expression 
can be controlled by the expression of the Cre recombinase enzyme, which will be introduced 
by crossing the NS5A transgenic mice with Alb-Cre transgenic mice in which the expression 
of Cre recombinase is controlled by the Albumin promoter. This strategy therefore limits the 
expression of NS5A transgene to the hepatic tissues. 
 
These transgenic mice are being currently developed in collaboration with genOway, a 
company that specializes in transgenesis. The mice are expected to be generated and validated 
within 12 months, at which point studies on the modification of cellular pathways leading to 
cellular transformation and carcinogenesis by NS5A can begin. The data collected from the 
studies will hopefully allow us to demonstrate a direct role of NS5A transactivation properties 
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in the modulation of genes linked to carcinogenesis and the development of hepatocellular 
carcinoma.  
 
3.2.4. Conclusions: 
 
During the course of the studies presented in this thesis, NS5A quasispecies variants isolated 
from HCV 1b infected individuals were characterized in terms of their transactivation 
potentials, and their impact on HCV-induced pathogenesis and in the HCV life cycle was 
studied. 
 
Our results revealed for some patients a genetic compartmentalization of NS5A variants 
between tumoral and adjacent non-tumoral hepatic tissues, suggesting for these patients the 
existence of a selective environment in tumoral or non-tumoral tissues which results in this 
genetic compartmentalization within the same infected organ at a single time point. It was 
further revealed that NS5A quasispecies variants isolated from the liver tissue of HCV-
infected individuals possess different transcriptional activation properties. The high variability 
of the results between patients, and the small number of patients in our cohort did not allow us 
to draw general conclusions on a specific tissue compartment harboring particular NS5A 
transactivation levels during HCV infection in a liver tumor bearing patient. However, a 
functional compartmentalization of quasispecies was demonstrated in a few patients of our 
cohort, for which tumoral tissues were harboring NS5A variants with the highest 
transactivation potential. 
Altogether, these observations led to two hypotheses: i) that quasispecies variants with higher 
transactivation potentials were involved in the onset or development of hepatocellular 
carcinogenesis and ii) such variants were better adapted to the selective tumoral environment 
(e.g. highly replicating hepatocytes, oxidative stress, vascularization etc.) and were selected 
for. We investigated these hypotheses by studying the role of NS5A transactivation properties 
in pathogenesis using murine-based models, and by examining the role of NS5A 
transactivation properties in HCV RNA replication using a subgenomic replicon model.  
 
To study the role of NS5A transactivation properties of NS5A in the perturbation of pathways 
implicated in liver carcinogenesis, an adenoviral vector for NS5A protein expression was 
developed. This adenoviral vector consisted of a last generation helper-dependent adenoviral 
vector (HdAd) in which the transgene expression cassette is inserted in a viral genome that is 
devoid of all coding sequences except inverted terminal repeat sequences and a packaging 
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signal. We successfully constructed NS5A transgene expression cassettes which were inserted 
in HdAd. Recombinant viral stocks were thus produced and used to transduce mice with the 
aim of inducing long-term stable hepatic expression of NS5A. However, our adenoviral 
vector failed to express both the NS5A transgene and the selected reporter gene. As an 
alternative strategy, we chose two complimentary approaches for in vivo and in vitro studies. 
For in vivo studies of the role of NS5A transactivation properties in liver pathogenesis, we 
have begun the development of two transgenic mouse lines expressing NS5A proteins with 
high or low transactivation properties. For in vitro studies on NS5A transactivation properties, 
we have successfully developed lentiviral vectors to express NS5A proteins in cultured 
primary human hepatocytes. To study the effect of these NS5A proteins on host-cell gene 
expression, we are currently performing global transcriptome analyses on primary hepatocytes 
transduced with these lentiviral vectors. This genome-wide approach is being performed by 
deep-sequencing RNAseq technology by Illumina.  
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3.3. Article: Regulation of Hepatitis C Virus Replication by Nuclear Translocation of 
Nonstructural 5A Protein and Transcriptional Activation of Host Genes 
 
As described in previous sections, we have demonstrated that NS5A possesses transcriptional 
activation properties. Furthermore, we have demonstrated that quasispecies variants of NS5A 
possess significantly different potentials of transactivation. However, the physiological 
relevance of these observations is still not clear. Several studies have suggested that 
transactivation potential of viral proteins could play an important role in the replication of the 
corresponding viruses (Tang et al., 2005; Althaus et al., 2010). Therefore we hypothesized 
that the transactivational properties of NS5A may play a role in HCV replication. To test our 
hypotheses we used the sub-genomic replicon model of HCV to study the effect of NS5A 
transactivation capacity on HCV RNA replication. This study has been submitted to the 
Journal of Virology and is presented here in the submitted article form. 
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ABSTRACT 
 
Hepatitis C virus (HCV) non-structural protein 5A (NS5A) is involved in regulating 
viral replication through its direct interaction with the HCV RNA-dependent RNA 
polymerase. NS5A also alters infected cell metabolism through complex interactions 
with numerous host cell proteins. NS5A has been suggested to act as a 
transcriptional activator, although the impact on viral replication is unclear. 
To study this, HCV NS5A variants were amplified from hepatic tissue from an HCV-
infected patient, and their abilities to activate gene transcription were analyzed in a 
single hybrid yeast model. Strikingly, different variants isolated from the same patient 
displayed different transactivational activities. When these variants were inserted into 
the HCV subgenomic replicon system, they demonstrated varying levels of RNA 
replication. Moreover, the replication of these replicons correlated with their 
transactivational activities. We showed that the C-terminal fragment of NS5A was 
localized to the nucleus, and that a functional NS5A NLS and cellular caspase 
activity were required for this process. Furthermore, nuclear localization of NS5A was 
necessary for viral replication. Finally, we demonstrate that nuclear NS5A binds to 
host-cell promoters of several genes previously identified as important for efficient 
HCV RNA replication, inducing their transcription. Taken together, these results 
demonstrate a new mechanism by which HCV modulates its cellular environment, 
thereby enhancing viral replication. 
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INTRODUCTION 
 
Hepatitis C Virus (HCV) infection is characterized by its high frequency of chronicity 
leading to about 130 million carriers, e.g. 2.2% of the worldwide population (27). 
Chronic HCV infection is a major risk factor in the development of chronic hepatitis, 
cirrhosis. It is responsible for development of hepatocellular carcinoma (HCC) or 
primary liver cancer at a rate of 1-4% of cirrhotic patients per year (11, 16). It has 
become the principal cause of primary liver cancer in Japan and modeling of the 
ongoing epidemics predicts a similar trend in Europe (2, 25).  
HCV proteins evolved in their sequence and functions to adapt the fitness of its 
replication in response to the immune and cellular environments. In that matter, the 
non-structural HCV proteins 5A (NS5A) precise enzymatic function remains largely 
unclear. However it has been shown to be a pleiotropic serine phosphoprotein, 
involved in many aspects of viral replication as well as interactions with host cell 
mechanisms (28). NS5A is an essential component of the HCV replication complex 
and plays a key role in viral RNA replication (34, 55). Many studies have suggested 
the potential role of NS5A protein in chronicity of HCV infection and subsequent 
carcinogenesis (32).  
 
HCV NS5A is localized predominantly in the cytoplasm and perinuclear regions 
despite the presence of a functional nuclear localization signal (NLS) in its C-terminal 
region (21, 23). Studies have shown that a small amphipathic α-helix in N-terminus of 
NS5A acts as an ER membrane retention signal (8). Accordingly, the NS5A mutants 
lacking N-terminus region, are almost exclusively localized in the nucleus. It has also 
been demonstrated that cellular caspases cleave the full-length NS5A to produce N-
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terminally deleted products that could translocate to the nucleus and may function as 
transcription factors (15, 23, 42). A recent study using the infectious HCV clone 
JFH1, has demonstrated that N-terminally truncated forms of NS5A are produced 
during viral infection and that these fragments of NS5A translocate to the nucleus 
(43). However physiological relevance of caspase mediated cleavage and nuclear 
localization of NS5A remains elusive.  
 
In this study we demonstrate that HCV NS5A protein nuclear localization is essential 
for in vitro viral RNA replication and that replication capacity is significantly impaired 
when caspase-mediated cleavage of NS5A and its release from endoplasmic 
reticulum is inhibited. We also demonstrate that NS5A transcriptional regulation 
capacity correlates with HCV RNA replication capacity in vitro.  
 
MATERIALS AND METHODS 
 
Cells 
NG cells, highly permissive to HCV RNA replication, were obtained from Abbott 
Laboratories (Abbott Park, IL). This cell line was derived by treatment with interferon-
α from Huh-7 cells carrying a stably-maintained replicon as described previously (31). 
These cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% fetal calf serum, 100 IU/ml penicillin and 100 µg/mL 
streptomycin. 
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Plasmid construction 
HCV subgenomic replicon shuttle vector. A subgenomic replicon shuttle vector 
(genotype 1b, strain Con1) was obtained from Abbott Laboratories (50, 58). This 
shuttle vector contains two unique restriction sites to facilitate the cloning of patient-
derived NS5A sequences: a single NotI site present within NS4B, 97 nt upstream of 
NS5A, and a PacI site present within NS5A, 18 nt upstream of NS5B. NS5A 
originating from pHCV-N (genotype 1b, acc. number #AF139594) was cloned into 
this vector to create SGR-Nim. Cloning of NS5A sequences isolated from patients 
were performed as described (50). 
Isolation and cloning of quasispecies variants. Total hepatic RNA was isolated from a 
single liver biopsy from a patient infected with HCV genotype 1b using a PARIS kit 
(Ambion, Austin, TX) according to the manufacturer’s protocol. Complementary DNA 
was synthesized from isolated RNA using a Superscript III Reverse transcription Kit 
(Life Technologies, Carlsbad, CA). Five NS5A quasispecies variants were amplified 
from patient cDNA using a nested PCR technique as described previously (50). 
Flanking restriction sites NotI and PacI, together with the adaptive mutation S2204I 
were introduced into all amplified NS5A sequences by PCR. Variants were cloned 
into the NotI-PacI site of the subgenomic replicon shuttle vector, and verified by 
sequencing. 
Site-directed mutagenesis. Site directed mutagenesis was performed using a 
QuickChange II XL kit (Agilent Technologies, Santa Clara, CA) according to the 
manufacturer’s instructions. NS5A Nuclear Localization Signal (NLS) was invalidated 
by mutagenesis as previously described by Yeh et al., 2005 (57) using the following 
primers: CCCCTCCAATACCACCTCCAGGGGGAATGGGGACGGTTGTCCTAACAG 
(forward) and 
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CTGTTAGGACAACCGTCCCCATTCCCCCTGGAGGTGGTATTGGAGGGG 
(reverse). Using this approach, the nuclear localization signal was mutated from 
PPPRRKRTVVLTESTL to PPPGGMGTVVLTESTL. Similarly, site-directed 
mutagenesis was performed to introduce a D154E mutation to invalidate a caspase 
cleavage site in NS5A, as described by Kalamvoki et al. (22). The following primers, 
adapted to the HCV 1b sequence, were used: 
ATTCTTCACAGAGGTGGAAGGGGTGCGGC (forward) and 
TAAGAAGTGTCTCCACCTTCCCCACGCCG (reverse). 
 
Lentiviral vector production 
NS5A variants were cloned into pLenti6.3/V5-TOPO (Life Technologies, Carlsbad, 
CA), and the nucleotide sequence of all constructs was verified by DNA sequencing. 
Recombinant lentiviral vector particles were synthesized by using the ViraPower 
HiPerform Lentiviral Expression System (Life Technologies) according to the 
manufacturer’s instructions. Briefly, lentiviral vector particles were produced by 
transient transfection of 5 x 106 293FT cells with pLenti vectors containing different 
NS5A sequences and the ViraPower packaging mix using lipofectamin 2000 (Life 
Technologies). The particles produced were used to transduce 2 x 105 Huh7.5 cells 
in 6-well culture plates to determine viral titer according to the manufacturer’s 
instructions.  
 
Transient replication assay 
Replicon shuttle vector DNA was linearized and purified by phenol-chloroform 
extraction. One microgram of purified DNA was used as a template for RNA 
synthesis using the T7 Megascript Kit (Life Technologies) according to the 
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manufacturer’s instructions. Synthesized RNA was purified using RNeasy Mini Kit 
(Qiagen, Hilden, Germany). 
Monolayers of NG cells seeded in 48-well plates (2 x 104 cells/well) were transfected 
with 0.25 µg RNA/well using TransIT-mRNA reagent (Mirus Bio LLC, Madison, WI) in 
Opti-MEM reduced serum medium (Life Technologies) containing 5% fetal calf serum 
(Life Technologies). Transfected cells (6 wells per construct) were divided into two 
equal samples: three wells harvested at 4 h post-transfection, and three wells 
harvested at 96 h post-transfection. Cells were washed, lysed in Cell Culture Lysis 
Buffer (Promega Corporation, Madison, WI), and the resultant luciferase activity was 
measured with a Mithras LB940 luminometer (Berthold Technologies, Bad Wildbad, 
Germany) in conjunction with luciferin substrate (Promega Corporation). All luciferase 
activity measurements were done in triplicate. Replication efficiency for each replicon 
clone was calculated as described previously (50). 
 
Yeast simple hybrid assay 
Nucleotide sequences encoding the NS5A transactivation domain (nt 6405-6981 of 
the subgenomic replicon) of selected variants was amplified by PCR as described 
previously by Pellerin et al. (38) and cloned into the BamHI-EcoRI sites of the yeast 
expression vector pGBT9 (Clontech, Takara Bio Inc. Shiga, Japan) to generate a 
fusion protein consisting of the NS5A transcriptional activation domain and the GAL4 
DNA-binding domain. The resulting plasmids were transformed into Y187 yeast using 
a Yeast Maker yeast transformation kit (Clontech). Transformants were grown on 
tryptophan-deficient (Trp–) synthetic dropout plates for 3 days at 30 °C, and screened 
by PCR. 
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Transcriptional activation of NS5A-GAL4 fusions were measured by a quantitative 
luminescent ß-galactosidase assay based on the Galacto Star kit (Tropix, Bedford, 
MA) according to the manufacturer’s protocol using an automated Mithras LB940 
luminometer. All assays were repeated with three independent transformants for 
each construct, each analysed in duplicate.  
 
Immunofluorescence 
For immunofluorescence studies, NG cells (0.5 x 105 cells/well) cultured in LabTek 4-
chamber slides (Thermo Fisher Scientific Inc., Waltham, MA) were transduced with 
lentivirus particles at multiplicity of infection (MOI) of 1.5. Forty-eight hours post-
transduction, cells were fixed with ice-cold 100% methanol at room temperature for 
five minutes, washed with PBS and incubated for 2 hours at room temperature with 
rabbit anti-NS5A polyclonal antibody (9). Bound antibody was detected with anti-
rabbit FITC-conjugated secondary antibody (Sigma Aldrich, St. Louis, MO), and 
cellular DNA marked with 1 µM of To-Pro-3 DNA stain (Life Technologies).  Samples 
were analyzed with a confocal laser scanning microscope (Leica DMRE-7/TCSSP2, 
Wetzlar, Germany) in conjunction with a 63X oil immersion objective and 633 HeNe 
and 488nm argon lasers. Confocal image z-stacks were obtained using optical slice 
intervals of 0.2 µm from the bottom to top of the cell, with three scans made per slice. 
The mean of the signal was recorded, and Imaris software (Bitplane AG, Zurich, 
Switzerland) was used to reconstruct 3D image projections. 
 
Immunoblotting 
Cells were lysed with Cell Culture Lysis Reagent (Promega), separated by SDS-
PAGE, and immobilized onto Hybond ECL Nitrocellulose membrane (GE Healthcare, 
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Chalfont St-Giles, UK). Bound polypeptides were detected using sheep anti-NS5A 
antibody (kindly provided by Pr Mark Harris, University of Leeds, UK), rabbit anti-
GAPDH (Abcam, Cambridge, UK), or mouse anti-actin antibody (Sigma Aldrich, St. 
Louis, MO). Immunodetection was achieved by enhanced chemiluminescence (GE 
Healthcare) in conjunction with horse-radish peroxidase conjugated anti-sheep 
(Sigma Aldrich) or anti-mouse (Sigma Aldrich) antibodies. Chemiluminescent signals 
were detected and quantified using an Image Quant Las 4000 Mini scanner and 
Image Quant software (GE Healthcare). 
 
Caspase inhibition assays 
NG cells were treated with the pan-caspase inhibitor z-VAD-fmk (R&D Systems Inc., 
Minneapolis, MN) at 10 µM or 20 µM final concentrations, two hours prior to 
transfection with replicon RNA. Four hours post-transfection, culture medium was 
changed and fresh z-VAD-fmk was added at the appropriate concentrations. 
 
Real-time quantitative gene expression assay 
Total RNA was extracted from NG cells transduced with the appropriate lentiviral 
expression vector particles (72 hours post-transduction) using a PARIS RNA Isolation 
Kit (Ambion). RNA quality and quantity were determined using a 2100 Bioanalyser 
and RNA Nano Chips (Agilent Technologies, Santa Clara, CA). RNA integrity number 
was calculated using the Agilent software, and samples displaying an RNA integrity 
number below 6 were discarded. 
Complementary DNA was synthesized using a High Capacity cDNA Synthesis Kit 
(Applied Biosystems, Life Technologies). Quantitative PCR was performed on pooled 
cDNA from two independent experiments using Applied Biosystems 7300 Thermal 
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Cycler and Taqman reagents (Applied Biosystems; see table 1 for primer 
information).  
 
Chromatin Immunoprecipitation 
NG cells were transduced with lentiviral vector particles at an MOI of 1.5. Forty-eight 
hours post-transduction, cells were fixed with 1% formaldehyde, lysed in 10 mM 
HEPES, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT, 0.1% NP-40 and protease 
inhibitors cocktail (Roche Applied Science, Indianapolis, IN), and nuclei were 
recovered and lysed in 50 mM Tris-HCl pH 8, 10 mM EDTA, 1% SDS, and protease 
inhibitors, and DNA sheared by sonication. Sheared chromatin was pre-cleared by 
incubation with Protein G Mag Sepharose beads (GE Healthcare) and incubated with 
rabbit-anti NS5A antibody. The precipitated DNA was purified by phenol/chloroform 
extraction and amplified by PCR using the following primers: IL8 5’-
GTTGTAGTATGCCCCTAAGAG-3’ (forward) and 5’-
CTCAGGGCAAACCTGAGTCATC-3’ (reverse); LTΒ 5’-
TACGGGCCTCTCTGGTACAC-3’ (forward) and 5’-ATATTCCCTCACCCCACCAT-3’ 
(reverse); NUAK2 5’-CCTGAAGTTGCTGCTGTGAA-3’ (forward) and 5’-
CCTGAAGGCCTAGAGAACACA-3’ (reverse); MAP2K7 5’-
AACGAGGTTCCAGGAATGC-3’ (forward) and 5’-GAAGGATGACGCCACCTAGA-3’ 
(reverse); TRAF2 5’-GGGAAGGGACCCAATTAGC-3’ (forward) and 5’-
CAGCCCTCAGGAAGCTGTAG-3’ (reverse); FBXL2 5’-
TGGGGTGAGTGTCGTTTTATC-3’ (forward) and 5’-
CGTATCTGGTCCATCCTCTCA-3’ (reverse). DNA immunoprecipitated from cells not 
expressing NS5A was used as a negative control. 
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Statistics 
Statistical comparisons of the data were performed using a Mann-Whitney test where 
appropriate. P values of less than 0.05 were considered statistically significant. All 
error bars indicate standard error of the mean. 
 
RESULTS 
Naturally occurring NS5A variants are associated with different transcriptional 
activation capacities in vitro 
The sequence of the five NS5A full length variants amplified from an HCV-infected 
patient’s liver extract is shown in Figure 1. Amino acid differences were observed 
over the full NS5A sequence, but were more frequent between amino acids 210 and 
450, a region which encompass the NS5A transactivation domain. In order to verify 
our previous findings that naturally occurring NS5A variants are associated with 
different transcriptional activation capacities in vitro (38), the NS5A transactivation 
domain (underlined in Figure 1) was amplified by PCR. The amplified domains, which 
were confirmed to be identical in sequence to the full-length variants, were 
subsequently cloned into the pGBT9 yeast expression vector to generate fusion 
proteins consisting of the NS5A transcriptional activation domain fused to the GAL4 
DNA-binding domain (Figure 2A). The capacity of each fusion protein to activate lacZ 
transcription (and thus β-galactosidase expression) was assayed in yeast. As shown 
in Figure 2B the five tested variants (v1 to v5) exhibited markedly different 
transcriptional activities in vitro, with the weakest activator (NS5A-v5) exhibiting 
transcriptional activities approximately 1 log below the activity of the strongest 
activator (NS5A-v1). 
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Naturally occurring NS5A variants are associated with different HCV RNA 
replication efficiencies in vitro  
To test the hypothesis that NS5A mutations naturally occurring in vivo could be 
associated with different replication capacities of the corresponding variants, the five 
distinct NS5A variants isolated from the liver of a patient infected with HCV genotype 
1b (variants v1 to v5) were cloned into a subgenomic replicon shuttle vector (50) 
containing a luciferase reporter gene and the replication capacity of the 
corresponding replicons was measured (Figure 3A). Western blotting analysis 
revealed that the five variants expressed NS5A at the same level 4 hours post-
transfection, i.e. in the timeframe of translation of the transfected RNA (Figure 3B, 
top panel). In contrast, at 96 hours post-transfection, the different constructs 
exhibited different levels of NS5A expression, suggesting that different NS5A variants 
could be associated with different replication capacities of the corresponding 
replicons (Figure 3B, lower panel).  
To assess the replication efficiencies of replicons harboring the different NS5A 
variant sequences, we quantified the luciferase activity from replicon-transfected cell 
extracts (Figure 3C). Different replication levels were observed, including higher (v1), 
nearly identical (v2 and v3) and lower replication efficiencies as compared to the wt 
subgenomic replicon (Figure 3C). In the latter, the replication level was close to that 
of a replicon containing a deficient RNA polymerase. Together, these results 
demonstrate that naturally occurring NS5A variants are associated with different RNA 
replication efficiencies in vitro. 
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HCV RNA replication efficiency in vitro correlates with NS5A variant 
transcriptional activation capacity 
As shown in Figure 3D, we found a statistically significant correlation (R2=0.9801, 
p<0.01) between the transactivation capacities of NS5A variants in vitro and the in 
vitro replication efficiency of the corresponding replicons. This result suggests that 
HCV RNA replication efficiency is, at least partly, related to the transcriptional 
activation properties of NS5A. 
 
NS5A nuclear localization is dependent upon NLS-driven nuclear import and 
cellular caspase activity. 
The transcriptional activation function of NS5A requires that at least a subset of this 
protein be translocated into the nucleus. In order to determine whether NS5A re-
locates to the nucleus, we performed immunofluorescence analysis of cells harboring 
the stable subgenomic replicon I389-neo/NS3-3’/5.1 (1), by means of confocal 
microscopy and 3D-reconstruction. A proportion of NS5A localized to the nucleus of 
cells stably harboring I389-neo/NS3-3’/5.1 (Figure 4A). To confirm these results in 
the absence of viral replication, we cloned NS5A-v1 or NS5A-v5 into a lentivirus 
vector (Figure 4B), and verified the expression of NS5A in cell transduced with these 
viruses (Figure 4C). Moreover, cells transduced with these lentiviruses also 
demonstrated a proportion of NS5A localized to the nucleus (Figure 4D). 
 
To confirm the role of the NS5A NLS in this process, we invalidated the NLS by site-
directed mutagenesis as previously described (57) (Figure 5A). After verifying that 
the constructs expressed similar amounts of NS5A (Figure 5B), immunofluorescence 
analyses were performed. As shown in Figure 5C (upper panel), abolition of the NLS 
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drastically reduced, but did not abolish, NS5A translocation to the nucleus. Taken 
together, these results indicate that the NLS of NS5A is functional and plays an 
important role in NS5A translocation to the nucleus. However, passive nuclear 
translocation of NS5A could also occur in this system. 
As NS5A is released from the ER membrane by caspase-mediated cleavage (20, 
42), we assessed in parallel whether caspase-mediated cleavage of NS5A is 
necessary for nuclear localization of NS5A. Mutation of the putative caspase 
recognition site at position 154 of the N-terminus of NS5A (D154E, Figure 5A) 
completely abolished nuclear translocation of NS5A (Figure 5C, lower image), 
demonstrating the importance of caspase cleavage in the release of NS5A from the 
ER before its subsequent translocation to the nucleus. 
 
HCV RNA replication efficiency in vitro is dependent upon nuclear 
translocation of NS5A 
To investigate whether NLS-mediated NS5A nuclear localization is important in HCV 
RNA replication, we analyzed the impact of NS5A NLS invalidation on replication of 
the sub-genomic replicons. Replicons encoding two different NS5A variants 
associated with high replication levels (v1 and v2) in which the NLS of NS5A was 
mutated (Figure 6A) exhibited reduced NS5A expression after 96h post-transfection 
(Figure 6B, lower panel), despite a similar expression at 4h (Figure 6B, upper panel), 
and a corresponding reduction in replicon replication in vitro (Figure 6C). These 
results demonstrate the importance of a functional NS5A NLS for efficient replication 
of the HCV subgenomic replicon. However, invalidation of the NLS did not completely 
abolish replication, in line with our findings that a proportion of NS5A translocates to 
the nucleus in the absence of a functional NLS (Figure 5C, upper panel).  
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In order to investigate the importance of caspase cleavage of NS5A in HCV 
replication, cells harboring sub-genomic replicons were treated with the pan-caspase 
inhibitor z-VAD-fmk and replication capacity was analyzed. As shown in Figure 6D, 
inhibition of cellular caspase activity substantially reduced, but did not abrogate, 
replicon replication. To verify that this result was not due to a non-specific effect of 
caspase activity inhibition, we analyzed the replicative capacity of an SGR mutated in 
the putative N-terminal caspase cleavage site (D154E) of NS5A (Figure 6D, inset). 
This mutation resulted in the complete loss of subgenomic replicon replication 
(Figure 6D).  
Taken together, these results demonstrate that caspase-mediated cleavage of NS5A, 
its release from the endoplasmic reticulum, and its subsequent localization to the 
nucleus is essential for the replication of the subgenomic HCV replicons. They are in 
line with the correlation between HCV replication efficiency and the NS5A 
transcriptional activation capacities. 
 
Different NS5A transcriptional activation properties are associated with 
differential expression of host cell genes essential for HCV RNA replication 
To better understand the mechanisms involved in regulation of HCV replication by 
NS5A transcriptional activation, the expression of 28 cellular genes previously shown 
to be essential for replication (listed in table 1) was analyzed in cells harboring 
replicons carrying an NS5A variant with high transcriptional and replication capacity 
(v1) and with low transcriptional and replication capacities (v5). When RTqPCR 
screening was used on cells harboring SGR-NS5A-v1 or SGR-NS5A-v5, no 
significant difference in gene expression profiles was observed (data not shown). 
Because the large number of untransfected cells in these transient assays could 
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have masked any differences, we made use of our lentivirus vectors expressing 
NS5A-v1 or NS5A-v5 (Figure 4B), allowing the transduction of a high proportion of 
cells and thus increasing signal-to-noise ratios. Analysis of host-cell gene expression 
in lentivirus-transduced cells revealed significant differences in the expression of five 
of the 28 genes analyzed. As shown in Figure 7, the genes of interleukin 8 (IL-8), 
lymphotoxin beta (LTΒ) and SNF-like kinase 2 (NUAK2) were significantly up-
regulated by Lenti-NS5A-v1, whereas they were either weakly up-regulated (IL-8 and 
NUAK2) or down-regulated (LTΒ) by Lenti-NS5A-v5. Expression of β-galactosidase 
using an identical lentiviral backbone had no impact on the expression of these 
genes, indicating that our observations were specifically due to expression of NS5A. 
In addition, MAP2K7 and TRAF2 genes were down-regulated by Lenti-NS5A-v5, 
whereas their levels were not significantly changed by Lenti-NS5A-v1. Together, 
these results suggest that NS5A variants with different transcriptional activation 
properties differentially regulate transcription of host-cell genes previously shown as 
required for viral replication and that this may impact HCV RNA replication.  
 
NS5A is recruited to host-cell promoters 
The deregulation of host-cell gene expression observed above might be due either to 
a direct interaction of NS5A with the promoter sequence of these genes, or to an 
indirect regulation involving NS5A-protein interactions. To investigate whether NS5A 
was capable of binding to the promoters of the genes identified above, we performed 
chromatin immunoprecipitation assays (ChIP) on nuclear extracts from cells 
transduced with lentiviruses encoding NS5A-v1 or NS5A-v5. Such experiments 
revealed that both NS5A-v1 and NS5A-v5 were able to bind specifically to the 
promoters of IL-8, LTΒ and NUAK2, but were absent from the promoters of MAP2K7, 
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TRAF2 and FBXL2 (Figure 8). The latter gene was included as a negative control, as 
its expression was unaltered by NS5A in previous experiments (data not shown). 
These data suggest that the regulation of MAP2K7 and TRAF2 by NS5A occurs via 
indirect mechanisms, which do not require the presence of NS5A on their respective 
promoters. Taken together, these results strongly suggest that NS5A directly 
interacts with the promoters of IL8, LTΒ and NUAK2, and that regulation of their 
expression through its intrinsic transactivation properties is important in modulating 
HCV replication. 
 
DISCUSSION: 
It is well established that in an infected individual, HCV exists as a quasispecies; a 
complex mixture of genetically distinct but closely related variants (33, 56). Using a 
functional analysis in a yeast single hybrid model, we have demonstrated that NS5A 
is able to transactivate the GAL4 minimum promoter. This is in agreement with 
previous reports in yeast and mammalian cells (10, 24, 44, 49). Moreover, 
quasispecies variants isolated from the liver tissue of an HCV-infected patient 
possessed different transactivation potentials. These data are in agreement with our 
previous observations of variants isolated from serum samples of HCV infected 
patients (38).  
We studied the effect of NS5A transactivation potential on HCV RNA replication 
using a subgenomic HCV replicon model in an Huh-7 derived cell line (50). 
Significantly different replication capacities were observed for replicons bearing 
NS5A variants with different transactivation potentials, despite similar levels of NS5A 
expression at 4 hours post-transfection. Moreover, we observed a significant 
correlation between NS5A transactivation potential and the replication capacity of the 
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subgenomic HCV replicon, indicating that NS5A transactivation could play a role in 
viral replication. It has previously been demonstrated that certain adaptive mutations 
in NS5A significantly increase the replication capacity of replicons by as yet unknown 
mechanisms (3, 6). Although none of our NS5A variants carried any of these 
previously identified mutations, our results suggested that the mutations carried by 
these variants played a similar role. Since this domain of NS5A is not well structured 
(18), any mutations in this area in our variants are unlikely to perturb the structural 
integrity of NS5A. As we suggested in our previous work (38), only a global change 
of the physical properties of this domain (e.g.: charge) might be involved in the 
modulation of its transactivation properties.  
 
Native NS5A is retained to the endoplasmic reticulum via trans-membrane 
sequences in domain 1, whereas to be able to directly exert its transcriptional 
activation functions, NS5A must translocate to the nucleus. Immunofluorescence 
confocal microscopy and 3D reconstruction analysis in cells harboring a stable 
subgenomic HCV replicon revealed a proportion of nuclear NS5A, demonstrating that 
NS5A could translocate to the nucleus. This was further confirmed by similar 
analyses of cells transduced with lentiviral vectors expressing NS5A-v1 and NS5A-
v5. We found that, both NS5A variants could translocate to the nucleus regardless of 
their transactivation potential, suggesting that the difference in transactivation 
properties between these variants was not due to their ability to translocate to the 
nucleus.  
 
Some studies have previously suggested that NS5A carries a functional NLS in its C-
terminal region and that N-terminally truncated forms of NS5A could translocate to 
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the nucleus (24, 46). In agreement with these findings, we observed that invalidation 
of the NS5A NLS provoked a significant reduction in the quantity of nuclear NS5A. 
However, a small proportion of NS5A was able to localize to the nucleus in the 
absence of a functional NLS, probably via passive diffusion. Previous studies have 
demonstrated that proteins up to 60kDa can passively diffuse through the nuclear 
pores even in the absence of active nuclear import (36, 45, 54). This suggested that, 
although not absolutely required, the NLS of NS5A plays an important role in its 
active nuclear translocation. In parallel, we found a significant reduction in the 
replication capacity of replicon whose NS5A NLS was invalidated, highlighting the 
importance of a functional NS5A NLS for HCV RNA replication. However, the 
replication capacity of these modified replicons was not completely abolished, in line 
with our observations that a proportion of NS5A could still translocate to the nucleus 
by passive diffusion in the absence of a functional NLS. It is probable that passively 
diffused NS5A may exert a role in the nucleus which may suffice for reduced viral 
replication. 
As previously mentioned, NS5A carries a small amphipathic α-helix in its N terminus 
that functions as an ER membrane retention signal (8). To be able to translocate into 
the nucleus, NS5A must be released from this anchor. Some studies have 
demonstrated that NS5A can be cleaved by cellular caspases to produce N-
terminally truncated fragments, which may represent a mechanism to release NS5A 
from the ER to allow its nuclear translocation and exert its transactivational function 
(15, 42). We inhibited this cleavage using either a pan-caspase inhibitor or a 
mutation in the putative N-terminal caspase cleavage site of NS5A. The former 
partially inhibited NS5A re-localization into the nucleus, while the latter resulted in a 
complete loss of nuclear NS5A, both without influencing its expression level. These 
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data strongly suggest that caspase-mediated release of NS5A from its N-terminal ER 
membrane anchor is indispensible for its translocation into the nucleus. More 
importantly, mutation of the conserved caspase cleavage site of NS5A resulted in 
complete loss of replication of the corresponding subgenomic replicon. These results 
are in contrast to those of Sauter et al. (43) who observed an inhibition of JFH1 
replication in Huh-7.5 cells over-expressing N-terminal truncated NS5A. These 
discrepancies may be due to the amount of nuclear NS5A produced in this system 
and the absence of characterization of the transactivation potential of NS5A in their 
model.  
 
NS5A has previously been demonstrated to modulate cellular responses to viral 
infection through interaction with several proteins involved in host cell signaling 
pathways related to interferon response, cell cycle and apoptosis etc. (4, 12, 13). We 
hypothesized that direct regulation of host gene transcription by NS5A represents 
another mechanism employed by HCV to achieve similar goals, providing a possible 
explanation for the correlation between HCV replication and NS5A transactivation 
properties observed. We therefore analyzed the expression of a subset of cellular 
genes whose expression has been previously described to be required for efficient 
HCV RNA replication (7, 14, 17, 35, 41, 47, 48, 51, 53). Our results indicated a 
significant difference in the expression of several of these genes between cells 
expressing NS5A-v1 and –v5. The mRNAs of interleukin 8 (IL8; also called CXCL-8), 
lymphotoxin beta (LTβ) and SNF like kinase 2 (NUAK2; also called SNARK) were 
significantly more abundant in cells expressing NS5A-v1 compared to NS5A-v5-
transduced cells. Furthermore, we demonstrated a direct interaction between NS5A 
and the promoters of these cellular genes. Modulation of IL-8 expression via NS5A 
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transactivation is in keeping with previously published results (39). In addition, JFH1 
infection stimulates the expression of this proinflammatory cytokines (5, 26) and high 
level of IL-8 are found in chronically infected patients (40). HCV RNA synthesis in 
replicon harboring cells was inhibited by IL-8 siRNA knockdown. IL-8 protein levels 
correlated positively with HCV RNA levels in subgenomic and genomic replicon lines. 
However, IL-8 may have opposing antiviral and proviral effects depending on the 
level of HCV replication, the cellular context, and whether the infection is acute or 
chronic (26). Moreover, HCV infection triggers dsRNA signaling pathways that induce 
IL-8 expression via transcriptional activation, and mutations of the interferon-
stimulated response element (ISRE) and NF-kappaB binding sites of this IL-8 
promoter reduced and abrogated IL-8 transcription (52). Overall, the regulation of IL-
8 gene transcription by HCV might involve multiple pathways, including a direct 
transactivatory effect of NS5A, leading to the inhibition of the antiviral actions of IFN, 
thus enhancing HCV replication. 
 
Knock-down of the membrane protein LTβ and the kinase NUAK2  in Huh-7 derived 
cells containing a subgenomic replicon identical to the one used in our study 
correlated with a 60 to 80% decrease in HCV replication (35). Our data suggest that 
NS5A directly activates the transcription of both these genes. LTβ is a member of the 
TNF superfamily which controls cell survival. Similarly to IL-8, this signaling pathway 
leads to the activation of NF-kappaB. In contrast, very little is known about the link 
between NUAK2 and HCV replication, although it is interesting to note that NUAK2 
might be an NF-kappaB-regulated anti-apoptotic gene (29). Interestingly, HCV 
infections have been described to increase the hepatic expression of LTΒ (30) whose 
Results 
 
  116 
sustained expression in turn has been shown to represent an important pathway in 
HCV induced primary liver tumors (19).  
 
Although we found that NS5A-v5 decreased the abundance of TRAF2 mRNA, we 
observed no direct interaction between NS5A and the TRAF2 promoter. It has been 
previously reported that TRAF2 and NS5A directly interact which results in an 
inhibition of NF-κB activation (37). Taken together, it is likely that NS5A modulates 
TNF-receptor signaling through direct interaction with its signaling complex rather 
than through repression of TRAF2 gene expression. 
 
In conclusion, we have demonstrated a novel mechanism by which HCV regulates 
host-cell gene expression. We observed that the ability of NS5A to transactivate a 
cellular promoter was correlated with the replication efficiency of HCV replicons. 
Furthermore, efficient replication of HCV RNA is dependent upon the caspase-
mediated release of NS5A and its subsequent NLS-mediated translocation to the 
nucleus. Finally, we provide compelling evidence that NS5A binds directly to cell 
promoters, thus modulating their activity. These data present a new mechanism by 
which HCV modulates its cellular environment, thereby enhancing viral replication. 
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FIGURE LEGENDS: 
 
Figure 1. Amino acid sequence alignment of isolated NS5A variants. Amino acid 
sequences of NS5A quasispecies variants (V1 to V5) isolated from the liver of a 
patient infected with HCV genotype 1b aligned with the SGR-Nim NS5A sequence 
used as a reference sequence. Numbers represent amino acid positions within 
NS5A. The underlined sequence represents the NS5A transactivation domain. * 
denotes mutations not conserved between all 5 variants. ~ indicates a deletion. 
 
Figure 2. Analysis of the transactivation properties of NS5A variants.  
(A) Schematic representation of yeast one-hybrid constructs encoding NS5A variants 
V1 to V5. The NS5A transcriptional activation domains (NS5A TrD) were amplified 
from patient cDNA and cloned into plasmid pGBT9, giving fusions of the GAL4 DNA 
binding domain (BD) with the respective NS5A transactivation domains of each 
variant (pGBT9-NS5A-v1 to v5).  
(B) Yeast one-hybrid vectors pGBT9-NS5A-v1 to v5 (described above) were 
transfected into yeast strain Y187. The potential of the hybrid proteins to activate 
transcription of the LacZ gene was analyzed by quantification of β-galactosidase 
activity, and the results are expressed as mean ± SEM transactivation levels 
obtained from at least three independent experiments. AU = arbitrary units.  
 
Figure 3. Impact of HCV NS5A transactivation properties on replication 
efficiency of subgenomic HCV replicons harboring different NS5A 
quasispecies variants. (A) Schematic representation of sub-genomic replicon 
constructs encoding NS5A variants V1 to V5. NS5A variant sequences were cloned 
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into a sub-genomic replicon shuttle vector. Filled triangles indicate the introduction of 
cell culture adaptive mutation S2204I. An open triangle indicates the introduction of 
the GDD to GND mutation in the NS5B polymerase. SGR-NS5A-vX is the 
subgenomic replicon carrying NS5A variant sequence vX; SGR-Nim is the wt replicon 
(50); SGR-GND is the nonreplicative control replicon. (B) NS5A protein expression in 
NG cells transfected with subgenomic replicons encoding different NS5A variants as 
analyzed by western blotting at 4 and 96 hours post-transfection. Actin expression 
was used as a loading control. Bands corresponding to 56 kDa NS5A or 42 kDa actin 
are indicated. (C) Replication efficiency of HCV sub-genomic replicons carrying 
different NS5A variants was analyzed in the cell lysates detailed in (B). Luciferase 
activities were assayed in transfected cells, and the replication efficiency was 
calculated as a percentage of that obtained with replicon SGR-Nim (represented by 
the dashed line). Data is indicative of mean±SEM replication efficiencies obtained 
from 7 independent experiments carried out in triplicate. (D) Relationship between 
the transcriptional activation capacities of NS5A variants and the replication 
efficiencies of the corresponding subgenomic replicons. Data points represent the 
mean transactivational capacities and replication efficiencies for each variant.  
 
Figure 4. Subcellular localization of NS5A. 
(A) Cells harboring the subgenomic replicon I389-neo/NS3-3’/5.1 were analyzed by 
confocal microscopy using anti-NS5A antibody in conjunction with anti-rabbit FITC-
conjugated secondary antibody. Nuclei were stained with To-Pro-3. Three-
dimensional representations were reconstructed from image z-stacks. Scale bar = 10 
μm. * denotes non-replicon harboring cells. (B) Schematic representations of 
lentivirus vectors carrying NS5A variants V1 and V5 and β-galactosidase. Filled 
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triangles indicate the presence of cell culture adaptive mutation S2204I. (C) 
Immunoblotting analysis of NS5A expression in cells transduced for 72 hours with the 
lentiviruses described in (B). Bands corresponding to 56 kDa NS5A or 42 kDa actin 
are indicated. (D) Confocal analysis of cells transduced with lenti-NS5A-v1 or –v5 
was carried out as described in (A). Scale bar = 10 μm. * denotes non-transduced 
cells. 
 
Figure 5. Analysis of mechanisms surrounding NS5A nuclear localization. 
(A) Schematic representations of lentivirus vectors carrying mutated NS5A-v1. An 
open triangle denotes invalidation of the NS5A NLS, a closed triangle indicates 
mutation of the caspase recognition site at amino acid position 154. (B) Western 
blotting analysis of NS5A expression in cells transduced for 72 hours with the 
mutated and non-mutated NS5A-v1 lentiviruses. Bands corresponding to 56 kDa 
NS5A or 39 kDa GAPDH are indicated. (C) Confocal analysis of cells transduced with 
the mutated and non-mutated NS5A-v1 lentiviruses was carried out as described in 
figure 4. Scale bar = 10 μm. * denotes non-transduced cells.  
 
Figure 6. The contribution of nuclear NS5A localization to HCV RNA replication. 
(A) Schematic representation of sub-genomic replicons encoding NS5A-v1 or v2 
containing mutated NLS. An open triangle denotes invalidation of the NS5A NLS, and 
a closed triangle indicates the presence of the cell culture adaptive mutation S2204I. 
(B) Western blotting analysis of NS5A expression in cells transfected with NLS-
mutated and non-mutated v1 and v2 replicons at 4 and 96 hours post-transfection. 
Actin expression was used as a loading control. Bands corresponding to 56 kDa 
NS5A or 42 kDa actin are indicated. (C) Replication efficiency of HCV sub-genomic 
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replicons carrying NS5A variants encoding mutated NLS was analyzed in the cell 
lysates 96h post-transduction. The replication efficiencies were calculated as 
described in the legend to Figure 3C. Data is indicative of the mean ± SEM 
replication efficiencies obtained from 7 independent experiments carried out in 
triplicate. The statistical significance of these data was analyzed unsing a Mann-
Whitney test. (D) The effect of caspase cleavage of NS5A on HCV replicon 
replication. (Upper panel) Schematic representation of a sub-genomic replicon 
encoding NS5A-v1 with a mutated caspase cleavage site. An open triangle denotes 
mutation of the caspase recognition site at amino acid position 154, and a closed 
triangle indicates the presence of the cell culture adaptive mutation S2204I. (Lower 
panel) Replication efficiency of the indicated subgenomic replicons was analyzed in 
the presence or absence of the caspase inhibitor z-VAD-fmk at the indicated 
concentrations. Data represents the mean ± SEM replication efficiencies obtained 
from 3 independent experiments carried out in triplicate. 
 
Figure 7. Gene expression analyses of cells expressing NS5A variants. 
mRNA expression in NG cell cultures transduced with Lenti-NS5A-v1 and Lenti-
NS5A-v5. The expression levels of the indicated genes were determined by 
quantitative real-time PCR from the pooled RNA of three independent experiments. 
The results were normalized to expression of GAPDH, and the mean ± SEM mRNA 
quantities are expressed in relation to control cells transduced with Lenti-β-gal. 
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Figure 8. Chromatin immunoprecipitation analyses of cells expressing NS5A-
V1 and -V5 
Chromatin was immunoprecipitated using an anti-NS5A antibody from NG cells 
transduced with lentiviruses expressing NS5A-V1 or NS5A-V5. Immunoprecipitated 
chromatin and input DNA were amplified using primers spanning the promoters of the 
indicated genes. The PCR products were analyzed by agarose gel electrophoresis. 
Cells transduced with Lenti-β-gal were used as a control. The promoter of FBXL2 
was amplified as a negative control. Numbers on the left indicate sizes in bp of the 
DNA ladder. 
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Table 1: RTqPCR Taqman probes for gene expression analysis. 
Primers Gene Acc. No. Assay ID Gene Name 
GAPDH 
 
NM_002046.3 Hs99999905_m1 Glyceraldehyde-3-phosphate dehydrogenase 
CDC42 
 
NM_001791.3 Hs03044122_g1 Cell division cycle 42 (GTP binding protein, 25kDa) 
COPZ1 
 
NM_016057.1 Hs00255433_m1 Coatomer protein complex, subunit zeta 1 
CSK 
 
NM_001127190.1 Hs01062579_g1 c-src tyrosine kinase 
CYP1A1 
 
NM_000499.3 Hs01054797_g1 Cytochrome P450, family 1, subfamily A, polypeptide 1 
DDX3X 
 
NM_001356.3 Hs00606179_m1 DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, X-linked 
DICER1 
 
NM_030621.3 Hs00998582_g1 Dicer 1, ribonuclease type III 
EIF2S3 
 
NM_001415.3 Hs00831673_gH Eukaryotic translation initiation factor 2, subunit 3 
gamma, 52kDa 
FBXL2 
 
NM_012157.3 Hs00247211_m1 F-box and leucine-rich repeat protein 2 
HAMP 
 
NM_021175.2 Hs01057160_g1 Hepcidin antimicrobial peptide 
JAK1 
 
NM_002227.2 Hs01026996_m1 Janus kinase 1 
LTΒ 
 
NM_009588.1 Hs00242739_m1 Lymphotoxin beta (TNF superfamily, member 3) 
MAP2K7 
 
NM_145185.2 Hs00178198_m1 Mitogen-activated protein kinase kinase 7 
NFKB2 
 
NM_001077493.1 Hs00174517_m1 Nuclear factor of kappa light polypeptide gene enhancer 
in B-cells 2 (p49/p100) 
NUAK2 
 
NM_030952.1 Hs00388292_m1 NUAK family, SNF1-like kinase, 2 
PI4KA 
 
NM_058004.2 Hs00176931_m1 Phosphatidylinositol 4-kinase 
PI4KB 
 
NM_002651.1 Hs00356327_m1 Phosphatidylinositol 4-kinase, catalytic, beta 
PPIA 
 
NM_021130.3 Hs99999904_m1 Peptidylprolyl isomerase A (cyclophilin A) 
RELA 
 
NM_001145138.1 Hs00153294_m1 v-rel reticuloendotheliosis viral oncogene homolog A  
SLC12A4 
 
NM_001145961.1 Hs00957122_m1 Solute carrier family 12 (potassium/chloride 
transporters), member 4 
SLC12A5 
 
NM_001134771.1 Hs00221168_m1 Solute carrier family 12 (potassium-chloride 
transporter), member 5 
TBXA2R 
 
NM_201636.2 Hs00169054_m1 Thromboxane A2 receptor 
TRAF2 
 
NM_021138.3 Hs00184186_m1 TNF receptor-associated factor 2 
TXNIP 
 
NM_006472.3 Hs01006900_g1 Thioredoxin interacting protein 
VAPA 
 
NM_194434.2 Hs00427749_m1 VAMP (vesicle-associated membrane protein)-
associated protein A, 33kDa 
VAPB 
 
NM_004738.3 Hs00191003_m1 VAMP (vesicle-associated membrane protein)-
associated protein B and C 
VRK1 
 
NM_003384.2 Hs00177470_m1 Vaccinia related kinase 1 
IL8 NM_000584.2 Hs99999034_m1 Interleukin 8 
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PLK1 NM_005030.3 Hs00983233_g1 Polo-like kinase 1 
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Figure 4A 
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Figure 6D 
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3.4. The AR2 Region of NS5A bears the transactivation potential of NS5A (Additional 
data not included in the J Virol paper.) 
 
As described above, NS5A quasispecies variants isolated from the hepatic tissue of an HCV-
infected individual demonstrated significantly different transactivation potentials. Sequence 
analysis of the transactivation domains of these variants demonstrated no correlation between 
specific amino acid residues and the transactivation potential of a variant (Figure 1 of the 
submitted article). These observations suggested that the transactivation potential of an NS5A 
variant may depend on the global physical properties of the region. Previously our group has 
reported that the calculation of hydrophobicity and the prediction of secondary structures by 
various methods reveal very close values and conformational differences amongst variants 
(Pellerin et al., 2004). In addition, in the same study it was suggested that amino acid 
substitutions among variants may affect the global charge of the polypeptide and may thus 
influence NS5A interactions and functions. To investigate this hypothesis, we correlated the 
global charge of each NS5A transactivation domain with the transactivation potential of the 
corresponding variant. Our results indicated a significant correlation between the global 
charge of the transactivation domain and its transactivation potential (Figure 3.18B). The 
transcriptional activation domain of HCV NS5A has been shown to contain two regions rich 
in acidic amino acids termed AR1 and AR2 (Figure 3.18A) (Tanimoto et al., 1997). To 
investigate whether one or both of these regions play a role in transactivation, we studied the 
correlation between the global charges of these acid-rich regions and the transactivation 
potential of the corresponding variant. For this, all isolated NS5A variants were divided into 
three categories based on their transactivation potential i.e., strong, average and weak 
transactivators. The global charge of polypeptides corresponding to the transactivation 
domain, AR1 or AR2 regions of variants in these categories were plotted. We observed a 
significant correlation between the global charge of AR2 and transactivation potential of the 
variant, although no such correlation was observed for AR1 (Figure 3.18B). These 
observations suggested that AR2 could play a major role in the transactivation properties of 
NS5A.  
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Figure 3.18: Role of AR2 in the transactivational properties of NS5A. [A] Schematic 
representation of acid rich regions AR1 and AR2 of the NS5A transactivation domain. [B] 
Correlation between the global charge of NS5A transcriptional activation domain, AR1 or 
AR2 and the transactivation potential of NS5A variants. Each bar represents the mean global 
charge of the indicated polypeptide region of all NS5A variants in the indicated group. 
 
 
 
To experimentally confirm these observations, we exchanged the AR2 region sequences 
between strong and weak transactivating NS5A variants (v1 and v5) as described in section 
2.4.12. We then cloned these chimeric variants into our yeast one-hybrid and sub-genomic 
replicon systems to study the subsequent effect NS5A transactivation properties and HCV 
RNA replication capacity.  
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Figure 3.19: Role of AR2 in NS5A transactivation and HCV RNA replication. The AR2 
region of the NS5A transactivation domain of strongly (NS5A-v1) and weakly (NS5A-v5) 
transactivating NS5A variants were swapped with each other (left). The effect of this 
exchange on NS5A transactivation properties and HCV RNA replication was studied in yeast 
one-hybrid (blue) and subgenomic replicon models (red) respectively. Error bars indicate 
SEM.  These results are indicative of three independent experiments. 
 
 
The results shown in figure 3.19 demonstrate that both the transactivation potential of the 
variant and the HCV RNA replication capacity of a replicon bearing such a variant were 
strongly reduced when the AR2 region of a strongly transactivating variant was replaced with 
that of a weakly transactivating variant. On the other hand, whilst the transactivation potential 
of a weakly transactivating variant increased significantly when the AR2 domain was 
replaced with that of a strongly transactivating variant, the corresponding replication capacity 
was nearly unaffected. Together these observations suggest that the AR2 region of NS5A is 
necessary but not sufficient for its transcriptional activity and its effect on HCV RNA 
replication. 
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With more than 170 million carriers around the world, HCV represents a serious public health 
problem. HCV infection becomes chronic in more than 80% of the patients and is often 
associated with liver steatosis, fibrosis, cirrhosis, and is a major risk factor for the 
development of hepatocellular carcinoma. Little is known about the mechanisms surrounding 
HCV-induced pathogenesis and it is unclear what, if any, role the direct HCV proteins play in 
these processes remains to be defined. In this context, we have investigated the role of the 
HCV NS5A protein, especially its transactivation properties, on viral replication and in liver 
pathogenesis. 
NS5A is a nonstructural protein and is an essential component of HCV replication complex, 
although no precise enzymatic function has been attributed to it. Some studies have suggested 
that N-terminal deletion mutants of HCV NS5A possess transcriptional activation properties, 
although the exact mechanisms involved are unclear (Kato et al., 1997; Tanimoto et al., 1997; 
Pellerin et al., 2004). It is well established that in an infected individual, HCV exists as a 
quasispecies; a complex mixture of genetically distinct but closely-related variants (Weiner et 
al., 1991; Martell et al., 1992). Using phylogenetic and functional analyses we demonstrated 
that hepatic quasispecies variants of NS5A possessed different levels of transactivation 
potential, suggesting that the accumulation of genetic mutations randomly generates viral 
protein variants with quantitatively different functional properties in infected cells. These data 
extend previous observations made using quasispecies variants isolated from serum samples 
(Pellerin et al., 2004). Moreover, our analysis of NS5A sequence distributions within a given 
patient revealed a genetic compartmentalization between tumoral and adjacent non-tumoral 
hepatic tissues. However, this finding was not observed in all patients from our cohort. This 
genetic compartmentalization was most evident in patients with non-cirrhotic liver tissues, 
although it is difficult to draw a valid conclusion from such a small group (n=4). Both 
decreased Shannon entropy of NS5A quasispecies and lower virus titers (HL, personal data) 
were observed in the tumoral tissue of these patients, indicating restrictions on virus genetic 
diversity in the tumoral environment. One possible explanation is that reduced genetic 
diversities and viral titers were due to a more recent infection of the tumoral tissues by HCV 
from the adjacent tissues. Similar virus diversity was proposed in the case of lymphoid and 
central nervous system tissues infection by neuropathogenic SIVsmmFGb. (Reeve et al., 
2009; Reeve et al., 2010). These studies also pinpointed that such compartmentalization 
evolved over the time of infection, therefore complicating any conclusions that may be drawn 
from such analyses. 
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A study has reported that HCV core protein sequences isolated from tumoral tissue could 
interact with the cellular transcription factor Smad3 and inhibit the TGF-β pathway, but that 
variants isolated from adjacent non-tumoral tissues could not (Pavio et al., 2005), thus 
demonstrating a functional compartmentalization of core protein. In our study, due to high 
variability between patients, we were unable to conclude that a specific tissue compartment 
was harboring particular NS5A transactivation levels.  
We found that the transactivation properties of a given NS5A variant and the amino-acid 
sequence of its transactivating domain were related, with certain regions exclusively mutated 
in variants with high transactivatory potentials. However, we did not observe any correlation 
between specific amino acid residues and transactivation properties, suggesting that the 
transactivation potential of a variant may rather depend on global physical properties of the 
polypeptide. Indeed, analysis of the variants revealed a significant correlation between their 
global charge and transactivation potential, confirming hypotheses posed by Pellerin et al. 
(2004). The central region of NS5A contains two domains rich in acidic amino acids and one 
proline rich region ((Tanimoto et al., 1997; Tan et al., 1999). Interestingly these structural 
characteristics are a typical feature of many viral and eukaryotic transcription factors such as 
HIV Tat, HSV VP16 and c-Jun (Hope et al., 1988; Lillie et al., 1989; Kamine et al., 1991; 
Tiley et al., 1992; Subramanian et al., 1994). We were able to pinpoint the domain AR2 as 
essential for NS5A transactivation properties. 
Although it has previously been suggested that NS5A protein may possess transactivation 
properties, the impact of such activity was not known. Here, we showed that NS5A 
transactivation potentials positively correlated with viral replication capacity. Thus, one 
possibility is that HCV NS5A may act in a manner analogous to HIV Tat and HSV-1 VP16 
during viral replication. Tat and VP16 are viral transactivators shown to be essential for viral 
replication as they are required for efficient transcription of viral genomes (Arya et al., 1985; 
Fisher et al., 1986; Tal-Singer et al., 1999).  
We have further shown that that NS5A transactivational activity plays an important role in 
viral replication by modulation of the host cell genes required for efficient replication of 
HCV. Indeed, other viral transactivators such as HIV Tat have also been shown to regulate 
HIV replication and chronicity by transactivating cellular genes (Buonaguro et al., 1992). 
Although NS5A has previously been shown to play a role in viral regulation by modulating 
the cellular responses through interactions with several proteins involved in host cell signaling 
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pathways related to interferon response, cell cycle and apoptosis (Gale et al., 1997; Gale et 
al., 1999; Arima et al., 2001), we have demonstrated that direct regulation of host gene 
transcription by NS5A represents another mechanism employed by HCV to achieve similar 
goals, providing a possible explanation for the correlation between HCV replication and 
NS5A transactivation properties observed.  
The translocation of a protein to the nucleus is essential for it to exert any putative 
transactivational activity. In line with this, we demonstrated that that caspase-mediated release 
of NS5A from its ER retention signal and its translocation to the nucleus is essential for HCV 
RNA replication in vitro. Although our study does not provide any data about the mechanisms 
by which NS5A may function as transcriptional activator, the use of formaldehyde in our 
ChIP experiments demonstrate that NS5A closely interacts with the cellular gene promoters. 
It is well known that different transcription factors function as transcriptional regulators by 
interacting with specific DNA elements (Kang et al., 2010). However as NS5A amino acid 
sequence does not contain any know DNA binding motif, it is less likely that it may interact 
directly with DNA. Interestingly, it has been demonstrated that NS5A colocalizes with Snf2-
related CREBBP activator protein (SRCAP), a cellular transcription factor, suggesting that 
NS5A may interact with cellular transcription factors to modulate their activity (Ghosh et al., 
2000b). Other viral transactivators that modulate host cell gene expression, such as Tat, have 
been shown to  target protein kinases involved in the phosphorylation of polymerase II C-
terminal domain thus influencing the transcription initiation as well as elongation (Herrmann 
et al., 1996; Gold et al., 1998). Recently, it has been suggested that viral transactivators such 
as VP16 may also function by enhancing the polyadenylation of targeted precursor mRNAs 
(Nagaike et al., 2011). It is possible that NS5A may act in a manner similar to these viral 
transactivators, although further work remains to be performed on the exact manner(s) in 
which NS5A exerts its transactivational activities. 
To completely understand the mechanisms of NS5A transactivation, it will be critical to 
characterize the cellular promoters bound by NS5A. Chromatin immunoprecipitation coupled 
with last-generation genome-wide deep sequencing (ChIP-seq) represents a powerful strategy 
to analyze the possible targets of transactivation by viral proteins (Kennedy et al., 2010). We 
are currently performing ChIP-seq analysis on primary human hepatocytes expressing weakly 
and strongly transactivating NS5A variants. Such analysis, coupled with transcriptome 
analysis of these cells, will allow us to define the complement of cellular genes transactivated 
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by NS5A. Using these data, we may be able to suggest a DNA motif necessary for NS5A 
DNA binding or transcription factors targeted by NS5A. 
Apart from enhancing HCV replication, NS5A mediated modulation of host cell gene 
expression may represent a mechanism by which HCV can override cellular control 
mechanisms such as the interferon response, cell cycle progression and apoptosis, 
contributing to persistent infection. We have demonstrated that NS5A can directly modulate 
the expression of several cellular proteins such as CXCL8, LTB, NUAK2, In agreement with 
our observations, it has been previously  demonstrated that NS5A induces the activity of 
CXCL8 promoter in reporter gene assays (Polyak et al., 2001b). Moreover it has been 
demonstrated that CXCL8 is induced to high levels by replicons with high replicative 
capacity (Koo et al., 2006). Interestingly our results demonstrated that NS5A variant with 
higher transactivation potential, induced higher levels of CXCL8 as well as conferred higher 
replication to corresponding replicon, suggesting that NS5A transactivation of CXCL8 may 
play an important role in enhancing the replication of HCV. NS5A transactivation of CXCL8 
may also represent one of the mechanisms involved in HCV induced pathogenesis. It has been 
demonstrated that increased expression of CXCL8 in HCV infected patients is associated to 
inhibition of antiviral effects of interferon (Polyak et al., 2001a). HCV has been suggested to 
increase levels of LTβ in liver tissues (Lowes et al., 2003) whose sustained expression 
represents an important factor in liver inflammation and HCV-induced HCC (Lowes et al., 
2003; Haybaeck et al., 2009). We observed a strong upregulation of LTβ by strongly 
transactivating NS5A variant, suggesting that NS5A mediated transcriptional activation may 
account for at least a partial increase in liver LTβ levels thus inducing liver inflammation. 
Similarly, NUAK2 is a potent anti-apoptotic kinase involved in increased death resistance and 
invasiveness of tumor cells (Legembre et al., 2004; Kim et al., 2008). No direct link between 
HCV and NUAK2 is known. However, it is a very important cell cycle regulator, therefore its 
modulation by NS5A might be one of the mechanisms by which HCV regulates the cell cycle 
thus play a role in HCV-induced pathogenesis. 
To study the role of NS5A transactivation in HCV induced pathogenesis in vivo, we tried to 
develop an adenoviral vector system to express well-characterized NS5A variants in murine 
hepatic tissues. However, our adenoviral vector system failed to efficiently express the NS5A 
transgene in vivo. We therefore decided to use two complementary approaches to study our 
hypotheses that the natural variability of NS5A may impact its proposed transactivation 
properties and that NS5A’s putative transactivation properties could play a role in liver 
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pathogenesis. Our alternative strategy was to use a lentiviral vector for in vitro studies, 
whereas for in vivo studies we developed transgenic mice expressing the patient-isolated 
NS5A variants we previously characterized. In order to investigate the role of NS5A 
transactivation in host gene regulation, we performed genome wide RNA-seq differential 
transcriptome analysis on in vitro cultured primary human hepatocytes transduced with 
lentiviral vectors encoding weakly and strongly transactivating NS5A variants. Such primary 
human cells were chosen because we assumed that major cellular pathways in these cells were 
closer to those found in patients than those of hepatoma cells (Huh-7 and derived clones). The 
data obtained will allow us to identify the host cell molecular pathways differentially 
regulated by NS5A variants. The role of NS5A variants in differential regulation of identified 
pathways and eventually the potential mechanisms of pathogenesis will be the subject of 
future studies. As with our previous approach, this approach is also based on expression of 
NS5A alone. This might represent a caveat in this study since during HCV lifecycle, NS5A is 
part of a multiprotein replication complex, absent from our models. The results obtained from 
this approach should then be confirmed using other models harboring the full HCV protein 
repertoire. Such full-length or infectious HCV replicon systems bear numerous other caveats, 
mainly concerning the cell types used. A better approach might involve recently developed in 
vivo infectious model in humanized mice (Mercer et al., 2001; Strick-Marchand et al., 2004; 
Meuleman et al., 2005). 
As described above, we are developing transgenic mice expressing NS5A variant proteins. 
Making use of advanced targeted transgenesis techniques, in which the transgene is inserted 
into a neutral locus, and is able to be conditionally expressed in a liver-and time-specific 
fashion, we have begun the development of transgenic mice expressing NS5A variants v1 and 
v2. We expect to obtain the first mice in March 2012.The double transgenic mice for both 
hepatic Cre recombinase and NS5A variants will be followed for 18 months to study the 
incidence of both spontaneous and chemically-induced HCC as a function of transactivation 
properties of NS5A variants, using Cre-negative littermates as negative controls. The absence 
of other viral proteins may be one of the limiting factors in the development of HCC: to 
overcome this problem, the Alb-Cre/NS5A mice will also be crossed with FL-N/35 mice 
(Lerat et al., 2002) that express the entire protein complement of HCV. Host cell pathways 
identified as potential targets of NS5A-mediated transcriptional regulation in in vitro RNAseq 
studies will be studied in these transgenic mice and their implication in HCV-induced 
pathogenesis will be defined. 
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In conclusion, the work presented in this thesis demonstrates that quasispecies nature of HCV 
gives rise to a large number of variant proteins with different functional properties. The 
difference of functional and biological properties among quasispecies variant proteins might 
play an important role in the development of HCV-induced liver pathogenesis. We have 
demonstrated a novel mechanism by which HCV regulates host-cell gene expression to 
facilitate HCV replication. We have further provided compelling evidence that NS5A directly 
interacts with cell promoters, thus modulating their activity. As a result, host genes involved 
in cell multiplication, apoptosis or other pathways key for cell fate are modulated by NS5A 
and might lead to perturbations of host cell functions, liver functions and the common 
pathologies observed in HCV-induced chronic hepatitis. It will be difficult, but interesting, to 
understand the origins of the modulation of the HCV cellular environment: are they collateral 
damages due to properties of HCV proteins originally involved in viral genome replication, or 
virus-targeted modulations of the host cell?  
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Appendix-Oligonucleotides 
Primer Name Primer Sequence (5’-3’) 
  
Bgl1_NS5Apop28_S GCAGCCCATCCGGCTCGTGGCTGAGGGA 
B-NS5A-swap CAAAGAAGGCGCAGACAACTGGCTAGC 
CACC-SrfI-T2A-S CACCTGCCCGGGCGA GGGCAGAGG 
C-NS5A-swap TTCCCCCCAGCGATGCCCATATGG 
E-NS5A-swap GCTATCCAGTTGTCTGCGCCTTCTTGT 
FBXL2-prom-AS CGTATCTGGTCCATCCTCTCA 
FBXL2-prom-S TGGGGTGAGTGTCGTTTTATC 
F-NS5A-swap CCCATATGGGCATCGCTGGGGGGA 
IL8-Prom3-AS CTCAGGGCAAACCTGAGTCATC 
IL8-Prom3-S GTTGTAGTATGCCCCTAAGAG 
LTB-prom1-AS ATATTCCCTCACCCCACCAT 
LTB-prom1-S TACGGGCCTCTCTGGTACAC 
MAP2K7-prom-AS GAAGGATGACGCCACCTAGA 
MAP2K7-prom-S AACGAGGTTCCAGGAATGC 
NS5A_Stop_XhoI_AS GTCCTCGAGTCAGCAGCAGGCGACGTTCTC 
NS5A-c1167a-AS CTTAGCAGCCGGCAGCTTTCGCCGTGC 
NS5A-c1167a-S GAATCGTCGGCCGTCGAAAGCGGCACG 
NS5A-HindIII GGAAGCTTGTCCGGCTCGTGGCTAAGG 
NS5A-kozak-S GCCACCATGTCCGGCTCGTGGCTA 
NS5A-NotI-S TAGCGGCCGGGAGCAGCAAACGACGTCCTC 
NS5A-PacI-AS CCTCTTAATTAACTCCTCGCTCACGGTAGACCAAGACCC 
NS5A-stop-AS CTACTAGCAGCAAACGACGTCCTC 
NS5A-t462a-AS TAAGAAGTGTCTCCACCTTCCCCACGCCG 
NS5A-t462a-S ATTCTTCACAGAGGTGGAAGGGGTGCGGC 
NUAK2-prom1-AS CCTGAAGGCCTAGAGAACACA 
NUAK2-prom1-S CCTGAAGTTGCTGCTGTGAA 
p1071-NLSmut-AS CTGTTAGGACAACCGTCCCCATTCCCCC 
TGGAGGTGGTATTGGAGGGG 
p1071-NLSmut-S CCCCTCCAATACCACCTCCAGGGGGAAT 
GGGGACGGTTGTCCTAACAG 
TopoT2A-XhoI-AS  ATGCATGCTCGAGCGGCCGC 
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TRAF2-prom-AS CAGCCCTCAGGAAGCTGTAG 
TRAF2-prom-S GGGAAGGGACCCAATTAGC 
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Summary 
Hepatitis C virus (HCV) causes a chronic infection in the majority of infected patients, 
ultimately leading to liver cirrhosis and hepatocellular carcinoma (HCC). Although the roles 
of the HCV proteins in the viral life cycle are increasingly understood, the precise function of 
the HCV NS5A protein has yet to be elucidated. To date, the only putative direct function 
attributed to NS5A is its transcriptional transactivation properties. Our group has previously 
shown that quasispecies variants of NS5A isolated from the serum samples of the same 
patient bear different transactivating properties according to their amino acid sequence. Based 
on these observations, we performed preliminary phylogenetic and functional analysis of 
NS5A variants isolated from liver tissue of individuals infected with HCV of genotype 1b. 
This analysis revealed genetic and functional compartmentation of NS5A variants in tumoral 
and adjacent non-tumoral tissue. We hypothesized that the natural variability of NS5A may 
impact its proposed transactivation properties. We also hypothesized that NS5A’s putative 
transactivation properties could play a role in HCV replication and in liver pathogenesis. The 
aim of the study presented in this thesis was to investigate the role of NS5A transactivation 
properties in the development of HCV-induced liver pathogenesis as well as in viral 
replication.  
To study the role of NS5A transcriptional activation properties in liver pathogenesis, we 
developed lentiviral vectors for the expression of selected NS5A variants bearing different 
transactivation potentials in cultured primary human hepatocytes. We now intend to extend 
these preparations using RNAseq technology to analyse the, transcriptome of primary 
hepatocytes transduced with lentiviral vectors encoding strongly and weakly transactivating 
NS5A variants to identify the cellular pathways targeted by NS5A, allowing us to decipher 
the role of NS5A mediated host gene regulation in development of HCV induced 
pathogenesis. For in vivo studies, we have begun the development of transgenic mice allowing 
liver-specific conditional expression of NS5A variants with high and low transactivation 
potentials. These transgenic mice will be used to study the possible role of NS5A 
transactivation properties in development of HCC. 
 
To study the role of NS5A transcriptional activation properties in HCV RNA replication, we 
used the sub-genomic replicon system expressing previously characterized NS5A sequences.. 
Using this system, we have demonstrated that a subset of NS5A protein can translocate to the 
nucleus and is recruited to cellular promoters of host cell genes known to be required for 
efficient replication of HCV replicon RNA as well as those implicated in pathogenesis. 
Moreover, we have shown that NS5A directly regulate the expression of these genes. 
Consequently, it was observed that replicons encoding NS5A variants with different 
transactivation potentials exhibited different replication capacities, and that this correlated 
with the transactivation potential of the corresponding NS5A variant. In agreement with these 
observations, inhibition of nuclear translocation of NS5A resulted in the inhibition of 
replication of the HCV subgenomic replicon, further confirming the role of NS5A 
transactivation properties in viral RNA replication.  
In conclusion, we have demonstrated that NS5A-mediated transcriptional regulation of 
cellular genes is required for HCV replication. Such NS5A-mediated modulation of cellular 
genes may also constitute one of the mechanisms involved in HCV-related liver pathogenesis 
and development of HCC, an aspect which is currently under investigation using the tools 
developed during this project. This study will contribute towards deciphering the role of 
NS5A in viral replication as well as providing insight into its role in HCV-induced liver 
pathogenesis. Furthermore, these data might open new anti-HCV drug developments based on 
inhibition of NS5A nuclear translocation.  
